ClinicalTrials.gg
CompletedNCT04368728Updated Mar 25, 2026Results posted

Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals

A Phase 2/3 interventional study of BNT162b1 and BNT162b2 in SARS-CoV-2 Infection and COVID-19, sponsored by BioNTech SE. Completed at 175 sites in 6 countries. Open to participants aged 12 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-25.

Sponsored by BioNTech SE · Phase 2/3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
46,969
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies testing BNT162 Vaccine in COVID-19 — 4 open to participants now, 6 under way, 1 of them phase 3. BNT162 Vaccine · COVID-19.

Enrollment
Largest of 54
46,969 · median 575
Started
2020
with 4 others
Phase 2/3
5 of 54
none open now
Registered
1st of 54
by date
Lead sponsor
20 of 54
BioNTech SE

Among the 54 studies testing BNT162 Vaccine in COVID-19, this one has the largest enrollment, is one of 5 that started in 2020, is one of 5 in phase 2/3, and was the 1st registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

4 of the 54 studies testing BNT162 Vaccine in COVID-19 are open now, in 6 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About BNT162 Vaccine

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 12 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing BNT162 Vaccine in COVID-19, or all of them as a file.
02

Study summary

This is a Phase 1/2/3, randomized, placebo-controlled, observer-blind, dose-finding, vaccine candidate-selection, and efficacy study in healthy individuals.

The study consists of 2 parts: Phase 1: to identify preferred vaccine candidate(s) and dose level(s); Phase 2/3: an expanded cohort and efficacy part.

The study will evaluate the safety, tolerability, and immunogenicity of 3 different SARS-CoV-2 RNA vaccine candidates against COVID-19 and the efficacy of 1 candidate:

  • As a 2-dose (separated by 21 days) schedule;
  • At various different dose levels in Phase 1;
  • As a booster;
  • In 3 age groups (Phase 1: 18 to 55 years of age, 65 to 85 years of age; Phase 2/3: ≥12 years of age [stratified as 12-15, 16-55 or >55 years of age]).

The candidate selected for efficacy evaluation in Phase 2/3 is BNT162b2 at a dose of 30 µg.

Participants who originally received placebo will be offered the opportunity to receive BNT162b2 at defined points as part of the study.

In order to describe the boostability of BNT162, and potential heterologous protection against emerging SARS-CoV-2 VOCs, an additional dose of BNT162b2 at 30 µg will be given to Phase 1 participants approximately 6 to 12 months after their second dose of BNT162b1 or BNT162b2. This will provide an early assessment of the safety of a third dose of BNT162, as well as its immunogenicity.

The assessment of boostability will be further expanded in a subset of Phase 3 participants at selected sites in the US who will receive a third dose of BNT162b2 at 30 µg or a third and potentially a fourth dose of prototype BNT162b2VOC at 30 µg (BNT162b2s01, based upon the South African variant and hereafter referred to as BNT162b2SA). A further subset of Phase 3 participants will receive a third, lower, dose of BNT162b2 at 5 or 10 µg.

To further describe potential homologous and heterologous protection against emerging SARS-CoV-2 VOCs, a new cohort of participants will be enrolled who are COVID-19 vaccine-naïve (ie, BNT162b2-naïve) and have not experienced COVID-19. They will receive BNT162b2SA given as a 2-dose series, separated by 21 days.

To reflect current and anticipated recommendations for COVID 19 vaccine boosters, participants in C4591001 who meet specified recommendations and have not already received one, will be offered a third dose of BNT162b2 after their second dose of BNT162.

03

Conditions studied

  • SARS-CoV-2 Infection
  • COVID-19

Keywords

  • COVID-19
  • Coronavirus
  • Vaccine
  • SARS-CoV-2
  • RNA Vaccine
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female participants between the ages of 18 and 55 years, inclusive, 65 and 85 years, inclusive, or ≥12 years, inclusive, at randomization (dependent upon study phase). For the boostability and protection-against-VOCs subset: Existing participants enrolled to receive a third dose of BNT162b2 at 30 µg or BNT162b2SA; male or female participants between the ages of 18 and 55 years, inclusive, at rerandomization.

Newly enrolled participants enrolled to receive 2 doses of BNT162b2SA; male or female participants between the ages of 18 and 55 years, inclusive, at enrollment.

Existing participants enrolled to receive a third dose of BNT162b2 at 5 or 10 µg; male or female participants ≥18 years at rerandomization.

Note that participants \<18 years of age cannot be enrolled in the EU.

  • Participants who are willing and able to comply with all scheduled visits, vaccination plan, laboratory tests, lifestyle considerations, and other study procedures.
  • Healthy participants who are determined by medical history, physical examination, and clinical judgment of the investigator to be eligible for inclusion in the study.
  • Participants who, in the judgment of the investigator, are at risk for acquiring COVID-19.
  • Boostability and protection-against-VOCs existing participant subset only: Participants who provided a serum sample at Visit 3, with Visit 3 occurring within the protocol-specified window.
  • Capable of giving personal signed

Exclusion criteria

Exclusion Criteria:

  • Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
  • Phases 1 and 2 only: Known infection with (HIV), virus (HCV), or virus (HBV).
  • History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study intervention(s).
  • Receipt of medications intended to prevent COVID 19.
  • Previous clinical (based on COVID-19 symptoms/signs alone, if a SARS-CoV-2 NAAT result was not available) or microbiological (based on COVID-19 symptoms/signs and a positive SARS-CoV-2 NAAT result) diagnosis of COVID 19
  • Phase 1 only: Individuals at high risk for severe COVID-19, including those with any of the following risk factors:

    • Hypertension
    • Diabetes mellitus
    • Chronic pulmonary disease
    • Asthma
    • Current vaping or smoking
    • History of chronic smoking within the prior year
    • >30 kg/m2
    • Anticipating the need for treatment within the next 6 months
  • Phase 1 only: Individuals currently working in occupations with high risk of exposure to SARS-CoV-2 (eg, healthcare worker, emergency response personnel).
  • Immunocompromised individuals with known or suspected immunodeficiency, as determined by history and/or laboratory/physical examination.
  • Phase 1 only: Individuals with a history of disease or an active autoimmune disease requiring therapeutic intervention.
  • Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection.
  • Women who are pregnant or breastfeeding.
  • Previous vaccination with any coronavirus vaccine.
  • Individuals who receive treatment with immunosuppressive therapy, including cytotoxic agents or systemic , eg, for cancer or an autoimmune disease, or planned receipt throughout the study.
  • Phase 1 only: Regular receipt of inhaled/nebulized corticosteroids.
  • Receipt of blood/plasma products or immunoglobulin, from 60 days before study intervention administration or planned receipt throughout the study.
  • Participation in other studies involving study intervention within 28 days prior to study entry through and including 6 months after the last dose of study intervention, with the exception of non-Pfizer interventional studies for prevention of COVID 19, which are prohibited throughout study participation.
  • Previous participation in other studies involving study intervention containing lipid nanoparticles.
  • Phase 1 only: Positive serological test for SARS-CoV-2 IgM and/or IgG antibodies at the screening visit.
  • Phase 1 only: Any screening hematology and/or blood chemistry laboratory value that meets the definition of a ≥ Grade 1 abnormality.
  • Phase 1 only: Positive test for HIV, hepatitis B surface antigen (HBsAg), hepatitis B core antibodies (HBc Abs), or hepatitis C virus antibodies (HCV Abs) at the screening visit.
  • Phase 1 only: SARS-CoV-2 NAAT-positive nasal swab within 24 hours before receipt of study intervention.
  • Investigator site staff or Pfizer employees directly involved in the conduct of the study, site staff otherwise supervised by the investigator, and their respective family members.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
46,969 participants (actual)

Study arms

  • Experimental
    10 µg dose, 18-55 years of age (2 doses)

    Biological: BNT162b1 · Biological: BNT162b2

  • Experimental
    20 µg dose, 18-55 years of age (2 doses)

    Biological: BNT162b1 · Biological: BNT162b2

  • Experimental
    30 µg dose, 18-55 years of age (2 doses)

    Biological: BNT162b1 · Biological: BNT162b2

  • Experimental
    10 µg dose, 65-85 years of age (2 doses)

    Biological: BNT162b1 · Biological: BNT162b2

  • Experimental
    20 µg dose, 65-85 years of age (2 doses)

    Biological: BNT162b1 · Biological: BNT162b2

  • Experimental
    30 µg dose, 65-85 years of age (2 doses)

    Biological: BNT162b1 · Biological: BNT162b2

  • Experimental
    30 µg dose, ≥12 years of age (2 doses)

    Biological: BNT162b2

  • Placebo comparator
    Placebo, 18-55 years of age

    Other: Placebo

  • Placebo comparator
    Placebo, 65-85 years of age

    Other: Placebo

  • Placebo comparator
    Placebo, ≥12 years of age

    Other: Placebo

  • Experimental
    100 µg dose, 18-55 years of age (2 doses)

    Biological: BNT162b1

  • Other
    Vaccination of Placebo recipients with BNT162b2 - Stage 1

    Participants ≥16 years of age who originally received placebo and are eligible for COVID-19 vaccination following any local or national recommendations will be offered the opportunity to receive BNT162b2 as part of the study.

    Biological: BNT162b2

  • Other
    Vaccination of placebo recipients with BNT162b2 - Stage 2

    Participants ≥16 years of age who originally received placebo will be offered the opportunity to receive BNT162b2 at defined points as part of the study.

    Biological: BNT162b2

  • Experimental
    Booster vaccination of Phase 1 participants with BNT162b2 at a dose of 30 µg

    Biological: BNT162b2

  • Experimental
    Booster vaccination of Phase 3 participants with BNT162b2 at a dose of 30 µg

    Biological: BNT162b2

  • Experimental
    Booster vaccination of Phase 3 participants with BNT162b2SA at a dose of 30 µg

    Biological: BNT162b2SA

  • Experimental
    Vaccination of BNT162b2-naive participants with BNT162b2SA at a dose of 30 µg

    Biological: BNT162b2SA

  • Experimental
    Booster and further vaccination of Phase 3 participants with BNT162b2SA at a dose of 30 µg

    Biological: BNT162b2SA

  • Experimental
    Booster vaccination of Phase 3 participants with BNT162b2 at a dose of 5 µg

    Biological: BNT162b2

  • Experimental
    Booster vaccination of Phase 3 participants with BNT162b2 at a dose of 10 µg

    Biological: BNT162b2

Interventions

  • BiologicalBNT162b1

    Intramuscular injection

  • BiologicalBNT162b2

    Intramuscular injection

  • OtherPlacebo

    Intramuscular injection

  • BiologicalBNT162b2SA

    Intramuscular injection

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Local Reactions Within 7 Days After Dose 1: Phase 1

    Local reactions included redness, swelling and, pain at the injection site, recorded by participants in an electronic diary (e-diary). Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 centimeter (cm). Redness and swelling were graded as mild (greater than \[\>\] 2.0 to 5.0 cm), moderate (\> 5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis or exfoliative dermatitis for redness and necrosis for swelling). Pain at injection site was graded as mild (does not interfere with activity), moderate (interferes with activity), severe (prevents daily activity) and Grade 4 (emergency room visit or hospitalization for severe pain).

    Time frame: Within 7 days after Dose 1

  2. Percentage of Participants With Local Reactions Within 7 Days After Dose 2: Phase 1

    Local reactions included redness, swelling and, pain at the injection site, recorded by participants in an e-diary. Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 cm. Redness and swelling were graded as mild (\> 2.0 to 5.0 cm), moderate (\> 5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis or exfoliative dermatitis for redness and necrosis for swelling). Pain at injection site was graded as mild (does not interfere with activity), moderate (interferes with activity), severe (prevents daily activity) and Grade 4 (emergency room visit or hospitalization for severe pain).

    Time frame: Within 7 days after Dose 2

  3. Percentage of Participants With Systemic Events Within 7 Days After Dose 1: Phase 1

    Systemic events included fever, fatigue, headache, chills, vomiting, diarrhea, new or worsened muscle pain, new or worsened joint pain recorded by participants or parents/legal guardians of participants using e-diary. Fever=temperature \>=38.0 deg C categorized as \>=38.0 to 38.4, \>38.4 to 38.9, \>38.9 to 40.0 and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain, new or worsened joint pain graded as mild (does not interfere with activity), moderate (some interference with activity), severe (prevents daily routine activity), Grade 4 (Emergency room visit/hospitalization). Vomiting: mild (1-2 times in 24 hours\[h\]), moderate (\>2 times in 24 h), severe (requires IV hydration), Grade 4 (emergency room visit/hospitalization for hypotensive shock). Diarrhea: mild (2-3 loose stools in 24h), moderate (4-5 loose stools in 24 h), severe (\>=6 loose stools in 24 h) and Grade 4 (emergency room visit/hospitalization).

    Time frame: Within 7 days after Dose 1

  4. Percentage of Participants With Systemic Events Within 7 Days After Dose 2: Phase 1

    Systemic events included fever, fatigue, headache, chills, vomiting, diarrhea, new or worsened muscle pain, new or worsened joint pain recorded by participants or parents/legal guardians of participants using e-diary. Fever=temperature \>=38.0 deg C categorized as \>=38.0 to 38.4, \>38.4 to 38.9, \>38.9 to 40.0 and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain, new or worsened joint pain graded as mild (does not interfere with activity), moderate (some interference with activity), severe (prevents daily routine activity), Grade 4 (Emergency room visit/hospitalization). Vomiting: mild (1-2 times in 24 h), moderate (\>2 times in 24 h), severe (requires IV hydration), Grade 4 (emergency room visit/hospitalization for hypotensive shock). Diarrhea: mild (2-3 loose stools in 24h), moderate (4-5 loose stools in 24 h), severe (\>=6 loose stools in 24 h) and Grade 4 (emergency room visit/hospitalization).

    Time frame: Within 7 days after Dose 2

  5. Percentage of Participants Reporting Adverse Events From Dose 1 to 1 Month After Dose 2: Phase 1

    An AE was any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. For BNT162b1 100 mcg, participants received one dose of 100 mcg, followed by one dose of 10 mcg.

    Time frame: From Dose 1 to 1 Month After Dose 2

  6. Percentage of Participants Reporting Serious Adverse Events From Dose 1 to 6 Months After Dose 2: Phase 1

    An SAE was any untoward medical occurrence that occurred, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent or significant disability/ incapacity; was a congenital anomaly/birth defect and other important medical events. For BNT162b1 100 mcg, participants received one dose of 100 mcg, followed by one dose of 10 mcg.

    Time frame: From Dose 1 to 6 Months After Dose 2

  7. Percentage of Participants With Abnormalities in Hematology Parameters 1 Day After Dose 1: Phase 1

    Hematology parameters that were assessed included hemoglobin, hematocrit, erythrocytes, Ery. mean corpuscular volume, Ery. mean corpuscular hemoglobin, Ery. mean corpuscular HGB concentration, platelets, leukocytes, lymphocytes, neutrophils, basophils, eosinophils and monocytes. Abnormal parameters were determined by following criteria: Hemoglobin : \<0.8x lower limit of normal (LLN), Hematocrit : \<0.8x LLN, Erythrocytes : \<0.8x LLN, Ery. Mean Corpuscular Volume: \<0.9x LLN, Ery. Mean Corpuscular Hemoglobin : \<0.9x LLN Ery. Mean Corpuscular HGB Concentration : \<0.9x LLN, Platelets : \<0.5x LLN, Leukocytes : \<0.6x LLN, Lymphocytes : \<0.8x LLN, Neutrophils : \<0.8x LLN, Basophils: \>1.2x upper limit of normal (ULN), Eosinophils \>1.2x ULN, Monocytes \>1.2x ULN. Only parameters with abnormal values were reported in this outcome measure.

    Time frame: 1 Day After Dose 1

  8. Percentage of Participants With Abnormalities in Hematology Parameters 7 Days After Dose 1: Phase 1

    Hematology parameters that were assessed included hemoglobin, hematocrit, erythrocytes, Ery. mean corpuscular volume, Ery. mean corpuscular hemoglobin, Ery. mean corpuscular HGB concentration, platelets, leukocytes, lymphocytes, neutrophils, basophils, eosinophils and monocytes. Abnormal parameters were determined by following criteria: Hemoglobin : \<0.8x LLN, Hematocrit : \<0.8x LLN, Erythrocytes : \<0.8x LLN, Ery. Mean Corpuscular Volume: \<0.9x LLN, Ery. Mean Corpuscular Hemoglobin : \<0.9x LLN Ery. Mean Corpuscular HGB Concentration : \<0.9x LLN, Platelets : \<0.5x LLN, Leukocytes : \<0.6x LLN, Lymphocytes : \<0.8x LLN, Neutrophils : \<0.8x LLN, Basophils: \>1.2x ULN, Eosinophils \>1.2x ULN, Monocytes \>1.2x ULN. Only parameters with abnormal values were reported in this outcome measure.

    Time frame: 7 Days After Dose 1

  9. Percentage of Participants With Abnormalities in Hematology Parameters Before Dose 2: Phase 1

    Hematology parameters that were assessed included hemoglobin, hematocrit, erythrocytes, Ery. mean corpuscular volume, Ery. mean corpuscular hemoglobin, Ery. mean corpuscular HGB concentration, platelets, leukocytes, lymphocytes, neutrophils, basophils, eosinophils and monocytes. Abnormal parameters were determined by following criteria: Hemoglobin : \<0.8x LLN, Hematocrit : \<0.8x LLN, Erythrocytes : \<0.8x LLN, Ery. Mean Corpuscular Volume: \<0.9x LLN, Ery. Mean Corpuscular Hemoglobin : \<0.9x LLN Ery. Mean Corpuscular HGB Concentration : \<0.9x LLN, Platelets : \<0.5x LLN, Leukocytes : \<0.6x LLN, Lymphocytes : \<0.8x LLN, Neutrophils : \<0.8x LLN, Basophils: \>1.2x ULN, Eosinophils \>1.2x ULN, Monocytes \>1.2x ULN. Only parameters with abnormal values were reported in this outcome measure.

    Time frame: Before Dose 2

  10. Percentage of Participants With Abnormalities in Hematology Parameters 7 Days After Dose 2: Phase 1

    Hematology parameters that were assessed included hemoglobin, hematocrit, erythrocytes, Ery. mean corpuscular volume, Ery. mean corpuscular hemoglobin, Ery. mean corpuscular HGB concentration, platelets, leukocytes, lymphocytes, neutrophils, basophils, eosinophils and monocytes. Abnormal parameters were determined by following criteria: Hemoglobin : \<0.8x LLN, Hematocrit : \<0.8x LLN, Erythrocytes : \<0.8x LLN, Ery. Mean Corpuscular Volume: \<0.9x LLN, Ery. Mean Corpuscular Hemoglobin : \<0.9x LLN Ery. Mean Corpuscular HGB Concentration : \<0.9x LLN, Platelets : \<0.5x LLN, Leukocytes : \<0.6x LLN, Lymphocytes : \<0.8x LLN, Neutrophils : \<0.8x LLN, Basophils: \>1.2x ULN, Eosinophils \>1.2x ULN, Monocytes \>1.2x ULN. Only parameters with abnormal values were reported in this outcome measure.

    Time frame: 7 Days After Dose 2

  11. Percentage of Participants With Abnormalities in Chemistry Parameters 1 Day After Dose 1: Phase 1

    Chemistry parameters that were assessed included bilirubin, aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), urea nitrogen, creatinine. Abnormal parameters were determined by following criteria: bilirubin: \>1.5x ULN, AST: \>3.0x ULN, ALT: \>3.0x ULN, ALP: \>3.0x ULN, urea nitrogen: \>1.3x ULN, creatinine: \>1.3x ULN. Abnormal values reported for this outcome measure are for bilirubin.

    Time frame: 1 Day After Dose 1

  12. Percentage of Participants With Abnormalities in Chemistry Parameters 7 Days After Dose 1: Phase 1

    Chemistry parameters that were assessed included bilirubin, AST, ALT, ALP, urea nitrogen, creatinine. Abnormal parameters were determined by following criteria: bilirubin: \>1.5x ULN, AST: \>3.0x ULN, ALT: \>3.0x ULN, ALP: \>3.0x ULN, urea nitrogen: \>1.3x ULN, creatinine: \>1.3x ULN. Abnormal values reported for this outcome measure are for bilirubin.

    Time frame: 7 Days After Dose 1

  13. Percentage of Participants With Abnormalities in Chemistry Parameters Before Dose 2: Phase 1

    Chemistry parameters that were assessed included bilirubin, AST, ALT, ALP, urea nitrogen, creatinine. Abnormal parameters were determined by following criteria: bilirubin: \>1.5x ULN, AST: \>3.0x ULN, ALT: \>3.0x ULN, ALP: \>3.0x ULN, urea nitrogen: \>1.3x ULN, creatinine: \>1.3x ULN. Abnormal values reported for this outcome measure are for bilirubin.

    Time frame: Before Dose 2

  14. Percentage of Participants With Abnormalities in Chemistry Parameters 7 Days After Dose 2: Phase 1

    Chemistry parameters that were assessed included bilirubin, AST, ALT, ALP, urea nitrogen, creatinine. Abnormal parameters were determined by following criteria: bilirubin: \>1.5x ULN, AST: \>3.0x ULN, ALT: \>3.0x ULN, ALP: \>3.0x ULN, urea nitrogen: \>1.3x ULN, creatinine: \>1.3x ULN. Abnormal values reported for this outcome measure are for bilirubin.

    Time frame: 7 Days After Dose 2

  15. Percentage of Participants With Grade Shift in Hematology Parameters 1 Day After Dose 1: Phase 1

    Percentage of participants with grade shift in hematology parameters reported in this outcome measure. Grade(G)1: Mild, G2:Moderate, G3:Severe, G4:potentially life threatening. Hemoglobin(Female): G1: 11.0 - 12.0grams per deciliter(g/dL), G2: 9.5 - 10.9, G3: 8.0 - 9.4, G4: \<8.0. Hemoglobin(Male): G1: 12.5 - 13.5, G2: 10.5 - 12.4, G3: 8.5 - 10.4, G4: \<8.5. WBC decrease(cells/mm3):G1: 2,500 - 3,500, G2: 1,500 - 2,499, G3: 1,000 - 1,499, G4: \<1,000 Lymphocytes decrease(cells/mm3): G1: 750 - 1,000, G2: 500 - 749, G3: 250 - 499, G4: \<250. Eosinophils(cells/mm3):G1: 650 - 1500, G2: 1501 - 5000, G3: \>5000, G4:Hypereosinophilic. Platelets decreased(cells/mm3): G1: 125,000 - 140,000, G2: 100,000 - 124,000, G3: 25,000 - 99,000, G4: \<25,000. Urea Nitrogen (mg/dl): G1: 23-26; G2:27-31; G3: \>31; G4: requires dialysis. Only parameters where grade shift was observed were reported.

    Time frame: 1 Day After Dose 1

  16. Percentage of Participants With Grade Shift in Hematology Parameters 7 Days After Dose 1: Phase 1

    Percentage of participants with grade shift in hematology parameters reported in this outcome measure. Grade(G)1: Mild, G2:Moderate, G3:Severe, G4:potentially life threatening. Hemoglobin(Female): G1: 11.0 - 12.0grams per deciliter(g/dL), G2: 9.5 - 10.9, G3: 8.0 - 9.4, G4: \<8.0. Hemoglobin(Male): G1: 12.5 - 13.5, G2: 10.5 - 12.4, G3: 8.5 - 10.4, G4: \<8.5. WBC decrease(cells/mm3):G1: 2,500 - 3,500, G2: 1,500 - 2,499, G3: 1,000 - 1,499, G4: \<1,000 Lymphocytes decrease(cells/mm3): G1: 750 - 1,000, G2: 500 - 749, G3: 250 - 499, G4: \<250. Eosinophils(cells/mm3):G1: 650 - 1500, G2: 1501 - 5000, G3: \>5000, G4:Hypereosinophilic. Platelets decreased(cells/mm3): G1: 125,000 - 140,000, G2: 100,000 - 124,000, G3: 25,000 - 99,000, G4: \<25,000. Urea Nitrogen (mg/dl): G1: 23-26; G2:27-31; G3: \>31; G4: requires dialysis. Only parameters where grade shift was observed were reported.

    Time frame: 7 Days After Dose 1

  17. Percentage of Participants With Grade Shift in Hematology Parameters Before Dose 2: Phase 1

    Percentage of participants with grade shift in hematology parameters reported in this outcome measure. Grade(G)1: Mild, G2:Moderate, G3:Severe, G4:potentially life threatening. Hemoglobin(Female): G1: 11.0 - 12.0grams per deciliter(g/dL), G2: 9.5 - 10.9, G3: 8.0 - 9.4, G4: \<8.0. Hemoglobin(Male): G1: 12.5 - 13.5, G2: 10.5 - 12.4, G3: 8.5 - 10.4, G4: \<8.5. WBC decrease(cells/mm3):G1: 2,500 - 3,500, G2: 1,500 - 2,499, G3: 1,000 - 1,499, G4: \<1,000 Lymphocytes decrease(cells/mm3): G1: 750 - 1,000, G2: 500 - 749, G3: 250 - 499, G4: \<250. Eosinophils(cells/mm3):G1: 650 - 1500, G2: 1501 - 5000, G3: \>5000, G4:Hypereosinophilic. Platelets decreased(cells/mm3): G1: 125,000 - 140,000, G2: 100,000 - 124,000, G3: 25,000 - 99,000, G4: \<25,000. Urea Nitrogen (mg/dl): G1: 23-26; G2:27-31; G3: \>31; G4: requires dialysis. Only parameters where grade shift was observed were reported.

    Time frame: Before Dose 2

  18. Percentage of Participants With Grade Shift in Hematology Parameters 7 Days After Dose 2: Phase 1

    Percentage of participants with grade shift in hematology parameters reported in this outcome measure. Grade(G)1: Mild, G2:Moderate, G3:Severe, G4:potentially life threatening. Hemoglobin(Female): G1: 11.0 - 12.0grams per deciliter(g/dL), G2: 9.5 - 10.9, G3: 8.0 - 9.4, G4: \<8.0. Hemoglobin(Male): G1: 12.5 - 13.5, G2: 10.5 - 12.4, G3: 8.5 - 10.4, G4: \<8.5. WBC decrease(cells/mm3):G1: 2,500 - 3,500, G2: 1,500 - 2,499, G3: 1,000 - 1,499, G4: \<1,000 Lymphocytes decrease(cells/mm3): G1: 750 - 1,000, G2: 500 - 749, G3: 250 - 499, G4: \<250. Eosinophils(cells/mm3):G1: 650 - 1500, G2: 1501 - 5000, G3: \>5000, G4:Hypereosinophilic. Platelets decreased(cells/mm3): G1: 125,000 - 140,000, G2: 100,000 - 124,000, G3: 25,000 - 99,000, G4: \<25,000. Urea Nitrogen (mg/dl): G1: 23-26; G2:27-31; G3: \>31; G4: requires dialysis. Only parameters where grade shift was observed were reported.

    Time frame: 7 Days After Dose 2

  19. Percentage of Participants With Grade Shift in Chemistry Parameters 1 Day After Dose 1: Phase 1

    Percentage of participants with grade shift in chemistry were reported in this outcome measure. G1: Mild, G2: Moderate, G3: Severe, G4: potentially life threatening. BUN(milligram per deciliter \[mg/dL\]): G1: 23 - 26, G2: 27 - 31, G3: \>31, G4: required dialysis. Creatinine(mg/dL): G1: 1.5 - 1.7, G2: 1.8 - 2.0, G3: 2.1 - 2.5, G4: \> 2.5 or required dialysis. Alkaline phosphate(increase by factor): G1: 1.1 - 2.0 x ULN G2: 2.1 - 3.0 x ULN G3: 3.1 -10 x ULN, G4: \>10 x ULN. Liver function tests(ALT, AST increase by factor): G1: 1.1 - 2.5 x ULN G2: 2.6 - 5.0 x ULN G3: 5.1 - 10 x ULN, G4: \>10 x ULN. Bilirubin(when accompanied by any increase in liver function test - increase by factor): G1: 1.1 - 1.25 x ULN G2: 1.26 - 1.5 x ULN G3: 1.51 - 1.75 x ULN, G4: \>1.75 x ULN. Bilirubin(when liver function test is normal - increase by factor): G1: 1.1 - 1.5 x ULN, G2: 1.6 - 2.0 x ULN, G3: 2.0 - 3.0 x ULN, G4: \>3.0 x ULN. Only parameters where grade shift was observed were reported.

    Time frame: 1 Day After Dose 1

  20. Percentage of Participants With Grade Shift in Chemistry Parameters 7 Days After Dose 1: Phase 1

    Percentage of participants with grade shift in chemistry were reported in this outcome measure. G1: Mild, G2: Moderate, G3: Severe, G4: potentially life threatening. BUN(mg/dL): G1: 23 - 26, G2: 27 - 31, G3: \>31, G4: required dialysis. Creatinine(mg/dL): G1: 1.5 - 1.7, G2: 1.8 - 2.0, G3: 2.1 - 2.5, G4: \> 2.5 or required dialysis. Alkaline phosphate(increase by factor): G1: 1.1 - 2.0 x ULN G2: 2.1 - 3.0 x ULN G3: 3.1 -10 x ULN, G4: \>10 x ULN. Liver function tests(ALT, AST increase by factor): G1: 1.1 - 2.5 x ULN G2: 2.6 - 5.0 x ULN G3: 5.1 - 10 x ULN, G4: \>10 x ULN. Bilirubin(when accompanied by any increase in liver function test - increase by factor): G1: 1.1 - 1.25 x ULN G2: 1.26 - 1.5 x ULN G3: 1.51 - 1.75 x ULN, G4: \>1.75 x ULN. Bilirubin(when liver function test is normal - increase by factor): G1: 1.1 - 1.5 x ULN, G2: 1.6 - 2.0 x ULN, G3: 2.0 - 3.0 x ULN, G4: \>3.0 x ULN. Only parameters where grade shift was observed were reported.

    Time frame: 7 Days After Dose 1

  21. Percentage of Participants With Grade Shift in Chemistry Parameters Before Dose 2: Phase 1

    Percentage of participants with grade shift in chemistry were reported in this outcome measure. G1: Mild, G2: Moderate, G3: Severe, G4: potentially life threatening. BUN(mg/dL): G1: 23 - 26, G2: 27 - 31, G3: \>31, G4: required dialysis. Creatinine(mg/dL): G1: 1.5 - 1.7, G2: 1.8 - 2.0, G3: 2.1 - 2.5, G4: \> 2.5 or required dialysis. Alkaline phosphate(increase by factor): G1: 1.1 - 2.0 x ULN G2: 2.1 - 3.0 x ULN G3: 3.1 -10 x ULN, G4: \>10 x ULN. Liver function tests(ALT, AST increase by factor): G1: 1.1 - 2.5 x ULN G2: 2.6 - 5.0 x ULN G3: 5.1 - 10 x ULN, G4: \>10 x ULN. Bilirubin(when accompanied by any increase in liver function test - increase by factor): G1: 1.1 - 1.25 x ULN G2: 1.26 - 1.5 x ULN G3: 1.51 - 1.75 x ULN, G4: \>1.75 x ULN. Bilirubin(when liver function test is normal - increase by factor): G1: 1.1 - 1.5 x ULN, G2: 1.6 - 2.0 x ULN, G3: 2.0 - 3.0 x ULN, G4: \>3.0 x ULN. Only parameters where grade shift was observed were reported.

    Time frame: Before Dose 2

  22. Percentage of Participants With Grade Shift in Chemistry Parameters 7 Days After Dose 2: Phase 1

    Percentage of participants with grade shift in chemistry were reported in this outcome measure. G1: Mild, G2: Moderate, G3: Severe, G4: potentially life threatening. BUN(mg/dL): G1: 23 - 26, G2: 27 - 31, G3: \>31, G4: required dialysis. Creatinine(mg/dL): G1: 1.5 - 1.7, G2: 1.8 - 2.0, G3: 2.1 - 2.5, G4: \> 2.5 or required dialysis. Alkaline phosphate(increase by factor): G1: 1.1 - 2.0 x ULN G2: 2.1 - 3.0 x ULN G3: 3.1 -10 x ULN, G4: \>10 x ULN. Liver function tests(ALT, AST increase by factor): G1: 1.1 - 2.5 x ULN G2: 2.6 - 5.0 x ULN G3: 5.1 - 10 x ULN, G4: \>10 x ULN. Bilirubin(when accompanied by any increase in liver function test - increase by factor): G1: 1.1 - 1.25 x ULN G2: 1.26 - 1.5 x ULN G3: 1.51 - 1.75 x ULN, G4: \>1.75 x ULN. Bilirubin(when liver function test is normal - increase by factor): G1: 1.1 - 1.5 x ULN, G2: 1.6 - 2.0 x ULN, G3: 2.0 - 3.0 x ULN, G4: \>3.0 x ULN. Only parameters where grade shift was observed were reported.

    Time frame: 7 Days After Dose 2

  23. Percentage of Participants With Local Reactions Within 7 Days After Dose 1: Phase 2/3

    Local reactions included redness, swelling and, pain at the injection site, recorded by participants or parents/legal guardians in an e-diary. Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 cm. Redness and swelling were graded as mild (\> 2.0 to 5.0 cm), moderate (\> 5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis or exfoliative dermatitis for redness and necrosis for swelling). Pain at injection site was graded as mild (does not interfere with activity), moderate (interferes with activity), severe (prevents daily activity) and Grade 4 (emergency room visit or hospitalization for severe pain).

    Time frame: Within 7 Days after Dose 1

  24. Percentage of Participants With Local Reactions Within 7 Days After Dose 2: Phase 2/3

    Local reactions included redness, swelling and, pain at the injection site, recorded by participants or parents/legal guardians in an e-diary. Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 cm. Redness and swelling were graded as mild (\> 2.0 to 5.0 cm), moderate (\> 5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis or exfoliative dermatitis for redness and necrosis for swelling). Pain at injection site was graded as mild (does not interfere with activity), moderate (interferes with activity), severe (prevents daily activity) and Grade 4 (emergency room visit or hospitalization for severe pain).

    Time frame: Within 7 Days after Dose 2

  25. Percentage of Participants With Systemic Events Within 7 Days After Dose 1: Phase 2/3

    Systemic events included fever, fatigue, headache, chills, vomiting, diarrhea, new or worsened muscle pain, new or worsened joint pain recorded by participants or parents/legal guardians of participants using e-diary. Fever=temperature \>=38.0 deg C categorized as \>=38.0 to 38.4, \>38.4 to 38.9, \>38.9 to 40.0 and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain, new or worsened joint pain graded as mild (does not interfere with activity), moderate (some interference with activity), severe (prevents daily routine activity), Grade 4 (Emergency room visit/hospitalization). Vomiting: mild (1-2 times in 24 h), moderate (\>2 times in 24 h), severe (requires IV hydration), Grade 4 (emergency room visit/hospitalization for hypotensive shock). Diarrhea: mild (2-3 loose stools in 24h), moderate (4-5 loose stools in 24 h), severe (\>=6 loose stools in 24 h) and Grade 4 (emergency room visit/hospitalization).

    Time frame: Within 7 Days after Dose 1

  26. Percentage of Participants With Systemic Events Within 7 Days After Dose 2: Phase 2/3

    Systemic events included fever, fatigue, headache, chills, vomiting, diarrhea, new or worsened muscle pain, new or worsened joint pain recorded by participants or parents/legal guardians of participants using e-diary. Fever=temperature \>=38.0 deg C categorized as \>=38.0 to 38.4, \>38.4 to 38.9, \>38.9 to 40.0 and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain, new or worsened joint pain graded as mild (does not interfere with activity), moderate (some interference with activity), severe (prevents daily routine activity), Grade 4 (Emergency room visit/hospitalization). Vomiting: mild (1-2 times in 24 h), moderate (\>2 times in 24 h), severe (requires IV hydration), Grade 4 (emergency room visit/hospitalization for hypotensive shock). Diarrhea: mild (2-3 loose stools in 24h), moderate (4-5 loose stools in 24 h), severe (\>=6 loose stools in 24 h) and Grade 4 (emergency room visit/hospitalization).

    Time frame: Within 7 Days after Dose 2

  27. Percentage of Participants Reporting Adverse Events From Dose 1 to 1 Month After Dose 2: Phase 2/3

    An AE was any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. HIV positive participants were excluded from this analysis.

    Time frame: From Dose 1 to 1 Month After Dose 2

  28. Percentage of Participants Reporting Serious Adverse Events From Dose 1 to 6 Months After Dose 2: Phase 2/3

    An SAE was any untoward medical occurrence that occurred, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent or significant disability/ incapacity; was a congenital anomaly/birth defect and other important medical events. HIV positive participants were excluded from this analysis.

    Time frame: From Dose 1 to 6 Months After Dose 2

  29. Percentage of Participants With Local Reactions Within 7 Days After Dose 1: Phase 2

    Local reactions included redness, swelling and, pain at the injection site, recorded by participants in an e-diary. Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 cm. Redness and swelling were graded as mild (\> 2.0 to 5.0 cm), moderate (\> 5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis or exfoliative dermatitis for redness and necrosis for swelling). Pain at injection site was graded as mild (does not interfere with activity), moderate (interferes with activity), severe (prevents daily activity) and Grade 4 (emergency room visit or hospitalization for severe pain).

    Time frame: Within 7 Days after Dose 1

  30. Percentage of Participants With Local Reactions Within 7 Days After Dose 2: Phase 2

    Local reactions included redness, swelling and, pain at the injection site, recorded by participants in an e-diary. Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 cm. Redness and swelling were graded as mild (\> 2.0 to 5.0 cm), moderate (\> 5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis or exfoliative dermatitis for redness and necrosis for swelling). Pain at injection site was graded as mild (does not interfere with activity), moderate (interferes with activity), severe (prevents daily activity) and Grade 4 (emergency room visit or hospitalization for severe pain).

    Time frame: Within 7 Days after Dose 2

  31. Percentage of Participants With Systemic Events Within 7 Days After Dose 1: Phase 2

    Systemic events included fever, fatigue, headache, chills, vomiting, diarrhea, new or worsened muscle pain, new or worsened joint pain recorded by participants or parents/legal guardians of participants using e-diary. Fever=temperature \>=38.0 deg C categorized as \>=38.0 to 38.4, \>38.4 to 38.9, \>38.9 to 40.0 and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain, new or worsened joint pain graded as mild (does not interfere with activity), moderate (some interference with activity), severe (prevents daily routine activity), Grade 4 (Emergency room visit/hospitalization). Vomiting: mild (1-2 times in 24 h), moderate (\>2 times in 24 h), severe (requires IV hydration), Grade 4 (emergency room visit/hospitalization for hypotensive shock). Diarrhea: mild (2-3 loose stools in 24h), moderate (4-5 loose stools in 24 h), severe (\>=6 loose stools in 24 h) and Grade 4 (emergency room visit/hospitalization).

    Time frame: Within 7 Days after Dose 1

  32. Percentage of Participants With Systemic Events Within 7 Days After Dose 2: Phase 2

    Systemic events included fever, fatigue, headache, chills, vomiting, diarrhea, new or worsened muscle pain, new or worsened joint pain recorded by participants or parents/legal guardians of participants using e-diary. Fever=temperature \>=38.0 deg C categorized as \>=38.0 to 38.4, \>38.4 to 38.9, \>38.9 to 40.0 and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain, new or worsened joint pain graded as mild (does not interfere with activity), moderate (some interference with activity), severe (prevents daily routine activity), Grade 4 (Emergency room visit/hospitalization). Vomiting: mild (1-2 times in 24 h), moderate (\>2 times in 24 h), severe (requires IV hydration), Grade 4 (emergency room visit/hospitalization for hypotensive shock). Diarrhea: mild (2-3 loose stools in 24h), moderate (4-5 loose stools in 24 h), severe (\>=6 loose stools in 24 h) and Grade 4 (emergency room visit/hospitalization).

    Time frame: Within 7 Days After Dose 2

  33. Percentage of Participants Reporting Adverse Events From Dose 1 to 7 Days After Dose 2: Phase 2

    An AE was any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment.

    Time frame: From Dose 1 to 7 Days After Dose 2

  34. Percentage of Participants Reporting Serious Adverse Events From Dose 1 to 7 Days After Dose 2: Phase 2

    A SAE was any untoward medical occurrence that occurred, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent or significant disability/ incapacity; was a congenital anomaly/birth defect and other important medical events.

    Time frame: From Dose 1 to 7 Days After Dose 2

  35. Percentage of Participants With Local Reactions Within 7 Days After Booster Dose: BNT162b2 Experienced Participants Who Were Rerandomized to Receive 1 Booster Dose

    Local reactions included redness, swelling and, pain at the injection site, recorded by participants or parents/legal guardians in an e-diary. Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 cm. Redness and swelling were graded as mild (\> 2.0 to 5.0 cm), moderate (\> 5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis or exfoliative dermatitis for redness and necrosis for swelling). Pain at injection site was graded as mild (does not interfere with activity), moderate (interferes with activity), severe (prevents daily activity) and Grade 4 (emergency room visit or hospitalization for severe pain). HIV positive participants were excluded.

    Time frame: Within 7 Days After Booster Dose

  36. Percentage of Participants With Systemic Events Within 7 Days After Booster Dose 1: BNT162b2 Experienced Participants Who Were Rerandomized to Receive 1 Booster Dose

    Systemic events included fever, fatigue, headache, chills, vomiting, diarrhea, new or worsened muscle pain, new or worsened joint pain recorded by participants or parents/legal guardians of participants using e-diary. Fever=temperature \>=38.0 deg C categorized as \>=38.0 to 38.4, \>38.4 to 38.9, \>38.9 to 40.0 and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain, new or worsened joint pain graded as mild (does not interfere with activity), moderate (some interference with activity), severe (prevents daily routine activity), Grade 4 (Emergency room visit/hospitalization). Vomiting: mild (1-2 times in 24 h), moderate (\>2 times in 24 h), severe (requires IV hydration), Grade 4 (emergency room visit/hospitalization for hypotensive shock). Diarrhea: mild (2-3 loose stools in 24h), moderate (4-5 loose stools in 24 h), severe (\>=6 loose stools in 24 h) and Grade 4 (emergency room visit/hospitalization). HIV positive participants were excluded.

    Time frame: Within 7 Days After Booster Dose

  37. Percentage of Participants Reporting Adverse Events From First Booster Dose to 1 Month After Booster Dose: BNT162b2 Experienced Participants Who Were Rerandomized to Receive 1 Booster Dose

    An AE was any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. HIV positive participants were excluded.

    Time frame: From First Booster Dose to 1 Month After Booster Dose

  38. Percentage of Participants Reporting Serious Adverse Events From First Booster Dose to 6 Months After Booster Dose: BNT162b2 Experienced Participants Who Were Rerandomized to Receive 1 Booster Dose

    A SAE was any untoward medical occurrence that occurred, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent or significant disability/ incapacity; was a congenital anomaly/birth defect and other important medical events. HIV positive participants were excluded.

    Time frame: From First Booster Dose to 6 Months After Booster Dose

  39. Percentage of Participants With Local Reactions Within 7 Days After Booster Dose 1: BNT162b2 Experienced Participants Assigned to Receive 2 Booster Doses of BNT162b2SA

    Local reactions included redness, swelling and, pain at the injection site, recorded by participants in an e-diary. Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 cm. Redness and swelling were graded as mild (\> 2.0 to 5.0 cm), moderate (\> 5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis or exfoliative dermatitis for redness and necrosis for swelling). Pain at injection site was graded as mild (does not interfere with activity), moderate (interferes with activity), severe (prevents daily activity) and Grade 4 (emergency room visit or hospitalization for severe pain). HIV positive participants were excluded from this analysis.

    Time frame: Within 7 Days After Booster Dose 1

  40. Percentage of Participants With Local Reactions Within 7 Days After Booster Dose 2: BNT162b2 Experienced Participants Assigned to Receive 2 Booster Doses of BNT162b2SA

    Local reactions included redness, swelling and, pain at the injection site, recorded by participants in an e-diary. Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 cm. Redness and swelling were graded as mild (\> 2.0 to 5.0 cm), moderate (\> 5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis or exfoliative dermatitis for redness and necrosis for swelling). Pain at injection site was graded as mild (does not interfere with activity), moderate (interferes with activity), severe (prevents daily activity) and Grade 4 (emergency room visit or hospitalization for severe pain). HIV positive participants were excluded from this analysis.

    Time frame: Within 7 Days after Booster Dose 2

  41. Percentage of Participants With Systemic Events Within 7 Days After Booster Dose 1: BNT162b2 Experienced Participants Assigned to Receive 2 Booster Doses of BNT162b2SA

    Systemic events included fever, fatigue, headache, chills, vomiting, diarrhea, new or worsened muscle pain, new or worsened joint pain recorded by participants or parents/legal guardians of participants using e-diary. Fever=temperature \>=38.0 deg C categorized as \>=38.0 to 38.4, \>38.4 to 38.9, \>38.9 to 40.0 and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain, new or worsened joint pain graded as mild (does not interfere with activity), moderate (some interference with activity), severe (prevents daily routine activity), Grade 4 (Emergency room visit/hospitalization). Vomiting: mild (1-2 times in 24 h), moderate (\>2 times in 24 h), severe (requires IV hydration), Grade 4 (emergency room visit/hospitalization for hypotensive shock). Diarrhea: mild (2-3 loose stools in 24h), moderate (4-5 loose stools in 24 h), severe (\>=6 loose stools in 24 h) and Grade 4 (emergency room visit/hospitalization). HIV positive participants excluded.

    Time frame: Within 7 Days After Booster Dose 1

  42. Percentage of Participants With Systemic Events Within 7 Days After Booster Dose 2: BNT162b2 Experienced Participants Assigned to Receive 2 Booster Doses of BNT162b2SA

    Systemic events included fever, fatigue, headache, chills, vomiting, diarrhea, new or worsened muscle pain, new or worsened joint pain recorded by participants or parents/legal guardians of participants using e-diary. Fever=temperature \>=38.0 deg C categorized as \>=38.0 to 38.4, \>38.4 to 38.9, \>38.9 to 40.0 and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain, new or worsened joint pain graded as mild (does not interfere with activity), moderate (some interference with activity), severe (prevents daily routine activity), Grade 4 (Emergency room visit/hospitalization). Vomiting: mild (1-2 times in 24 h), moderate (\>2 times in 24 h), severe (requires IV hydration), Grade 4 (emergency room visit/hospitalization for hypotensive shock). Diarrhea: mild (2-3 loose stools in 24h), moderate (4-5 loose stools in 24 h), severe (\>=6 loose stools in 24 h) and Grade 4 (emergency room visit/hospitalization). HIV positive participants excluded.

    Time frame: Within 7 Days After Booster Dose 2

  43. Percentage of Participants Reporting Adverse Events From First Booster Dose to 1 Month After Second Booster Dose: BNT162b2 Experienced Participants Assigned to Receive 2 Booster Doses of BNT162b2SA

    An AE was any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. HIV positive participants were excluded.

    Time frame: From First Booster Dose to 1 Month After Second Booster Dose

  44. Percentage of Participants Reporting Serious Adverse Events From First Booster Dose to 5 Months After Second Booster Dose: BNT162b2 Experienced Participants Assigned to Receive 2 Booster Doses of BNT162b2SA

    An SAE was any untoward medical occurrence that occurred, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent or significant disability/ incapacity; was a congenital anomaly/birth defect and other important medical events. HIV positive participants were excluded.

    Time frame: From First Booster Dose to 5 Months After Second Booster Dose

  45. Percentage of Participants With Local Reactions Within 7 Days After Dose 1: BNT162b2 Naive Participants Who Were Enrolled to Receive BNT162b2SA

    Local reactions included redness, swelling and, pain at the injection site, recorded by participants in an e-diary. Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 cm. Redness and swelling were graded as mild (\> 2.0 to 5.0 cm), moderate (\> 5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis or exfoliative dermatitis for redness and necrosis for swelling). Pain at injection site was graded as mild (does not interfere with activity), moderate (interferes with activity), severe (prevents daily activity) and Grade 4 (emergency room visit or hospitalization for severe pain). HIV positive participants were excluded.

    Time frame: Within 7 Days After Dose 1

  46. Percentage of Participants With Local Reactions Within 7 Days After Dose 2: BNT162b2 Naive Participants Who Were Enrolled to Receive BNT162b2SA

    Local reactions included redness, swelling and, pain at the injection site, recorded by participants in an e-diary. Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 cm. Redness and swelling were graded as mild (\> 2.0 to 5.0 cm), moderate (\> 5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis or exfoliative dermatitis for redness and necrosis for swelling). Pain at injection site was graded as mild (does not interfere with activity), moderate (interferes with activity), severe (prevents daily activity) and Grade 4 (emergency room visit or hospitalization for severe pain). HIV positive participants were excluded.

    Time frame: Within 7 Days After Dose 2

  47. Percentage of Participants With Systemic Events Within 7 Days After Dose 1: BNT162b2 Naive Participants Who Were Enrolled to Receive BNT162b2SA

    Systemic events included fever, fatigue, headache, chills, vomiting, diarrhea, new or worsened muscle pain, new or worsened joint pain recorded by participants or parents/legal guardians of participants using e-diary. Fever=temperature \>=38.0 deg C categorized as \>=38.0 to 38.4, \>38.4 to 38.9, \>38.9 to 40.0 and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain, new or worsened joint pain graded as mild (does not interfere with activity), moderate (some interference with activity), severe (prevents daily routine activity), Grade 4 (Emergency room visit/hospitalization). Vomiting: mild (1-2 times in 24 h), moderate (\>2 times in 24 h), severe (requires IV hydration), Grade 4 (emergency room visit/hospitalization for hypotensive shock). Diarrhea: mild (2-3 loose stools in 24h), moderate (4-5 loose stools in 24 h), severe (\>=6 loose stools in 24 h) and Grade 4 (emergency room visit/hospitalization). HIV positive participants were excluded.

    Time frame: Within 7 Days After Dose 1

  48. Percentage of Participants With Systemic Events Within 7 Days After Dose 2: BNT162b2 Naive Participants Who Were Enrolled to Receive BNT162b2SA

    Systemic events included fever, fatigue, headache, chills, vomiting, diarrhea, new or worsened muscle pain, new or worsened joint pain recorded by participants or parents/legal guardians of participants using e-diary. Fever=temperature \>=38.0 deg C categorized as \>=38.0 to 38.4, \>38.4 to 38.9, \>38.9 to 40.0 and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain, new or worsened joint pain graded as mild (does not interfere with activity), moderate (some interference with activity), severe (prevents daily routine activity), Grade 4 (Emergency room visit/hospitalization). Vomiting: mild (1-2 times in 24 h), moderate (\>2 times in 24 h), severe (requires IV hydration), Grade 4 (emergency room visit/hospitalization for hypotensive shock). Diarrhea: mild (2-3 loose stools in 24h), moderate (4-5 loose stools in 24 h), severe (\>=6 loose stools in 24 h) and Grade 4 (emergency room visit/hospitalization). HIV positive participants were excluded.

    Time frame: Within 7 Days After Dose 2

  49. Percentage of Participants Reporting Adverse Events From Dose 1 to 1 Month After Dose 2: BNT162b2-Naïve Participants Who Were Enrolled to Receive BNT162b2SA

    An AE was any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. HIV positive participants were excluded.

    Time frame: From Dose 1 Through 1 Month After Dose 2

  50. Percentage of Participants Reporting Serious Adverse Events From Dose 1 to 6 Months After Dose 2: BNT162b2-Naïve Participants Who Were Enrolled to Receive BNT162b2SA

    A SAE was any untoward medical occurrence that occurred, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent or significant disability/ incapacity; was a congenital anomaly/birth defect and other important medical events. HIV positive participants were excluded.

    Time frame: From Dose 1 to 6 Months After Dose 2

  51. Percentage of Participants With Local Reactions Within 7 Days After Booster Dose: BNT162b2-Experienced Participants Who Were Rerandomized to Receive 1 Booster Dose of BNT162b2 (Lower Dose)

    Local reactions included redness, swelling and, pain at the injection site, recorded by participants in an e-diary. Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 cm. Redness and swelling were graded as mild (\> 2.0 to 5.0 cm), moderate (\> 5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis or exfoliative dermatitis for redness and necrosis for swelling). Pain at injection site was graded as mild (does not interfere with activity), moderate (interferes with activity), severe (prevents daily activity) and Grade 4 (emergency room visit or hospitalization for severe pain). HIV positive participants were excluded.

    Time frame: Within 7 days After Booster Dose

  52. Percentage of Participants With Systemic Events Within 7 Days After Booster Dose: BNT162b2-Experienced Participants Who Were Rerandomized to Receive 1 Booster Dose of BNT162b2 (Lower Dose)

    Systemic events included fever, fatigue, headache, chills, vomiting, diarrhea, new or worsened muscle pain, new or worsened joint pain recorded by participants or parents/legal guardians of participants using e-diary. Fever=temperature \>=38.0 deg C categorized as \>=38.0 to 38.4, \>38.4 to 38.9, \>38.9 to 40.0 and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain, new or worsened joint pain graded as mild (does not interfere with activity), moderate (some interference with activity), severe (prevents daily routine activity), Grade 4 (Emergency room visit/hospitalization). Vomiting: mild (1-2 times in 24 h), moderate (\>2 times in 24 h), severe (requires IV hydration), Grade 4 (emergency room visit/hospitalization for hypotensive shock). Diarrhea: mild (2-3 loose stools in 24h), moderate (4-5 loose stools in 24 h), severe (\>=6 loose stools in 24 h) and Grade 4 (emergency room visit/hospitalization). HIV positive participants were excluded.

    Time frame: Within 7 days After Booster Dose

  53. Percentage of Participants Reporting Adverse Events From Booster Dose to 1 Month After Booster Dose: BNT162b2-Experienced Participants Who Were Rerandomized to Receive 1 Booster Dose of BNT162b2 (Lower Dose)

    An AE was any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. HIV positive participants were excluded.

    Time frame: From Booster Dose to 1 Months After Booster Dose

  54. Percentage of Participants Reporting Serious Adverse Events From Booster Dose to 6 Months After Booster Dose: BNT162b2-Experienced Participants Who Were Rerandomized to Receive 1 Booster Dose of BNT162b2 (Lower Dose)

    A SAE was any untoward medical occurrence that occurred, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent or significant disability/ incapacity; was a congenital anomaly/birth defect and other important medical events. HIV positive participants were excluded.

    Time frame: From Booster Dose to 6 Months after Booster Dose

  55. COVID-19 Incidence Based on Central Laboratory or Locally Confirmed Nucleic Acid Amplification Test (NAAT) in Participants Without Serological or Virological Evidence: Phase 2/3

    Occurrences of first COVID-19 infection in participants followed up based on central laboratory or locally confirmed NAAT in participants, without serological or virological evidence of prior SARS-CoV-2 infection were reported in this outcome measure. HIV positive participants were excluded from this analysis.

    Time frame: From 7 days after Dose 2 (Surveillance time [1000 person-years]: BNT162b2 - 6.247, Placebo - 6.003)

  56. COVID-19 Incidence Based on Central Laboratory or Locally Confirmed Nucleic Acid Amplification Test (NAAT) in Participants Without Serological or Virological Evidence: Phase 2/3 (Analysis for EUA)

    Occurrences of first COVID-19 infection in participants followed up based on central laboratory or locally confirmed NAAT in participants, without serological or virological evidence of prior SARS-CoV-2 infection (analysis for EUA) were reported in this outcome measure.

    Time frame: From 7 days after Dose 2 (Surveillance time [1000 person-years]: BNT162b2 - 2.214, Placebo - 2.222)

  57. COVID-19 Incidence Based on Central Laboratory or Locally Confirmed Nucleic Acid Amplification Test (NAAT) in Participants With or Without Serological or Virological Evidence: Phase 2/3

    Occurrences of first COVID-19 infection in participants followed up based on central laboratory or locally confirmed NAAT in participants, with or without serological or virological evidence of prior SARS-CoV-2 infection were reported in this outcome measure.

    Time frame: From 7 days after Dose 2 (Surveillance time [1000 person-years]: BNT162b2 - 6.509, Placebo - 6.274)

  58. COVID-19 Incidence Based on Central Laboratory or Locally Confirmed Nucleic Acid Amplification Test (NAAT) in Participants With or Without Serological or Virological Evidence: Phase 2/3 (Analysis for EUA)

    Occurrences of first COVID-19 infection in participants followed up based on central laboratory or locally confirmed NAAT in participants, with or without serological or virological evidence (analysis for EUA) of prior SARS-CoV-2 infection were reported in this outcome measure. HIV positive participants were excluded from this analysis.

    Time frame: From 7 days after Dose 2 (Surveillance time [1000 person-years]: BNT162b2 - 2.332, Placebo - 2.345)

  59. GMR Based on Geometric Mean Titer (N1a) - Comparison of 1 Month After Dose 2 Between Vaccine Groups: BNT162b2-Naïve Participants Without Evidence of Infection (N1a) up to 1 Month After Dose 2: Phase 3

    GMR based on geometric mean titer, comparison of 1 month after dose 2 between vaccine groups: BNT162b2-naive participants without evidence of infection up to 1 month after dose 2 were reported in this outcome measure. HIV positive participants excluded from this analysis.

    Time frame: 1 Month After Dose 2

  60. Percentage Difference of Participants Achieving Seroresponse Comparison (N1b) of 1 Month After Dose 2 Between Vaccine Groups: BNT162b2-Naïve Participants Without Evidence of Infection up to 1 Month After Dose 2: Phase 3

    Seroresponse was defined as achieving a \>=4-fold rise from baseline (before Dose 1). If the baseline measurement was below the lower limit of quantification (LLOQ), a post vaccination assay result \>=4 × LLOQ was considered a seroresponse. HIV positive participants excluded.

    Time frame: 1 Month After Dose 2

  61. GMR of Neutralizing Titers (E1a) - Comparison of 1 Month After Booster Dose to 1 Month After Dose 2: BNT162b2-Experienced Participants That Received a Booster Dose of BNT162b2: Phase 3

    GMR based on geometric mean titer, comparison of 1 month after booster dose to 1 month after dose 2 for BNT162b2-experienced participants were reported in this outcome measure. HIV positive participants excluded from this analysis.

    Time frame: 1 Month After Booster Dose to 1 Month After Dose 2

  62. Percentage Difference of Participants Achieving Seroresponse (E1b) - Comparison of 1 Month After Booster Dose to 1 Month After Dose 2: BNT162b2-Experienced Participants That Received a Booster Dose of BNT162b2: Phase 3

    Percentage difference of participants achieving seroresponse - comparison of 1 month after booster dose to 1 month after Dose 2 BNT162b2-experienced participants without evidence of infection up to 1 month after booster dose who were rerandomized to receive 1 booster dose were reported in this outcome measure. Seroresponse was defined as achieving a \>=4-fold rise from baseline (before Dose 1). If the baseline measurement was below the LLOQ, a postvaccination assay result \>=4 × LLOQ was considered a seroresponse. HIV positive participants excluded.

    Time frame: 1 Month After Booster Dose to 1 Month After Dose 2

  63. GMR of Neutralizing Titers (E2a) - Comparison of 1 Month After Booster Dose to 1 Month After Dose 2: BNT162b2-Experienced Participants: Phase 3

    GMR of neutralizing titers (E2a) for comparison of 1 month after booster dose to 1 month after dose 2: BNT162b2-experienced participants in Phase 3 were reported in this outcome measure. HIV positive participants were excluded from this analysis.

    Time frame: 1 Month After Booster Dose to 1 Month After Dose 2

  64. Percentage Difference of Participants Achieving Seroresponse (E2b) - Comparison of 1 Month After Booster Dose to 1 Month After Dose 2: BNT162b2-Experienced Participants: Phase 3

    Percentage difference of participants achieving seroresponse - comparison of 1 month after booster dose to 1 month after Dose 2 BNT162b2-experienced participants without evidence of infection up to 1 month after booster dose who were rerandomized to receive 1 booster dose were reported in this outcome measure. Seroresponse was defined as achieving a \>=4-fold rise from baseline (before Dose 1). If the baseline measurement was below the LLOQ, a postvaccination assay result \>=4 × LLOQ was considered a seroresponse. HIV positive participants excluded.

    Time frame: 1 Month After Booster Dose to 1 Month After Dose 2

Secondary outcomes

  1. Geometric Mean Titers (GMTs) of Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Titers: Phase 1

    GMTs of severe acute respiratory syndrome coronavirus 2 neutralizing titers were reported in this outcome measure. SARS-CoV-2 neutralization assay - NT50 and SARS-CoV-2 neutralization assay - NT90 were evaluated and reported in this outcome measure.

    Time frame: 7, 21 days after Dose 1; 7, 14 days and 1, 6 months after Dose 2

  2. Geometric Mean Concentrations (GMCs) of Severe Acute Respiratory Syndrome Coronavirus 2: S1-binding and RBD-binding IgG Level Assay: Phase 1

    GMCs of severe acute respiratory syndrome coronavirus S1-binding and RBD-binding IgG level were reported in this outcome measure.

    Time frame: 7, 21 days after Dose 1; 7, 14 days and 1, 6 months after Dose 2

  3. Geometric Mean Fold Rise (GMFR) of SARS-CoV-2 Neutralizing Titers: Phase 1

    GMFR of SARS-CoV-2 neutralizing titers were reported in this outcome measure. HIV positive participants excluded.

    Time frame: 7, 21 days after Dose 1; 7, 14 days and 1, 6 months after Dose 2

  4. Geometric Mean Fold Rise (GMFR) of SARS-CoV-2 S1-binding and RBD-binding IgG Level Assay: Phase 1

    GMFR of SARS-CoV-2 S1-binding and RBD-binding IgG level assay in Phase 1 were reported in this outcome measure. HIV positive participants were excluded from this analysis.

    Time frame: 7, 21 days after Dose 1; 7, 14 days and 1, 6 months after Dose 2

  5. Percentage of Participants Achieving a >= 4-Fold Rise From Before Vaccination to After Vaccination: Neutralizing Titers: Phase 1

    Percentage of participants achieving a \>= 4-fold rise from before vaccination to after vaccination: neutralizing titers in Phase 1 were reported in this outcome measure. HIV positive participants were excluded from this analysis.

    Time frame: 7, 21 days after Dose 1; 7, 14 days and 1, 6 months after Dose 2

  6. Percentage of Participants Achieving a >= 4-Fold Rise From Before Vaccination to After Vaccination: S1-binding and RBD-binding IgG Level Assay: Phase 1

    Percentage of participants achieving a \>= 4-fold rise from before vaccination to after vaccination: S1-binding and RBD-binding IgG level assay in Phase 1 were reported in this outcome measure. HIV positive participants were excluded from this analysis.

    Time frame: From before vaccination to after vaccination

  7. GMR Based on Reference Strain NT - Comparison of Participants 12 to 15 Years of Age to Participants 16 to 25 Years of Age- Participants Without Evidence of Infection up to 1 Month After Dose 2 - Dose 2 Evaluable Immunogenicity Population: Phase2/3

    GMR based on reference strain NT, comparison of participants 12 to 15 years of age to participants 16 to 25 years of age of participants without evidence of infection up to 1 month after dose 2 in Phase2/3 were reported in this outcome measure. HIV positive participants were excluded from this analysis.

    Time frame: 1 Month After Dose 2

  8. Incidence of Asymptomatic SARS-CoV-2 Infection Per 1000 Person Years Follow-up Without Serological or Virological Evidence (Up to Start of Asymptomatic Surveillance Period) of Past Infection: Phase 3

    Incidence of asymptomatic SARS-CoV-2 infection per 1000 person years follow-up without serological or virological evidence (up to start of asymptomatic surveillance period) of past infection were reported in this outcome measure.

    Time frame: From start of asymptomatic surveillance (Surveillance time [1000 person-years]: BNT162b2 - 0.383; Placebo - 0.200

  9. Incidence of Asymptomatic SARS-CoV-2 Infection Per 1000 Person Years Follow-up Without Serological or Virological Evidence of Past Infection Based on N-binding Antibody Seroconversion: Phase 3

    Incidence of asymptomatic SARS-CoV-2 infection per 1000 person years follow-up without serological or virological evidence of past infection based on N-binding antibody seroconversion were reported in this outcome measure.

    Time frame: From Dose 2 to the end of the surveillance period ([1000 person-years]: BNT162b2 - 13.840, Placebo - 6.481)

  10. COVID-19 Incidence Per 1000 Person-Years of Follow-up With or Without Evidence of Infection 7 Days After Second Dose of BNT162b2 Based on CDC-Defined Symptoms (Analysis for EUA): Phase 3

    COVID-19 incidence per 1000 person years follow-up with or without the evidence of infection were reported in this outcome measure.

    Time frame: From 7 Days After Dose 2 (Surveillance time [1000 person-years]: BNT162b2 - 2.330, Placebo - 2.343)

  11. COVID-19 Incidence Per 1000 Person-Years of Follow-up With or Without Evidence of Infection 14 Days After Second Dose of BNT162b2 Based on CDC-Defined Symptoms (Analysis for EUA): Phase 3

    COVID-19 incidence per 1000 person years follow-up with or without the evidence of infection were reported in this outcome measure.

    Time frame: From 14 Days After Dose 2 (Surveillance time [1000 person-years]: BNT162b2 - 1.983, Placebo - 1.993)

  12. COVID-19 Incidence Per 1000 Person-Years of Follow-up Without Evidence of Infection: 7 Days After Dose 2 Based on CDC Defined Symptoms (Analysis for EUA): Phase 3

    COVID-19 incidence per 1000 person years follow-up without the evidence of infection (analysis for EUA) were reported in this outcome measure.

    Time frame: From 7 days after Dose 2 (Surveillance time [1000 person-years]: BNT162b2 - 2.213; Placebo - 2.220)

  13. COVID-19 Incidence Per 1000 Person-Years of Follow-up Without Evidence of Infection: 14 Days After Dose 2 Based on CDC Defined Symptoms (Analysis for EUA): Phase 3

    COVID-19 incidence per 1000 person years follow-up without the evidence of infection were reported in this outcome measure.

    Time frame: From 14 days after Dose 2 (Surveillance time [1000 person-years]: BNT162b2 - 1.886; Placebo - 1.891)

  14. Severe COVID-19 Incidence Per 1000 Person-Years of Follow-up With or Without Evidence of Infection: 7 Days After Dose 2: Phase 3

    Severe COVID-19 incidence per 1000 person years follow-up with or without the evidence of infection were reported in this outcome measure.

    Time frame: From 7 days after Dose 2 (Surveillance time [1000 person-years]: BNT162b2 - 6.522; Placebo - 6.404)

  15. Severe COVID-19 Incidence Per 1000 Person-Years of Follow-up With or Without Evidence of Infection: 14 Days After Dose 2 (Analysis for EUA): Phase 3

    Severe COVID-19 incidence per 1000 person years follow-up with or without the evidence of infection (analysis for EUA) were reported in this outcome measure.

    Time frame: From 14 days after Dose 2 (Surveillance time [1000 person-years]: BNT162b2 - 1.985; Placebo - 2.007)

  16. Severe COVID-19 Incidence Per 1000 Person-Years of Follow-up Without Evidence of Infection: 7 Days After Dose 2: Phase 3

    Severe COVID-19 incidence per 1000 person years follow-up without the evidence of infection were reported in this outcome measure.

    Time frame: From 7 days after Dose 2 (Surveillance time [1000 person-years]: BNT162b2 - 6.257; Placebo - 6.120)

  17. Severe COVID-19 Incidence Per 1000 Person-Years of Follow-up Without Evidence of Infection: 14 Days After Dose 2 (Analysis for EUA): Phase 3

    Severe COVID-19 incidence per 1000 person years follow-up without the evidence of infection (analysis for EUA) were reported in this outcome measure.

    Time frame: From 14 days after Dose 2 (Surveillance time [1000 person-years]: BNT162b2 - 1.888; Placebo - 1.901)

  18. COVID-19 Incidence Per 1000 Person-Years of With or Without Evidence of Infection: 14 Days After Dose 2 (EUA Analysis): Phase 3

    COVID-19 incidence per 1000 person years follow-up with or without the evidence of infection (analysis for EUA) were reported in this outcome measure.

    Time frame: From 14 days after Dose 2 (Surveillance time [1000 person-years]: BNT162b2 - 1.984; Placebo - 1.995)

  19. COVID-19 Incidence Per 1000 Person-Years of Follow-up Without Evidence of Infection: 14 Days After Dose 2 (EUA Analysis): Phase 3

    COVID-19 incidence per 1000 person years follow-up without the evidence of infection (analysis for EUA) were reported in this outcome measure.

    Time frame: From 14 days after Dose 2 (Surveillance time [1000 person-years]: BNT162b2 - 1.887; Placebo - 1.893)

  20. Percentage Difference of Participants Achieving Seroresponse (Reference Strain) 1 Month After Second Dose in BNT162b2-Naive Participants: Phase 3

    Seroresponse was defined as achieving a \>=4-fold rise from baseline (before Dose 1). If the baseline measurement was below the lower limit of quantification (LLOQ), a post vaccination assay result \>=4 × LLOQ was considered a seroresponse. HIV positive participants were excluded from this analysis.

    Time frame: 1 Month After Dose 2

  21. GMR Based on Geometric Mean Titer (Reference Strain) 1 Month After Second Dose in BNT162b2-Naive Participants: Phase 3

    GMR based on GMT (Reference Strain) 1 month after second dose of BNT162b2SA and 1 month after the second dose of BNT162b2 in BNT162b2-naive participant were reported in this outcome measure.

    Time frame: 1 Month After Dose 2

  22. GMR Based on Geometric Mean Titer of SA NT 1 Month After Second Dose of BNT162b2SA to 1 Month After the Second Dose (N2a) of BNT162b2 Naive Participants: Phase 3

    GMR based on geometric mean titer of SA NT 1 Month after second dose of BNT162b2SA to 1 Month after the second dose (N2a) of BNT162b2 naive participants of Phase 3 were reported in this outcome measure.

    Time frame: 1 month after the second dose

  23. Percentage Difference of Participants Achieving Seroresponse (N2b) Comparison of 1 Month After Dose 2 Between Vaccine Groups: BNT162b2-Naïve Participants Without Evidence of Infection up to 1 Month After Dose 2: Phase 3

    Seroresponse was defined as achieving a \>=4-fold rise from baseline (before Dose 1). If the baseline measurement was below the LLOQ, a postvaccination assay result \>=4 × LLOQ was considered a seroresponse.

    Time frame: 1 Month After Dose 2

  24. GMR of Neutralizing Titers (E3a) - Comparison of 1 Month After Booster Dose to 1 Month After Dose 2: BNT162b2-Experienced Participants That Received a Booster Dose of BNT162b2: Phase 3

    GMR of neutralizing titers (E3a) - comparison of 1 month after booster dose to 1 month after dose 2: BNT162b2-experienced participants of Phase 3 were reported in this outcome measure.

    Time frame: 1 Month After Booster Dose to 1 Month After Dose 2

  25. Percentage Difference of Participants Achieving Seroresponse (E3b) - Comparison of 1 Month After Booster Dose to 1 Month After Dose 2: BNT162b2-Experienced Participants That Received a Booster Dose of BNT162b2: Phase 3

    Percentage difference of participants achieving seroresponse (E3b) - comparison of 1 month after booster dose to 1 month after dose 2 BNT162b2-experienced participants without evidence of infection up to 1 month after booster dose who were rerandomized to receive 1 booster dose were reported in this outcome measure.

    Time frame: 1 Month After Booster Dose to 1 Month After Dose 2

  26. GMR of Neutralizing Titers (E4a) - Comparison of 1 Month After Booster Dose to 1 Month After Dose 2: BNT162b2-Experienced Participants: Phase 3

    GMR of neutralizing titers (E4a) - comparison of 1 month after booster dose to 1 month after dose 2: BNT162b2-experienced participants of Phase 3 were reported in this outcome measure.

    Time frame: 1 Month After Booster Dose to 1 Month After Dose 2

  27. Percentage Difference of Participants Achieving Seroresponse (E4b) - Comparison of 1 Month After Booster Dose to 1 Month After Dose 2: BNT162b2-Experienced Participants: Phase 3

    Percentage difference of participants achieving seroresponse (E4b) - comparison of 1 month after booster dose to 1 month after dose 2 BNT162b2-experienced participants without evidence of infection up to 1 month after booster dose who were rerandomized to receive 1 booster dose were reported in this outcome measure.

    Time frame: 1 Month After Booster Dose to 1 Month After Dose 2

  28. Percentage Difference of Participants Achieving Seroresponse for SA Variant NT Comparison of 1 Month After Second Booster Dose to 1 Month After Dose 2 of BNT162b2 in Participants Assigned to Receive 2 Booster Doses of BNT162b2SA: Phase 3

    Percentage difference of participants achieving seroresponse for SA variant NT comparison of 1 Month after second booster dose to 1 Month after Dose 2 of BNT162b2 in participants assigned to receive 2 booster doses of BNT162b2SA of Phase 3 were reported in this outcome measure.

    Time frame: 1 Month after Second Booster Dose to 1 Month After Dose 2 of BNT162b2

  29. GMR of SA Variant NT 1 Month After Second Booster Dose to 1 Month After Dose 2 of BNT162b2 in Participants Assigned to Receive 2 Booster Doses of BNT1612b2SA: Phase 3

    GMR of SA variant NT 1 month after second booster dose to 1 month after dose 2 of BNT162b2 in participants assigned to receive 2 booster doses of BNT1612b2SA were reported in this outcome measure.

    Time frame: 1 Month After Second Booster Dose to 1 Month After Dose 2 of BNT162b2

  30. Percentage Difference of Participants Achieving Seroresponse for SA Variant NT: BNT162b2-Experienced Participants Without Evidence of Infection up to 1 Month After Booster Dose Who Were Rerandomized to Receive 1 Booster Dose: Phase 3

    Percentage difference of participants achieving seroresponse for SA variant NT: BNT162b2-experienced participants without evidence of infection up to 1 month after booster dose who were rerandomized to receive 1 booster dose were reported in this outcome measure.

    Time frame: 1 Month After Booster Dose

  31. GMR of SA Variant NT: BNT162b2-Experienced Participants Without Evidence of Infection up to 1 Month After Booster Dose Who Were Rerandomized to Receive 1 Booster Dose: Phase 3

    GMR of SA Variant NT: BNT162b2-experienced participants without evidence of infection up to 1 month after booster dose who were rerandomized to receive 1 booster dose were reported in this outcome measure.

    Time frame: 1 Month After Booster Dose

07

Results

Posted Mar 25, 2026

Participant flow

Phase 1
Participant flow — Phase 1
MilestonePhase 1:BNT162b1 10 mcg Dose: 18-85 Years of AgePhase 1:BNT162b1 20 mcg Dose:18-85 Years of AgePhase 1:BNT162b1 30 mcg Dose:18-85 Years of AgePhase1:BNT162b1 100 mcg Dose:18-55 Years of AgePhase 1: Placebo: 18-85 Years of AgePhase 1: BNT162b2: 10 mcg Dose: 18-85 Years of AgePhase 1: BNT162b2: 20 mcg Dose: 18-85 Years of AgePhase 1: BNT162b2: 30 mcg Dose: 18-85 Years of AgePhase 2/3: BNT162b2 30 mcg: 12-15 Years of AgePhase 2/3: Placebo 12-15 Years of AgePhase 2/3: BNT162b2 30 mcg: >=16 Years of AgePhase 2/3: Placebo for >=16 Years of AgePhase 2/3: BNT162b2 30mcg: 12-15 Years of AgePhase 2/3: Placebo: 12-15 Years of AgePhase 2/3: BNT162b2 30 mcg >=16 Years of AgePhase 2/3: Placebo: >=16 Years of AgePhase 3: BNT162b2 SA 30 mcg: 18-55 Years of Age
Started2424241239242424000000000
Completed141813823201916000000000
Not completed10611416458000000000
Withdrew: Protocol violation55426032000000000
Withdrew: Withdrawal by subject01201000000000000
Withdrew: Lost to follow-up00010001000000000
Withdrew: No longer meets eligibility criteria50517314000000000
Withdrew: Other00002111000000000
Phase 2/3: Blinded Period
Participant flow — Phase 2/3: Blinded Period
MilestonePhase 1:BNT162b1 10 mcg Dose: 18-85 Years of AgePhase 1:BNT162b1 20 mcg Dose:18-85 Years of AgePhase 1:BNT162b1 30 mcg Dose:18-85 Years of AgePhase1:BNT162b1 100 mcg Dose:18-55 Years of AgePhase 1: Placebo: 18-85 Years of AgePhase 1: BNT162b2: 10 mcg Dose: 18-85 Years of AgePhase 1: BNT162b2: 20 mcg Dose: 18-85 Years of AgePhase 1: BNT162b2: 30 mcg Dose: 18-85 Years of AgePhase 2/3: BNT162b2 30 mcg: 12-15 Years of AgePhase 2/3: Placebo 12-15 Years of AgePhase 2/3: BNT162b2 30 mcg: >=16 Years of AgePhase 2/3: Placebo for >=16 Years of AgePhase 2/3: BNT162b2 30mcg: 12-15 Years of AgePhase 2/3: Placebo: 12-15 Years of AgePhase 2/3: BNT162b2 30 mcg >=16 Years of AgePhase 2/3: Placebo: >=16 Years of AgePhase 3: BNT162b2 SA 30 mcg: 18-55 Years of Age
Started0000000011341130220712207100000
Completed0000000032213700000
Not completed0000000011311128220502203400000
Withdrew: Protocol violation0000000000153900000
Withdrew: Withdrawal by subject000000001713925000000
Withdrew: Lost to follow-up000000004225628100000
Withdrew: Physician decision00000000005700000
Withdrew: Pregnancy00000000000100000
Withdrew: Death0000000000181600000
Withdrew: Adverse event00000000009900000
Withdrew: Refused further study procedures00000000002000000
Withdrew: Medication error without associated adverse event00000000001000000
Withdrew: No longer meets eligibility criteria0000000002162100000
Withdrew: Withdrawal by parent/guardian00000000151000000
Withdrew: Other0000000031331100000
Withdrew: Participants entered open label period0000000011191110215002135100000
Withdrew: Randomized but not vaccinated0000000031554800000
Phase 2/3: Open Label
Participant flow — Phase 2/3: Open Label
MilestonePhase 1:BNT162b1 10 mcg Dose: 18-85 Years of AgePhase 1:BNT162b1 20 mcg Dose:18-85 Years of AgePhase 1:BNT162b1 30 mcg Dose:18-85 Years of AgePhase1:BNT162b1 100 mcg Dose:18-55 Years of AgePhase 1: Placebo: 18-85 Years of AgePhase 1: BNT162b2: 10 mcg Dose: 18-85 Years of AgePhase 1: BNT162b2: 20 mcg Dose: 18-85 Years of AgePhase 1: BNT162b2: 30 mcg Dose: 18-85 Years of AgePhase 2/3: BNT162b2 30 mcg: 12-15 Years of AgePhase 2/3: Placebo 12-15 Years of AgePhase 2/3: BNT162b2 30 mcg: >=16 Years of AgePhase 2/3: Placebo for >=16 Years of AgePhase 2/3: BNT162b2 30mcg: 12-15 Years of AgePhase 2/3: Placebo: 12-15 Years of AgePhase 2/3: BNT162b2 30 mcg >=16 Years of AgePhase 2/3: Placebo: >=16 Years of AgePhase 3: BNT162b2 SA 30 mcg: 18-55 Years of Age
Started0000000000001119111021500213510
Completed0000000000005606616954104280
Not completed00000000000055944914546109230
Withdrew: Protocol violation0000000000003735125424220
Withdrew: Withdrawal by subject0000000000004952150017920
Withdrew: Lost to follow-up0000000000005955108914020
Withdrew: Physician decision0000000000000035310
Withdrew: Death0000000000000167680
Withdrew: Adverse event00000000000000460
Withdrew: Pregnancy00000000000000120
Withdrew: Withdrawal by parent/guardian0000000000001419200
Withdrew: Refused further study procedure000000000000007120
Withdrew: No longer meets eligibility criteria00000000000010711494015800
Withdrew: Other000000000000293173964736080
Phase 3: BNT162b2 Naive Participants
Participant flow — Phase 3: BNT162b2 Naive Participants
MilestonePhase 1:BNT162b1 10 mcg Dose: 18-85 Years of AgePhase 1:BNT162b1 20 mcg Dose:18-85 Years of AgePhase 1:BNT162b1 30 mcg Dose:18-85 Years of AgePhase1:BNT162b1 100 mcg Dose:18-55 Years of AgePhase 1: Placebo: 18-85 Years of AgePhase 1: BNT162b2: 10 mcg Dose: 18-85 Years of AgePhase 1: BNT162b2: 20 mcg Dose: 18-85 Years of AgePhase 1: BNT162b2: 30 mcg Dose: 18-85 Years of AgePhase 2/3: BNT162b2 30 mcg: 12-15 Years of AgePhase 2/3: Placebo 12-15 Years of AgePhase 2/3: BNT162b2 30 mcg: >=16 Years of AgePhase 2/3: Placebo for >=16 Years of AgePhase 2/3: BNT162b2 30mcg: 12-15 Years of AgePhase 2/3: Placebo: 12-15 Years of AgePhase 2/3: BNT162b2 30 mcg >=16 Years of AgePhase 2/3: Placebo: >=16 Years of AgePhase 3: BNT162b2 SA 30 mcg: 18-55 Years of Age
Started0000000000000000333
Completed0000000000000000228
Not completed0000000000000000105
Withdrew: Protocol violation00000000000000003
Withdrew: Withdrawal by subject000000000000000019
Withdrew: Lost to follow-up000000000000000050
Withdrew: Adverse event00000000000000001
Withdrew: No longer meets eligibility criteria00000000000000008
Withdrew: Other000000000000000024

Outcome measures

PrimaryPercentage of Participants With Local Reactions Within 7 Days After Dose 1: Phase 1

Local reactions included redness, swelling and, pain at the injection site, recorded by participants in an electronic diary (e-diary). Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 centimeter (cm). Redness and swelling were graded as mild (greater than \[\>\] 2.0 to 5.0 cm), moderate (\> 5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis or exfoliative dermatitis for redness and necrosis for swelling). Pain at injection site was graded as mild (does not interfere with activity), moderate (interferes with activity), severe (prevents daily activity) and Grade 4 (emergency room visit or hospitalization for severe pain).

Time frame:
Within 7 days after Dose 1
Reported as:
Number · Percentage of participants
Percentage of Participants With Local Reactions Within 7 Days After Dose 1: Phase 1
Percentage of participantsBNT162b1 10 mcg Dose: 18-55 Years of AgeBNT162b1 20 mcg Dose: 18-55 Years of AgeBNT162b1 30 mcg Dose: 18-55 Years of AgePlacebo: 18-55 Years of Age for BNT162b1BNT162b1 100 mcg Dose, 18-55 Years of AgePlacebo 18-55 Years of Age for BNT162b1 100 mcgBNT162b2 10 mcg Dose, 18-55 Years of AgeBNT162b2 20 mcg Dose, 18-55 Years of AgeBNT162b2 30 mcg Dose, 18-55 Years of AgePlacebo: 18-55 Years of Age for BNT162b2BNT162b1 10 mcg Dose, 65-85 Years of AgeBNT162b1 20 mcg Dose, 65-85 Years of AgeBNT162b1 30 mcg Dose, 65-85 Years of AgePlacebo, 65-85 Years of Age for BNT162b1BNT162b2 10 mcg Dose, 65-85 Years of AgeBNT162b2 20 mcg Dose, 65-85 Years of AgeBNT162b2 30 mcg Dose, 65-85 Years of AgePlacebo: 65-85 Years of Age for BNT162b2
Redness: Mild0 (0.0 to 26.5)0 (0.0 to 26.5)8.3 (0.2 to 38.5)0 (0.0 to 33.6)16.7 (2.1 to 48.4)0 (0.0 to 70.8)0 (0.0 to 26.5)0 (0.0 to 26.5)8.3 (0.2 to 38.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)
Redness: Moderate0 (0.0 to 26.5)0 (0.0 to 26.5)8.3 (0.2 to 38.5)0 (0.0 to 33.6)16.7 (2.1 to 48.4)0 (0.0 to 70.8)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)
Redness: Severe0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 70.8)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)
Redness: Grade 40 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 70.8)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)
Swelling: Mild0 (0.0 to 26.5)16.7 (2.1 to 48.4)8.3 (0.2 to 38.5)0 (0.0 to 33.6)25.0 (5.5 to 57.2)0 (0.0 to 70.8)16.7 (2.1 to 48.4)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)8.3 (0.2 to 38.5)0 (0.0 to 26.5)16.7 (2.1 to 48.4)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)
Swelling: Moderate0 (0.0 to 26.5)8.3 (0.2 to 38.5)8.3 (0.2 to 38.5)0 (0.0 to 33.6)16.7 (2.1 to 48.4)0 (0.0 to 70.8)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)8.3 (0.2 to 38.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)
Swelling: Severe0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 70.8)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)
Swelling: Grade 40 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 70.8)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)
Pain at injection site: Mild58.3 (27.7 to 84.8)50.0 (21.1 to 78.9)41.7 (15.2 to 72.3)0 (0.0 to 33.6)33.3 (9.9 to 65.1)66.7 (9.4 to 99.2)58.3 (27.7 to 84.8)50.0 (21.1 to 78.9)75.0 (42.8 to 94.5)0 (0.0 to 33.6)58.3 (27.7 to 84.8)83.3 (51.6 to 97.9)66.7 (34.9 to 90.1)11.1 (0.3 to 48.2)33.3 (9.9 to 65.1)58.3 (27.7 to 84.8)75.0 (42.8 to 94.5)0 (0.0 to 33.6)
Pain at injection site: Moderate0 (0.0 to 26.5)25.0 (5.5 to 57.2)58.3 (27.7 to 84.8)0 (0.0 to 33.6)58.3 (27.7 to 84.8)0 (0.0 to 70.8)8.3 (0.2 to 38.5)16.7 (2.1 to 48.4)8.3 (0.2 to 38.5)0 (0.0 to 33.6)0 (0.0 to 26.5)8.3 (0.2 to 38.5)25.0 (5.5 to 57.2)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)
Pain at injection site: Severe0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)8.3 (0.2 to 38.5)0 (0.0 to 70.8)0 (0.0 to 26.5)0 (0.0 to 26.5)8.3 (0.2 to 38.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)
Pain at injection site: Grade 40 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 70.8)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)
PrimaryPercentage of Participants With Local Reactions Within 7 Days After Dose 2: Phase 1

Local reactions included redness, swelling and, pain at the injection site, recorded by participants in an e-diary. Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 cm. Redness and swelling were graded as mild (\> 2.0 to 5.0 cm), moderate (\> 5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis or exfoliative dermatitis for redness and necrosis for swelling). Pain at injection site was graded as mild (does not interfere with activity), moderate (interferes with activity), severe (prevents daily activity) and Grade 4 (emergency room visit or hospitalization for severe pain).

Time frame:
Within 7 days after Dose 2
Reported as:
Number · Percentage of participants
Percentage of Participants With Local Reactions Within 7 Days After Dose 2: Phase 1
Percentage of participantsBNT162b1 10 mcg Dose: 18-55 Years of AgeBNT162b1 20 mcg Dose: 18-55 Years of AgeBNT162b1 30 mcg Dose: 18-55 Years of AgePlacebo: 18-55 Years of Age for BNT162b1BNT162b2 10 mcg Dose, 18-55 Years of AgeBNT162b2 20 mcg Dose, 18-55 Years of AgeBNT162b2 30 mcg Dose, 18-55 Years of AgePlacebo: 18-55 Years of Age for BNT162b2BNT162b1 10 mcg Dose, 65-85 Years of AgeBNT162b1 20 mcg Dose, 65-85 Years of AgeBNT162b1 30 mcg Dose, 65-85 Years of AgePlacebo, 65-85 Years of Age for BNT162b1BNT162b2 10 mcg Dose, 65-85 Years of AgeBNT162b2 20 mcg Dose, 65-85 Years of AgeBNT162b2 30 mcg Dose, 65-85 Years of AgePlacebo: 65-85 Years of Age for BNT162b2
Redness: Mild0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)8.3 (0.2 to 38.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)
Redness: Moderate0 (0.0 to 26.5)0 (0.0 to 26.5)16.7 (2.1 to 48.4)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)8.3 (0.2 to 38.5)8.3 (0.2 to 38.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)
Redness: Severe0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)
Redness: Grade 40 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)
Swelling: Mild0 (0.0 to 26.5)8.3 (0.2 to 38.5)8.3 (0.2 to 38.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)16.7 (2.1 to 48.4)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)
Swelling: Moderate0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.6)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)8.3 (0.2 to 38.5)16.7 (2.1 to 48.4)8.3 (0.2 to 38.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)
Swelling: Severe0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)
Swelling: Grade 40 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)
Pain at injection site: Mild75.0 (42.8 to 94.5)50.0 (21.1 to 78.9)66.7 (34.9 to 90.1)22.2 (2.8 to 60.0)50.0 (21.1 to 78.9)58.3 (27.7 to 84.8)75.0 (42.8 to 94.5)22.2 (2.8 to 60.0)50.0 (21.1 to 78.9)66.7 (34.9 to 90.1)58.3 (27.7 to 84.8)0 (0.0 to 33.6)25.0 (5.5 to 57.2)58.3 (27.7 to 84.8)50.0 (34.9 to 90.1)11.1 (0.3 to 48.2)
Pain at injection site: Moderate8.3 (0.2 to 38.5)25.0 (5.5 to 57.2)33.3 (9.9 to 65.1)0 (0.0 to 33.6)8.3 (0.2 to 38.5)25.0 (5.5 to 27.2)8.3 (0.2 to 38.5)0 (0.0 to 33.6)16.7 (2.1 to 48.4)8.3 (0.2 to 38.5)16.7 (2.1 to 48.4)0 (0.0 to 33.6)8.3 (0.2 to 38.5)0 (0.0 to 26.5)16.7 (2.1 to 48.4)0 (0.0 to 33.6)
Pain at injection site: Severe0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)
Pain at injection site: Grade 40 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)
PrimaryPercentage of Participants With Systemic Events Within 7 Days After Dose 1: Phase 1

Systemic events included fever, fatigue, headache, chills, vomiting, diarrhea, new or worsened muscle pain, new or worsened joint pain recorded by participants or parents/legal guardians of participants using e-diary. Fever=temperature \>=38.0 deg C categorized as \>=38.0 to 38.4, \>38.4 to 38.9, \>38.9 to 40.0 and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain, new or worsened joint pain graded as mild (does not interfere with activity), moderate (some interference with activity), severe (prevents daily routine activity), Grade 4 (Emergency room visit/hospitalization). Vomiting: mild (1-2 times in 24 hours\[h\]), moderate (\>2 times in 24 h), severe (requires IV hydration), Grade 4 (emergency room visit/hospitalization for hypotensive shock). Diarrhea: mild (2-3 loose stools in 24h), moderate (4-5 loose stools in 24 h), severe (\>=6 loose stools in 24 h) and Grade 4 (emergency room visit/hospitalization).

Time frame:
Within 7 days after Dose 1
Reported as:
Number · Percentage of participants
Percentage of Participants With Systemic Events Within 7 Days After Dose 1: Phase 1
Percentage of participantsBNT162b1 10 mcg Dose: 18-55 Years of AgeBNT162b1 20 mcg Dose: 18-55 Years of AgeBNT162b1 30 mcg Dose: 18-55 Years of AgePlacebo: 18-55 Years of Age for BNT162b1BNT162b1 100 mcg Dose, 18-55 Years of AgePlacebo 18-55 Years of Age for BNT162b1 100 mcgBNT162b2 10 mcg Dose, 18-55 Years of AgeBNT162b2 20 mcg Dose, 18-55 Years of AgeBNT162b2 30 mcg Dose, 18-55 Years of AgePlacebo: 18-55 Years of Age for BNT162b2BNT162b1 10 mcg Dose, 65-85 Years of AgeBNT162b1 20 mcg Dose, 65-85 Years of AgeBNT162b1 30 mcg Dose, 65-85 Years of AgePlacebo, 65-85 Years of Age for BNT162b1BNT162b2 10 mcg Dose, 65-85 Years of AgeBNT162b2 20 mcg Dose, 65-85 Years of AgeBNT162b2 30 mcg Dose, 65-85 Years of AgePlacebo: 65-85 Years of Age for BNT162b2
Fever: 38.0°C to 38.4°C0 (0.0 to 26.5)0 (0.0 to 26.5)8.3 (0.2 to 38.5)0 (0.0 to 33.6)33.3 (9.9 to 65.1)0 (0.0 to 70.8)0 (0.0 to 26.5)0 (0.0 to 26.5)8.3 (0.2 to 38.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)16.7 (2.1 to 48.4)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)
Fever: >38.4°C to 38.9°C8.3 (0.2 to 38.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)16.7 (2.1 to 48.4)0 (0.0 to 70.8)0 (0.0 to 26.5)0 (0.0 to 26.5)8.3 (0.2 to 38.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)8.3 (0.2 to 38.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)
Fever: >38.9°C to 40.0°C0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 70.8)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)
Fever: >40.0°C0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 70.8)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)
Fatigue: Mild25.0 (5.5 to 57.2)41.7 (15.2 to 72.3)25.0 (5.5 to 57.2)11.1 (0.3 to 48.2)16.7 (2.1 to 48.4)33.3 (0.8 to 90.6)25.0 (5.5 to 57.2)33.3 (9.9 to 65.1)16.7 (2.1 to 48.4)22.2 (2.8 to 60.0)16.7 (2.1 to 48.4)41.7 (15.2 to 72.3)16.7 (2.1 to 48.4)33.3 (7.5 to 70.1)8.3 (0.2 to 38.5)33.3 (9.9 to 65.1)16.7 (2.1 to 48.4)0 (0.0 to 33.6)
Fatigue: Moderate8.3 (0.2 to 38.5)25.0 (5.5 to 57.2)25.0 (5.5 to 57.2)11.1 (0.3 to 48.2)50.0 (2.1 to 78.9)0 (0.0 to 70.8)0 (0.0 to 26.5)8.3 (0.2 to 38.5)16.7 (2.1 to 48.4)11.1 (0.3 to 48.2)0 (0.0 to 26.5)16.7 (2.1 to 48.4)25.0 (5.5 to 57.2)11.1 (0.3 to 48.2)0 (0.0 to 26.5)0 (0.0 to 26.5)8.3 (0.2 to 38.5)22.2 (2.8 to 60.0)
Fatigue: Severe0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)16.7 (2.1 to 48.4)0 (0.0 to 70.8)0 (0.0 to 26.5)0 (0.0 to 26.5)8.3 (0.2 to 38.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)8.3 (0.2 to 38.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)
Fatigue: Grade 40 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 70.8)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)
Headache: Mild33.3 (9.9 to 65.1)41.7 (15.2 to 72.3)16.7 (2.1 to 48.4)11.1 (0.3 to 48.2)41.7 (15.2 to 72.3)66.7 (9.4 to 99.2)33.3 (9.9 to 65.1)25.0 (5.5 to 57.2)25.0 (5.5 to 57.2)22.8 (2.8 to 60.0)16.7 (2.1 to 48.4)16.7 (2.1 to 48.4)41.7 (15.2 to 72.3)0 (0.0 to 33.6)8.3 (0.2 to 38.5)16.7 (2.1 to 48.4)0 (0.0 to 26.5)0 (0.0 to 33.6)
Headache: Moderate8.3 (0.2 to 38.5)8.3 (0.2 to 38.5)33.3 (9.9 to 65.1)0. (0.0 to 33.6)25.0 (5.5 to 57.2)0 (0.0 to 70.8)0 (0.0 to 26.5)8.3 (0.2 to 38.5)8.3 (0.2 to 38.5)11.1 (0.3 to 48.2)8.3 (0.2 to 38.5)16.7 (2.1 to 48.4)8.3 (0.2 to 38.5)0 (0.0 to 33.6)0 (0.0 to 26.5)8.3 (0.2 to 38.5)0 (0.0 to 26.5)11.1 (0.3 to 48.2)
Headache: Severe0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)8.3 (0.2 to 38.5)0 (0.0 to 70.8)0 (0.0 to 26.5)0 (0.0 to 26.5)16.7 (2.1 to 48.4)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)
Headache: Grade 40 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 70.8)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)
Chills: Mild0 (0.0 to 26.5)8.3 (0.2 to 38.5)25.0 (5.5 to 57.2)0 (0.0 to 33.6)41.7 (15.2 to 72.3)0 (0.0 to 70.8)0 (0.0 to 26.5)0 (0.0 to 26.5)16.7 (2.1 to 48.4)0 (0.0 to 33.6)8.3 (0.2 to 38.5)8.3 (0.2 to 38.5)8.3 (0.2 to 38.5)22.2 (2.8 to 60.0)0 (0.0 to 26.5)8.3 (0.2 to 38.5)0 (0.0 to 26.5)0 (0.0 to 33.6)
Chills: Moderate8.3 (0.2 to 38.5)16.7 (2.1 to 48.4)33.3 (9.9 to 65.1)0 (0.0 to 33.6)33.3 (9.9 to 65.1)0 (0.0 to 70.8)0 (0.0 to 26.5)0 (0.0 to 26.5)8.3 (0.2 to 38.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)8.3 (0.2 to 38.5)0 (0.0 to 33.6)0 (0.0 to 26.5)8.3 (0.2 to 38.5)0 (0.0 to 26.5)0 (0.0 to 33.6)
Chills: Severe0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)8.3 (0.2 to 38.5)0 (0.0 to 70.8)0 (0.0 to 26.5)0 (0.0 to 26.5)8.3 (0.2 to 38.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)
Chills: Grade 40 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 70.8)0 (0.0 to 26.5)0 (0.0 to 26.5)0.0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0. to 026.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)
Vomiting: Mild0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 70.8)0 (0.0 to 26.5)0 (0.0 to 26.5)8.3 (0.2 to 38.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)
Vomiting: Moderate0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 70.8)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)
Vomiting: Severe0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 70.8)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0.0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)
Vomiting: Grade 40 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 70.8)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)
Diarrhea: Mild16.7 (2.1 to 48.4)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)33.3 (9.9 to 65.1)0 (0.0 to 70.8)0 (0.0 to 26.5)8.3 (0.2 to 38.5)8.3 (0.2 to 38.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)11.1 (0.3 to 48.2)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)11.1 (0.3 to 48.2)
Diarrhea: Moderate0 (0.0 to 26.5)0 (0.0 to 26.5)8.3 (0.2 to 38.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 70.8)0 (0.0 to 26.5)0 (0.0 to 26.5)8.3 (0.2 to 38.5)0 (0.0 to 33.6)0.0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)
Diarrhea: Severe0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 70.8)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)
Diarrhea: Grade 40 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 70.8)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)
New or worsened muscle pain: Mild8.3 (0.2 to 38.5)25.0 (5.5 to 57.2)16.7 (2.1 to 48.4)0 (0.0 to 33.6)41.7 (15.2 to 72.3)0 (0.0 to 70.8)25.0 (5.5 to 57.2)8.3 (0.2 to 38.5)8.3 (0.2 to 38.5)0 (0.0 to 33.6)16.7 (2.1 to 48.4)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)8.3 (0.2 to 38.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)
New or worsened muscle pain: Moderate0.0 (0.0 to 26.5)8.3 (0.2 to 38.5)8.3 (0.2 to 38.5)0 (0.0 to 33.6)8.3 (0.2 to 38.5)0 (0.0 to 70.8)0 (0.0 to 26.5)8.3 (0.2 to 38.5)8.3 (0.2 to 38.5)0 (0.0 to 33.6)16.7 (2.1 to 48.4)8.3 (0.2 to 38.5)0 (0.0 to 26.5)0 (0.0 to 26.5)8.3 (0.2 to 38.5)0.0 (0.0 to 26.5)0 (0.0 to 26.5)11.1 (0.3 to 48.2)
New or worsened muscle pain: Severe0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)8.3 (0.2 to 38.5)0 (0.0 to 70.8)0 (0.0 to 26.5)8.3 (0.2 to 38.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)11.1 (0.3 to 48.2)0.0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)11.1 (0.3 to 48.2)
New or worsened muscle pain: Grade 40 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 70.8)0 (0.0 to 26.5)0.0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0.0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 48.2)
New or worsened joint pain: Mild16.7 (2.1 to 48.4)0 (0.0 to 26.5)0 (0.0 to 26.5)11.1 (0.3 to 48.2)8.3 (0.2 to 38.5)0 (0.0 to 70.8)8.3 (0.2 to 38.5)0 (0.0 to 26.5)8.3 (0.2 to 38.5)0 (0.0 to 33.6)16.7 (2.1 to 48.4)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0.0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)
New or worsened joint pain: Moderate0 (0.0 to 26.5)8.3 (0.2 to 38.5)0 (0.0 to 26.5)0 (0.0 to 33.6)8.3 (0.2 to 38.5)0 (0.0 to 70.8)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)8.3 (0.2 to 38.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)11.1 (0.3 to 48.2)
New or worsened joint pain: Severe0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)8.3 (0.2 to 38.5)0 (0.0 to 70.8)0 (0.0 to 26.5)0 (0.0 to 26.5)8.3 (0.2 to 38.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)
New or worsened joint pain: Grade 40 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 70.8)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)8.3 (0.2 to 38.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)
PrimaryPercentage of Participants With Systemic Events Within 7 Days After Dose 2: Phase 1

Systemic events included fever, fatigue, headache, chills, vomiting, diarrhea, new or worsened muscle pain, new or worsened joint pain recorded by participants or parents/legal guardians of participants using e-diary. Fever=temperature \>=38.0 deg C categorized as \>=38.0 to 38.4, \>38.4 to 38.9, \>38.9 to 40.0 and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain, new or worsened joint pain graded as mild (does not interfere with activity), moderate (some interference with activity), severe (prevents daily routine activity), Grade 4 (Emergency room visit/hospitalization). Vomiting: mild (1-2 times in 24 h), moderate (\>2 times in 24 h), severe (requires IV hydration), Grade 4 (emergency room visit/hospitalization for hypotensive shock). Diarrhea: mild (2-3 loose stools in 24h), moderate (4-5 loose stools in 24 h), severe (\>=6 loose stools in 24 h) and Grade 4 (emergency room visit/hospitalization).

Time frame:
Within 7 days after Dose 2
Reported as:
Number · Percentage of participants
Percentage of Participants With Systemic Events Within 7 Days After Dose 2: Phase 1
Percentage of participantsBNT162b1 10 mcg Dose: 18-55 Years of AgeBNT162b1 20 mcg Dose: 18-55 Years of AgeBNT162b1 30 mcg Dose: 18-55 Years of AgePlacebo: 18-55 Years of Age for BNT162b1BNT162b2 10 mcg Dose, 18-55 Years of AgeBNT162b2 20 mcg Dose, 18-55 Years of AgeBNT162b2 30 mcg Dose, 18-55 Years of AgePlacebo: 18-55 Years of Age for BNT162b2BNT162b1 10 mcg Dose, 65-85 Years of AgeBNT162b1 20 mcg Dose, 65-85 Years of AgeBNT162b1 30 mcg Dose, 65-85 Years of AgePlacebo, 65-85 Years of Age for BNT162b1BNT162b2 10 mcg Dose, 65-85 Years of AgeBNT162b2 20 mcg Dose, 65-85 Years of AgeBNT162b2 30 mcg Dose, 65-85 Years of AgePlacebo: 65-85 Years of Age for BNT162b2
Fever: 38.0°C to 38.4°C0 (0.0 to 26.5)8.3 (0.2 to 38.5)16.7 (2.1 to 48.4)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)8.3 (0.2 to 38.5)0 (0.0 to 33.6)0 (0.0 to 26.5)25.0 (5.5 to 57.2)16.7 (2.1 to 48.4)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)
Fever: >38.4°C to 38.9°C8.3 (0.2 to 38.5)8.3 (0.2 to 38.5)58.3 (27.7 to 84.8)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)8.3 (0.2 to 38.5)0 (0.0 to 33.6)0 (0.0 to 26.5)25.0 (5.5 to 57.2)8.3 (0.2 to 38.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)
Fever: >38.9°C to 40.0°C0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)8.3 (0.2 to 38.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)
Fever: >40.0°C0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)
Fatigue: Mild25.0 (5.5 to 57.2)50.0 (21.1 to 78.9)16.7 (2.1 to 48.4)11.1 (0.3 to 48.2)25.0 (5.5 to 57.2)33.3 (9.9 to 65.1)16.7 (2.1 to 48.4)22.2 (2.8 to 60.0)16.7 (2.1 to 48.4)8.3 (0.2 to 38.5)25.0 (5.5 to 57.2)11.1 (0.3 to 48.2)8.3 (0.2 to 38.5)33.3 (9.9 to 65.1)16.7 (2.1 to 48.4)0 (0.0 to 33.6)
Fatigue: Moderate33.3 (9.9 to 65.1)25.0 (5.5 to 57.2)66.7 (34.9 to 90.1)11.1 (0.3 to 48.2)0 (0.0 to 26.5)8.3 (0.2 to 38.5)16.7 (2.1 to 48.4)11.1 (0.3 to 48.2)8.3 (0.2 to 38.5)41.7 (15.2 to 72.3)33.3 (9.9 to 65.1)11.1 (0.3 to 48.2)0 (0.0 to 26.5)0 (0.0 to 26.5)8.3 (0.2 to 38.5)11.1 (0.3 to 48.2)
Fatigue: Severe8.3 (0.2 to 38.5)8.3 (0.2 to 38.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)8.3 (0.2 to 38.5)0 (0.0 to 33.6)0 (0.0 to 26.5)8.3 (0.2 to 38.5)8.3 (0.2 to 38.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)
Fatigue: Grade 40 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)
Headache: Mild58.3 (27.7 to 84.8)50.0 (21.1 to 78.9)58.3 (27.7 to 84.8)0 (0.0 to 33.6)33.3 (9.9 to 65.1)25.0 (5.5 to 57.2)25.0 (5.5 to 57.2)22.8 (2.8 to 60.0)33.3 (9.9 to 65.1)33.3 (9.9 to 65.1)50.0 (2.1 to 78.9)11.1 (0.3 to 48.2)25.0 (5.5 to 57.2)25.0 (5.5 to 57.2)0 (0.0 to 26.5)0 (0.0 to 33.6)
Headache: Moderate25.0 (5.5 to 57.2)16.7 (2.1 to 48.4)41.7 (15.2 to 72.3)0. (0.0 to 33.6)0 (0.0 to 26.5)8.3 (0.2 to 38.5)8.3 (0.2 to 38.5)11.1 (0.3 to 48.2)8.3 (0.2 to 38.5)33.3 (9.9 to 65.1)25.0 (5.5 to 57.2)0 (0.0 to 33.6)8.3 (0.2 to 38.5)8.3 (0.2 to 38.5)0 (0.0 to 26.5)11.1 (0.3 to 48.2)
Headache: Severe0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)16.7 (2.1 to 48.4)0 (0.0 to 33.6)0 (0.0 to 26.5)8.3 (0.2 to 38.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)
Headache: Grade 40 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)
Chills: Mild0 (0.0 to 26.5)16.7 (2.1 to 48.4)41.7 (15.2 to 72.3)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)16.7 (2.1 to 48.4)0 (0.0 to 33.6)16.7 (2.1 to 48.4)33.3 (9.9 to 65.1)8.3 (0.2 to 38.5)0 (0.0 to 33.6)16.7 (2.1 to 48.4)8.3 (0.2 to 38.5)0 (0.0 to 26.5)0 (0.0 to 33.6)
Chills: Moderate25.0 (5.5 to 57.2)33.3 (9.9 to 65.1)16.7 (2.1 to 48.4)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)8.3 (0.2 to 38.5)0 (0.0 to 33.6)8.3 (0.2 to 38.5)25.0 (5.5 to 57.2)25.0 (5.5 to 57.2)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)8.3 (0.2 to 38.5)0 (0.0 to 33.6)
Chills: Severe0 (0.0 to 26.5)0 (0.0 to 26.5)8.3 (0.2 to 38.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)8.3 (0.2 to 38.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)
Chills: Grade 40 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0. to 026.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)
Vomiting: Mild0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)8.3 (0.2 to 38.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)8.3 (0.2 to 38.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)
Vomiting: Moderate0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)
Vomiting: Severe0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)
Vomiting: Grade 40 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)
Diarrhea: Mild0 (0.0 to 26.5)8.3 (0.2 to 38.5)8.3 (0.2 to 38.5)0 (0.0 to 33.6)0 (0.0 to 26.5)8.3 (0.2 to 38.5)8.3 (0.2 to 38.5)0 (0.0 to 33.6)0 (0.0 to 26.5)8.3 (0.2 to 38.5)16.7 (2.1 to 48.4)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)11.1 (0.3 to 48.2)
Diarrhea: Moderate0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)8.3 (0.2 to 38.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)
Diarrhea: Severe0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)
Diarrhea: Grade 40 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)
New or worsened muscle pain: Mild33.3 (9.9 to 65.1)16.7 (2.1 to 48.4)16.7 (2.1 to 48.4)0 (0.0 to 33.6)25.0 (5.5 to 57.2)8.3 (0.2 to 38.5)8.3 (0.2 to 38.5)0 (0.0 to 33.6)16.7 (2.1 to 48.4)8.3 (0.2 to 38.5)16.7 (2.1 to 48.4)0 (0.0 to 33.6)8.3 (0.2 to 38.5)8.3 (0.2 to 38.5)16.7 (2.1 to 48.4)0 (0.0 to 33.6)
New or worsened muscle pain: Moderate8.3 (0.2 to 38.5)58.3 (27.7 to 84.8)41.7 (15.2 to 72.3)0 (0.0 to 33.6)0 (0.0 to 26.5)8.3 (0.2 to 38.5)8.3 (0.2 to 38.5)0 (0.0 to 33.6)16.7 (2.1 to 48.4)25.0 (5.5 to 57.2)16.7 (2.1 to 48.4)0 (0.0 to 33.6)0 (0.0 to 28.5)0 (0.0 to 26.5)8.3 (0.2 to 38.5)11.1 (0.3 to 48.2)
New or worsened muscle pain: Severe0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)8.3 (0.2 to 38.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)
New or worsened muscle pain: Grade 40 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)
New or worsened joint pain: Mild8.3 (0.2 to 38.5)33.3 (9.9 to 65.1)8.3 (0.2 to 38.5)0 (0.0 to 33.6)8.3 (0.2 to 38.5)0 (0.0 to 26.5)8.3 (0.2 to 38.5)0 (0.0 to 33.6)16.7 (2.1 to 48.4)16.7 (2.1 to 48.4)8.3 (0.2 to 38.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)
New or worsened joint pain: Moderate25.0 (5.5 to 57.2)16.7 (2.1 to 48.4)16.7 (2.1 to 48.4)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)8.3 (0.2 to 38.5)8.3 (0.2 to 38.5)8.3 (0.2 to 38.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)8.3 (0.2 to 38.5)11.1 (0.3 to 48.2)
New or worsened joint pain: Severe0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)8.3 (0.2 to 38.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)
New or worsened joint pain: Grade 40 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 26.5)0 (0.0 to 33.6)
PrimaryPercentage of Participants Reporting Adverse Events From Dose 1 to 1 Month After Dose 2: Phase 1

An AE was any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. For BNT162b1 100 mcg, participants received one dose of 100 mcg, followed by one dose of 10 mcg.

Time frame:
From Dose 1 to 1 Month After Dose 2
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting Adverse Events From Dose 1 to 1 Month After Dose 2: Phase 1
Percentage of participantsBNT162b1 10 mcg Dose: 18-55 Years of AgeBNT162b1 20 mcg Dose: 18-55 Years of AgeBNT162b1 30 mcg Dose: 18-55 Years of AgePlacebo: 18-55 Years of Age for BNT162b1BNT162b1 100 mcg Dose, 18-55 Years of AgePlacebo 18-55 Years of Age for BNT162b1 100 mcgBNT162b2 10 mcg Dose, 18-55 Years of AgeBNT162b2 20 mcg Dose, 18-55 Years of AgeBNT162b2 30 mcg Dose, 18-55 Years of AgePlacebo: 18-55 Years of Age for BNT162b2BNT162b1 10 mcg Dose, 65-85 Years of AgeBNT162b1 20 mcg Dose, 65-85 Years of AgeBNT162b1 30 mcg Dose, 65-85 Years of AgePlacebo, 65-85 Years of Age for BNT162b1BNT162b2 10 mcg Dose, 65-85 Years of AgeBNT162b2 20 mcg Dose, 65-85 Years of AgeBNT162b2 30 mcg Dose, 65-85 Years of AgePlacebo: 65-85 Years of Age for BNT162b2
Percentage of Participants Reporting Adverse Events From Dose 1 to 1 Month After Dose 2: Phase 150.0 (21.1 to 78.9)41.7 (15.2 to 72.3)50.0 (21.1 to 78.9)22.2 (2.8 to 60.0)66.7 (34.9 to 90.1)33.3 (0.8 to 90.6)33.3 (9.9 to 65.1)41.7 (15.2 to 72.3)41.7 (15.2 to 72.3)22.2 (2.8 to 60.0)50.0 (21.1 to 78.9)58.3 (27.7 to 84.8)25.0 (5.5 to 57.2)44.4 (13.7 to 78.8)8.3 (0.2 to 38.5)8.3 (0.2 to 38.5)25.0 (5.5 to 57.2)22.2 (2.8 to 60.0)
PrimaryPercentage of Participants Reporting Serious Adverse Events From Dose 1 to 6 Months After Dose 2: Phase 1

An SAE was any untoward medical occurrence that occurred, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent or significant disability/ incapacity; was a congenital anomaly/birth defect and other important medical events. For BNT162b1 100 mcg, participants received one dose of 100 mcg, followed by one dose of 10 mcg.

Time frame:
From Dose 1 to 6 Months After Dose 2
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting Serious Adverse Events From Dose 1 to 6 Months After Dose 2: Phase 1
Percentage of participantsBNT162b1 10 mcg Dose, 18-85 Years of AgeBNT162b1 20 mcg Dose, 18-85 Years of AgeBNT162b1 30 mcg Dose, 18-85 Years of AgeBNT162b1 100 mcg: 18-55 Years of AgeBNT162b2 10 mcg Dose, 18-85 Years of AgeBNT162b2 20 mcg Dose, 18-85 Years of AgeBNT162b2 30 mcg Dose, 18-85 Years of AgePlacebo/BNT162b2 30 mcg: 18-85 Years of Age
Percentage of Participants Reporting Serious Adverse Events From Dose 1 to 6 Months After Dose 2: Phase 10 (0.0 to 14.2)0 (0.0 to 14.2)0 (0.0 to 14.2)0 (0.0 to 26.5)0 (0.0 to 14.2)4.2 (0.1 to 21.1)4.2 (0.1 to 21.1)0 (0.0 to 10.0)
PrimaryPercentage of Participants With Abnormalities in Hematology Parameters 1 Day After Dose 1: Phase 1

Hematology parameters that were assessed included hemoglobin, hematocrit, erythrocytes, Ery. mean corpuscular volume, Ery. mean corpuscular hemoglobin, Ery. mean corpuscular HGB concentration, platelets, leukocytes, lymphocytes, neutrophils, basophils, eosinophils and monocytes. Abnormal parameters were determined by following criteria: Hemoglobin : \<0.8x lower limit of normal (LLN), Hematocrit : \<0.8x LLN, Erythrocytes : \<0.8x LLN, Ery. Mean Corpuscular Volume: \<0.9x LLN, Ery. Mean Corpuscular Hemoglobin : \<0.9x LLN Ery. Mean Corpuscular HGB Concentration : \<0.9x LLN, Platelets : \<0.5x LLN, Leukocytes : \<0.6x LLN, Lymphocytes : \<0.8x LLN, Neutrophils : \<0.8x LLN, Basophils: \>1.2x upper limit of normal (ULN), Eosinophils \>1.2x ULN, Monocytes \>1.2x ULN. Only parameters with abnormal values were reported in this outcome measure.

Time frame:
1 Day After Dose 1
Reported as:
Number · Percentage of participants
Percentage of Participants With Abnormalities in Hematology Parameters 1 Day After Dose 1: Phase 1
Percentage of participantsBNT162b1 10 mcg Dose: 18-55 Years of AgeBNT162b1 20 mcg Dose: 18-55 Years of AgeBNT162b1 30 mcg Dose: 18-55 Years of AgePlacebo: 18-55 Years of Age for BNT162b1BNT162b1 100 mcg Dose, 18-55 Years of AgePlacebo 18-55 Years of Age for BNT162b1 100 mcgBNT162b2 10 mcg Dose, 18-55 Years of AgeBNT162b2 20 mcg Dose, 18-55 Years of AgeBNT162b2 30 mcg Dose, 18-55 Years of AgePlacebo: 18-55 Years of Age for BNT162b2BNT162b1 10 mcg Dose, 65-85 Years of AgeBNT162b1 20 mcg Dose, 65-85 Years of AgeBNT162b1 30 mcg Dose, 65-85 Years of AgePlacebo, 65-85 Years of Age for BNT162b1BNT162b2 10 mcg Dose, 65-85 Years of AgeBNT162b2 20 mcg Dose, 65-85 Years of AgeBNT162b2 30 mcg Dose, 65-85 Years of AgePlacebo: 65-85 Years of Age for BNT162b2
Lymphocytes8.333.354.5075.075.008.38.308.325.016.708.38.38.30
Neutrophils8.3000008.30000000016.700
Ery. Mean Corpuscular Hemoglobin000000008.3000000000
PrimaryPercentage of Participants With Abnormalities in Hematology Parameters 7 Days After Dose 1: Phase 1

Hematology parameters that were assessed included hemoglobin, hematocrit, erythrocytes, Ery. mean corpuscular volume, Ery. mean corpuscular hemoglobin, Ery. mean corpuscular HGB concentration, platelets, leukocytes, lymphocytes, neutrophils, basophils, eosinophils and monocytes. Abnormal parameters were determined by following criteria: Hemoglobin : \<0.8x LLN, Hematocrit : \<0.8x LLN, Erythrocytes : \<0.8x LLN, Ery. Mean Corpuscular Volume: \<0.9x LLN, Ery. Mean Corpuscular Hemoglobin : \<0.9x LLN Ery. Mean Corpuscular HGB Concentration : \<0.9x LLN, Platelets : \<0.5x LLN, Leukocytes : \<0.6x LLN, Lymphocytes : \<0.8x LLN, Neutrophils : \<0.8x LLN, Basophils: \>1.2x ULN, Eosinophils \>1.2x ULN, Monocytes \>1.2x ULN. Only parameters with abnormal values were reported in this outcome measure.

Time frame:
7 Days After Dose 1
Reported as:
Number · Percentage of participants
Percentage of Participants With Abnormalities in Hematology Parameters 7 Days After Dose 1: Phase 1
Percentage of participantsBNT162b1 10 mcg Dose: 18-55 Years of AgeBNT162b1 20 mcg Dose: 18-55 Years of AgeBNT162b1 30 mcg Dose: 18-55 Years of AgePlacebo: 18-55 Years of Age for BNT162b1BNT162b1 100 mcg Dose, 18-55 Years of AgePlacebo 18-55 Years of Age for BNT162b1 100 mcgBNT162b2 10 mcg Dose, 18-55 Years of AgeBNT162b2 20 mcg Dose, 18-55 Years of AgeBNT162b2 30 mcg Dose, 18-55 Years of AgePlacebo: 18-55 Years of Age for BNT162b2BNT162b1 10 mcg Dose, 65-85 Years of AgeBNT162b1 20 mcg Dose, 65-85 Years of AgeBNT162b1 30 mcg Dose, 65-85 Years of AgePlacebo, 65-85 Years of Age for BNT162b1BNT162b2 10 mcg Dose, 65-85 Years of AgeBNT162b2 20 mcg Dose, 65-85 Years of AgeBNT162b2 30 mcg Dose, 65-85 Years of AgePlacebo: 65-85 Years of Age for BNT162b2
Lymphocytes0000011.1000000008.308.311.1
Neutrophils0000000000016.7008.3000
Ery. Mean Corpuscular Hemoglobin000000008.3000000000
PrimaryPercentage of Participants With Abnormalities in Hematology Parameters Before Dose 2: Phase 1

Hematology parameters that were assessed included hemoglobin, hematocrit, erythrocytes, Ery. mean corpuscular volume, Ery. mean corpuscular hemoglobin, Ery. mean corpuscular HGB concentration, platelets, leukocytes, lymphocytes, neutrophils, basophils, eosinophils and monocytes. Abnormal parameters were determined by following criteria: Hemoglobin : \<0.8x LLN, Hematocrit : \<0.8x LLN, Erythrocytes : \<0.8x LLN, Ery. Mean Corpuscular Volume: \<0.9x LLN, Ery. Mean Corpuscular Hemoglobin : \<0.9x LLN Ery. Mean Corpuscular HGB Concentration : \<0.9x LLN, Platelets : \<0.5x LLN, Leukocytes : \<0.6x LLN, Lymphocytes : \<0.8x LLN, Neutrophils : \<0.8x LLN, Basophils: \>1.2x ULN, Eosinophils \>1.2x ULN, Monocytes \>1.2x ULN. Only parameters with abnormal values were reported in this outcome measure.

Time frame:
Before Dose 2
Reported as:
Number · Percentage of participants
Percentage of Participants With Abnormalities in Hematology Parameters Before Dose 2: Phase 1
Percentage of participantsBNT162b1 10 mcg Dose: 18-55 Years of AgeBNT162b1 20 mcg Dose: 18-55 Years of AgeBNT162b1 30 mcg Dose: 18-55 Years of AgePlacebo: 18-55 Years of Age for BNT162b1BNT162b1 100 mcg Dose, 18-55 Years of AgePlacebo 18-55 Years of Age for BNT162b1 100 mcgBNT162b2 10 mcg Dose, 18-55 Years of AgeBNT162b2 20 mcg Dose, 18-55 Years of AgeBNT162b2 30 mcg Dose, 18-55 Years of AgePlacebo: 18-55 Years of Age for BNT162b2BNT162b1 10 mcg Dose, 65-85 Years of AgeBNT162b1 20 mcg Dose, 65-85 Years of AgeBNT162b1 30 mcg Dose, 65-85 Years of AgePlacebo, 65-85 Years of Age for BNT162b1BNT162b2 10 mcg Dose, 65-85 Years of AgeBNT162b2 20 mcg Dose, 65-85 Years of AgeBNT162b2 30 mcg Dose, 65-85 Years of AgePlacebo: 65-85 Years of Age for BNT162b2
Ery. Mean Corpuscular Hemoglobin000000008.3000000000
Neutrophils0000008.300000008.3000
Lymphocytes000000000000011.18.308.30
Eosinophils0000000000008.300000
PrimaryPercentage of Participants With Abnormalities in Hematology Parameters 7 Days After Dose 2: Phase 1

Hematology parameters that were assessed included hemoglobin, hematocrit, erythrocytes, Ery. mean corpuscular volume, Ery. mean corpuscular hemoglobin, Ery. mean corpuscular HGB concentration, platelets, leukocytes, lymphocytes, neutrophils, basophils, eosinophils and monocytes. Abnormal parameters were determined by following criteria: Hemoglobin : \<0.8x LLN, Hematocrit : \<0.8x LLN, Erythrocytes : \<0.8x LLN, Ery. Mean Corpuscular Volume: \<0.9x LLN, Ery. Mean Corpuscular Hemoglobin : \<0.9x LLN Ery. Mean Corpuscular HGB Concentration : \<0.9x LLN, Platelets : \<0.5x LLN, Leukocytes : \<0.6x LLN, Lymphocytes : \<0.8x LLN, Neutrophils : \<0.8x LLN, Basophils: \>1.2x ULN, Eosinophils \>1.2x ULN, Monocytes \>1.2x ULN. Only parameters with abnormal values were reported in this outcome measure.

Time frame:
7 Days After Dose 2
Reported as:
Number · Percentage of participants
Percentage of Participants With Abnormalities in Hematology Parameters 7 Days After Dose 2: Phase 1
Percentage of participantsBNT162b1 10 mcg Dose: 18-55 Years of AgeBNT162b1 20 mcg Dose: 18-55 Years of AgeBNT162b1 30 mcg Dose: 18-55 Years of AgePlacebo: 18-55 Years of Age for BNT162b1BNT162b2 10 mcg Dose, 18-55 Years of AgeBNT162b2 20 mcg Dose, 18-55 Years of AgeBNT162b2 30 mcg Dose, 18-55 Years of AgePlacebo: 18-55 Years of Age for BNT162b2BNT162b1 10 mcg Dose, 65-85 Years of AgeBNT162b1 20 mcg Dose, 65-85 Years of AgeBNT162b1 30 mcg Dose, 65-85 Years of AgePlacebo, 65-85 Years of Age for BNT162b1BNT162b2 10 mcg Dose, 65-85 Years of AgeBNT162b2 20 mcg Dose, 65-85 Years of AgeBNT162b2 30 mcg Dose, 65-85 Years of AgePlacebo: 65-85 Years of Age for BNT162b2
Neutrophils8.308.3008.30000008.3000
Monocytes000008.3011.100000000
Eosinophils000008.30000000000
Lymphocytes0000000000008.308.30
Ery. Mean Corpuscular Hemoglobin0000000008.3000000
PrimaryPercentage of Participants With Abnormalities in Chemistry Parameters 1 Day After Dose 1: Phase 1

Chemistry parameters that were assessed included bilirubin, aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), urea nitrogen, creatinine. Abnormal parameters were determined by following criteria: bilirubin: \>1.5x ULN, AST: \>3.0x ULN, ALT: \>3.0x ULN, ALP: \>3.0x ULN, urea nitrogen: \>1.3x ULN, creatinine: \>1.3x ULN. Abnormal values reported for this outcome measure are for bilirubin.

Time frame:
1 Day After Dose 1
Reported as:
Number · Percentage of participants
Percentage of Participants With Abnormalities in Chemistry Parameters 1 Day After Dose 1: Phase 1
Percentage of participantsBNT162b1 10 mcg Dose: 18-55 Years of AgeBNT162b1 20 mcg Dose: 18-55 Years of AgeBNT162b1 30 mcg Dose: 18-55 Years of AgePlacebo: 18-55 Years of Age for BNT162b1BNT162b1 100 mcg Dose, 18-55 Years of AgePlacebo 18-55 Years of Age for BNT162b1 100 mcgBNT162b2 10 mcg Dose, 18-55 Years of AgeBNT162b2 20 mcg Dose, 18-55 Years of AgeBNT162b2 30 mcg Dose, 18-55 Years of AgePlacebo: 18-55 Years of Age for BNT162b2BNT162b1 10 mcg Dose, 65-85 Years of AgeBNT162b1 20 mcg Dose, 65-85 Years of AgeBNT162b1 30 mcg Dose, 65-85 Years of AgePlacebo, 65-85 Years of Age for BNT162b1BNT162b2 10 mcg Dose, 65-85 Years of AgeBNT162b2 20 mcg Dose, 65-85 Years of AgeBNT162b2 30 mcg Dose, 65-85 Years of AgePlacebo: 65-85 Years of Age for BNT162b2
Percentage of Participants With Abnormalities in Chemistry Parameters 1 Day After Dose 1: Phase 10000008.300000000000
PrimaryPercentage of Participants With Abnormalities in Chemistry Parameters 7 Days After Dose 1: Phase 1

Chemistry parameters that were assessed included bilirubin, AST, ALT, ALP, urea nitrogen, creatinine. Abnormal parameters were determined by following criteria: bilirubin: \>1.5x ULN, AST: \>3.0x ULN, ALT: \>3.0x ULN, ALP: \>3.0x ULN, urea nitrogen: \>1.3x ULN, creatinine: \>1.3x ULN. Abnormal values reported for this outcome measure are for bilirubin.

Time frame:
7 Days After Dose 1
Reported as:
Number · Percentage of participants
Percentage of Participants With Abnormalities in Chemistry Parameters 7 Days After Dose 1: Phase 1
Percentage of participantsBNT162b1 10 mcg Dose: 18-55 Years of AgeBNT162b1 20 mcg Dose: 18-55 Years of AgeBNT162b1 30 mcg Dose: 18-55 Years of AgePlacebo: 18-55 Years of Age for BNT162b1BNT162b1 100 mcg Dose, 18-55 Years of AgePlacebo 18-55 Years of Age for BNT162b1 100 mcgBNT162b2 10 mcg Dose, 18-55 Years of AgeBNT162b2 20 mcg Dose, 18-55 Years of AgeBNT162b2 30 mcg Dose, 18-55 Years of AgePlacebo: 18-55 Years of Age for BNT162b2BNT162b1 10 mcg Dose, 65-85 Years of AgeBNT162b1 20 mcg Dose, 65-85 Years of AgeBNT162b1 30 mcg Dose, 65-85 Years of AgePlacebo, 65-85 Years of Age for BNT162b1BNT162b2 10 mcg Dose, 65-85 Years of AgeBNT162b2 20 mcg Dose, 65-85 Years of AgeBNT162b2 30 mcg Dose, 65-85 Years of AgePlacebo: 65-85 Years of Age for BNT162b2
Percentage of Participants With Abnormalities in Chemistry Parameters 7 Days After Dose 1: Phase 100000000011.100000000
PrimaryPercentage of Participants With Abnormalities in Chemistry Parameters Before Dose 2: Phase 1

Chemistry parameters that were assessed included bilirubin, AST, ALT, ALP, urea nitrogen, creatinine. Abnormal parameters were determined by following criteria: bilirubin: \>1.5x ULN, AST: \>3.0x ULN, ALT: \>3.0x ULN, ALP: \>3.0x ULN, urea nitrogen: \>1.3x ULN, creatinine: \>1.3x ULN. Abnormal values reported for this outcome measure are for bilirubin.

Time frame:
Before Dose 2
Reported as:
Number · Percentage of participants
Percentage of Participants With Abnormalities in Chemistry Parameters Before Dose 2: Phase 1
Percentage of participantsBNT162b1 10 mcg Dose: 18-55 Years of AgeBNT162b1 20 mcg Dose: 18-55 Years of AgeBNT162b1 30 mcg Dose: 18-55 Years of AgePlacebo: 18-55 Years of Age for BNT162b1BNT162b1 100 mcg Dose, 18-55 Years of AgePlacebo 18-55 Years of Age for BNT162b1 100 mcgBNT162b2 10 mcg Dose, 18-55 Years of AgeBNT162b2 20 mcg Dose, 18-55 Years of AgeBNT162b2 30 mcg Dose, 18-55 Years of AgePlacebo: 18-55 Years of Age for BNT162b2BNT162b1 10 mcg Dose, 65-85 Years of AgeBNT162b1 20 mcg Dose, 65-85 Years of AgeBNT162b1 30 mcg Dose, 65-85 Years of AgePlacebo, 65-85 Years of Age for BNT162b1BNT162b2 10 mcg Dose, 65-85 Years of AgeBNT162b2 20 mcg Dose, 65-85 Years of AgeBNT162b2 30 mcg Dose, 65-85 Years of AgePlacebo: 65-85 Years of Age for BNT162b2
Percentage of Participants With Abnormalities in Chemistry Parameters Before Dose 2: Phase 1000000000000000000
PrimaryPercentage of Participants With Abnormalities in Chemistry Parameters 7 Days After Dose 2: Phase 1

Chemistry parameters that were assessed included bilirubin, AST, ALT, ALP, urea nitrogen, creatinine. Abnormal parameters were determined by following criteria: bilirubin: \>1.5x ULN, AST: \>3.0x ULN, ALT: \>3.0x ULN, ALP: \>3.0x ULN, urea nitrogen: \>1.3x ULN, creatinine: \>1.3x ULN. Abnormal values reported for this outcome measure are for bilirubin.

Time frame:
7 Days After Dose 2
Reported as:
Number · Percentage of participants
Percentage of Participants With Abnormalities in Chemistry Parameters 7 Days After Dose 2: Phase 1
Percentage of participantsBNT162b1 10 mcg Dose: 18-55 Years of AgeBNT162b1 20 mcg Dose: 18-55 Years of AgeBNT162b1 30 mcg Dose: 18-55 Years of AgePlacebo: 18-55 Years of Age for BNT162b1BNT162b2 10 mcg Dose, 18-55 Years of AgeBNT162b2 20 mcg Dose, 18-55 Years of AgeBNT162b2 30 mcg Dose, 18-55 Years of AgePlacebo: 18-55 Years of Age for BNT162b2BNT162b1 10 mcg Dose, 65-85 Years of AgeBNT162b1 20 mcg Dose, 65-85 Years of AgeBNT162b1 30 mcg Dose, 65-85 Years of AgePlacebo, 65-85 Years of Age for BNT162b1BNT162b2 10 mcg Dose, 65-85 Years of AgeBNT162b2 20 mcg Dose, 65-85 Years of AgeBNT162b2 30 mcg Dose, 65-85 Years of AgePlacebo: 65-85 Years of Age for BNT162b2
Percentage of Participants With Abnormalities in Chemistry Parameters 7 Days After Dose 2: Phase 1000000011.100000000
PrimaryPercentage of Participants With Grade Shift in Hematology Parameters 1 Day After Dose 1: Phase 1

Percentage of participants with grade shift in hematology parameters reported in this outcome measure. Grade(G)1: Mild, G2:Moderate, G3:Severe, G4:potentially life threatening. Hemoglobin(Female): G1: 11.0 - 12.0grams per deciliter(g/dL), G2: 9.5 - 10.9, G3: 8.0 - 9.4, G4: \<8.0. Hemoglobin(Male): G1: 12.5 - 13.5, G2: 10.5 - 12.4, G3: 8.5 - 10.4, G4: \<8.5. WBC decrease(cells/mm3):G1: 2,500 - 3,500, G2: 1,500 - 2,499, G3: 1,000 - 1,499, G4: \<1,000 Lymphocytes decrease(cells/mm3): G1: 750 - 1,000, G2: 500 - 749, G3: 250 - 499, G4: \<250. Eosinophils(cells/mm3):G1: 650 - 1500, G2: 1501 - 5000, G3: \>5000, G4:Hypereosinophilic. Platelets decreased(cells/mm3): G1: 125,000 - 140,000, G2: 100,000 - 124,000, G3: 25,000 - 99,000, G4: \<25,000. Urea Nitrogen (mg/dl): G1: 23-26; G2:27-31; G3: \>31; G4: requires dialysis. Only parameters where grade shift was observed were reported.

Time frame:
1 Day After Dose 1
Reported as:
Number · Percentage of participants
Percentage of Participants With Grade Shift in Hematology Parameters 1 Day After Dose 1: Phase 1
Percentage of participantsBNT162b1 10 mcg Dose: 18-55 Years of AgeBNT162b1 20 mcg Dose: 18-55 Years of AgeBNT162b1 30 mcg Dose: 18-55 Years of AgePlacebo: 18-55 Years of Age for BNT162b1BNT162b1 100 mcg Dose, 18-55 Years of AgePlacebo 18-55 Years of Age for BNT162b1 100 mcgBNT162b2 10 mcg Dose, 18-55 Years of AgeBNT162b2 20 mcg Dose, 18-55 Years of AgeBNT162b2 30 mcg Dose, 18-55 Years of AgePlacebo: 18-55 Years of Age for BNT162b2BNT162b1 10 mcg Dose, 65-85 Years of AgeBNT162b1 20 mcg Dose, 65-85 Years of AgeBNT162b1 30 mcg Dose, 65-85 Years of AgePlacebo, 65-85 Years of Age for BNT162b1BNT162b2 10 mcg Dose, 65-85 Years of AgeBNT162b2 20 mcg Dose, 65-85 Years of AgeBNT162b2 30 mcg Dose, 65-85 Years of AgePlacebo: 65-85 Years of Age for BNT162b2
Hemoglobin: Baseline Normal to Normal75.075.0100.0100.0100.0100.0100.0100.083.387.591.791.7100.088.983.391.783.388.9
Hemoglobin: Normal to Grade 18.38.300000016.7000011.18.308.311.1
Hemoglobin: Grade 1 to Normal16.70000000012.58.30000000
Hemoglobin: Grade1 to Grade108.30000000000008.38.38.30
Hemoglobin: Grade1 to Grade208.30000000008.3000000
Eosinophils: Baseline Normal to Normal100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Lymphocytes: Baseline Normal to Normal66.725.018.2100.00100.075.075.058.3100.033.316.741.7100.075.033.366.788.9
Lymphocytes: Normal to Grade116.741.727.3016.7025.016.733.3050.016.733.3016.750.025.00
Lymphocytes: Normal to Grade28.316.745.5050.0008.38.308.366.716.70016.700
Lymphocytes: Normal to Grade38.316.79.1033.300000008.308.3000
Lymphocytes: Normal to Grade 400000000008.30000000
Lymphocytes: Grade1 to Grade 10000000000000000011.1
Lymphocytes: Grade 1 to Grade 300000000000000008.30
Platelets Decrease: Normal to Normal100.091.7100.0100.0100.0100.0100.0100.087.5100.091.791.791.7100.083.391.783.377.8
Platelet Decrease: Normal to Grade 108.300000012.5000008.38.38.311.1
Platelet Decrease: Normal to Grade 200000000008.38.3008.308.30
Platelet decrease: Grade 1 to Grade 10000000000008.3000011.1
Urea Nitrogen: Baseline Normal to Normal100.091.7100.0100.0100.0100.0100.0100.0100.088.991.7100.0100.088.9100.0100.091.7100.0
Urea Nitrogen: Normal to Grade 100000000008.30000000
Urea Nitrogen: Normal to Grade 2000000000000011.1008.30
Urea Nitrogen: Grade 1 to Normal08.3000000011.100000000
WBC Decrease: Baseline Normal to Normal91.791.7100.0100.0100.0100.0100.091.7100.0100.083.375.0100.088.983.375.091.7100.0
WBC Decrease: Baseline normal to Grade 18.38.3000008.30016.725.0011.18.38.300
WBC Decrease: Normal to Grade 200000000000000016.700
WBC Decrease: Grade 1 to Grade 100000000000000008.30
WBC Decrease: Grade 1 to Grade 2000000000000008.3000
PrimaryPercentage of Participants With Grade Shift in Hematology Parameters 7 Days After Dose 1: Phase 1

Percentage of participants with grade shift in hematology parameters reported in this outcome measure. Grade(G)1: Mild, G2:Moderate, G3:Severe, G4:potentially life threatening. Hemoglobin(Female): G1: 11.0 - 12.0grams per deciliter(g/dL), G2: 9.5 - 10.9, G3: 8.0 - 9.4, G4: \<8.0. Hemoglobin(Male): G1: 12.5 - 13.5, G2: 10.5 - 12.4, G3: 8.5 - 10.4, G4: \<8.5. WBC decrease(cells/mm3):G1: 2,500 - 3,500, G2: 1,500 - 2,499, G3: 1,000 - 1,499, G4: \<1,000 Lymphocytes decrease(cells/mm3): G1: 750 - 1,000, G2: 500 - 749, G3: 250 - 499, G4: \<250. Eosinophils(cells/mm3):G1: 650 - 1500, G2: 1501 - 5000, G3: \>5000, G4:Hypereosinophilic. Platelets decreased(cells/mm3): G1: 125,000 - 140,000, G2: 100,000 - 124,000, G3: 25,000 - 99,000, G4: \<25,000. Urea Nitrogen (mg/dl): G1: 23-26; G2:27-31; G3: \>31; G4: requires dialysis. Only parameters where grade shift was observed were reported.

Time frame:
7 Days After Dose 1
Reported as:
Number · Percentage of participants
Percentage of Participants With Grade Shift in Hematology Parameters 7 Days After Dose 1: Phase 1
Percentage of participantsBNT162b1 10 mcg Dose: 18-55 Years of AgeBNT162b1 20 mcg Dose: 18-55 Years of AgeBNT162b1 30 mcg Dose: 18-55 Years of AgePlacebo: 18-55 Years of Age for BNT162b1BNT162b1 100 mcg Dose, 18-55 Years of AgePlacebo 18-55 Years of Age for BNT162b1 100 mcgBNT162b2 10 mcg Dose, 18-55 Years of AgeBNT162b2 20 mcg Dose, 18-55 Years of AgeBNT162b2 30 mcg Dose, 18-55 Years of AgePlacebo: 18-55 Years of Age for BNT162b2BNT162b1 10 mcg Dose, 65-85 Years of AgeBNT162b1 20 mcg Dose, 65-85 Years of AgeBNT162b1 30 mcg Dose, 65-85 Years of AgePlacebo, 65-85 Years of Age for BNT162b1BNT162b2 10 mcg Dose, 65-85 Years of AgeBNT162b2 20 mcg Dose, 65-85 Years of AgeBNT162b2 30 mcg Dose, 65-85 Years of AgePlacebo: 65-85 Years of Age for BNT162b2
Hemoglobin: Baseline Normal to Normal83.375.0100.0100.091.7100.091.7100.0100.088.991.783.3100.0100.091.791.791.788.9
Hemoglobin: Grade1 to Normal16.70000000011.18.30000000
Hemoglobin: Normal to Grade108.3008.308.300008.30000011.1
Hemoglobin: Grade1 to Grade1016.70000000000008.38.38.30
Hemoglobin: Grade1 to Grade2000000000008.3000000
Eosinophils: Baseline Normal to Normal100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0
Lymphocytes: Baseline Normal to Normal100.091.7100.0100.0100.0100.0100.0100.091.777.8100.0100.0100.0100.0100.091.791.788.9
Lymphocytes: Normal to Grade108.30000008.311.1000008.300
Lymphocytes: Grade1 to Normal00000000011.1000000011.1
Lymphocytes: Grade 1 to Grade 100000000000000008.30
Platelets Decrease: Baseline Normal to Normal100.0100.0100.0100.0100.0100.0100.0100.0100.0100.091.791.790.9100.090.9100.0100.077.8
Platelets Decrease: Normal to Grade100000000008.38.3009.10011.1
Platelets Decrease: Grade1 to Normal0000000000009.100000
Platelets Decrease: Grade 1 to Grade 20000000000000000011.1
Urea Nitrogen: Baseline Normal to Normal100.091.7100.0100.0100.0100.091.7100.0100.088.991.791.791.788.9100.091.783.388.9
Urea Nitrogen: Grade1 to Normal0000008.30008.38.38.3008.3011.1
Urea Nitrogen: Normal to Grade1000000000000011.10016.70
Urea Nitrogen: Grade1 to Grade208.30000000000000000
Urea Nitrogen: Normal to Grade 200000000011.100011.10016.70
WBC decrease: Baseline Normal to Normal100.091.7100.0100.0100.0100.0100.0100.0100.0100.0100.083.3100.0100.083.3100.091.788.9
WBC decrease: Normal to Grade108.300000000016.7008.30011.1
WBC Decrease: Grade 1 to Normal00000000000000008.30
WBC Decrease: Grade 1 to Grade 1000000000000008.3000
PrimaryPercentage of Participants With Grade Shift in Hematology Parameters Before Dose 2: Phase 1

Percentage of participants with grade shift in hematology parameters reported in this outcome measure. Grade(G)1: Mild, G2:Moderate, G3:Severe, G4:potentially life threatening. Hemoglobin(Female): G1: 11.0 - 12.0grams per deciliter(g/dL), G2: 9.5 - 10.9, G3: 8.0 - 9.4, G4: \<8.0. Hemoglobin(Male): G1: 12.5 - 13.5, G2: 10.5 - 12.4, G3: 8.5 - 10.4, G4: \<8.5. WBC decrease(cells/mm3):G1: 2,500 - 3,500, G2: 1,500 - 2,499, G3: 1,000 - 1,499, G4: \<1,000 Lymphocytes decrease(cells/mm3): G1: 750 - 1,000, G2: 500 - 749, G3: 250 - 499, G4: \<250. Eosinophils(cells/mm3):G1: 650 - 1500, G2: 1501 - 5000, G3: \>5000, G4:Hypereosinophilic. Platelets decreased(cells/mm3): G1: 125,000 - 140,000, G2: 100,000 - 124,000, G3: 25,000 - 99,000, G4: \<25,000. Urea Nitrogen (mg/dl): G1: 23-26; G2:27-31; G3: \>31; G4: requires dialysis. Only parameters where grade shift was observed were reported.

Time frame:
Before Dose 2
Reported as:
Number · Percentage of participants
Percentage of Participants With Grade Shift in Hematology Parameters Before Dose 2: Phase 1
Percentage of participantsBNT162b1 10 mcg Dose: 18-55 Years of AgeBNT162b1 20 mcg Dose: 18-55 Years of AgeBNT162b1 30 mcg Dose: 18-55 Years of AgePlacebo: 18-55 Years of Age for BNT162b1BNT162b1 100 mcg Dose, 18-55 Years of AgePlacebo 18-55 Years of Age for BNT162b1 100 mcgBNT162b2 10 mcg Dose, 18-55 Years of AgeBNT162b2 20 mcg Dose, 18-55 Years of AgeBNT162b2 30 mcg Dose, 18-55 Years of AgePlacebo: 18-55 Years of Age for BNT162b2BNT162b1 10 mcg Dose, 65-85 Years of AgeBNT162b1 20 mcg Dose, 65-85 Years of AgeBNT162b1 30 mcg Dose, 65-85 Years of AgePlacebo, 65-85 Years of Age for BNT162b1BNT162b2 10 mcg Dose, 65-85 Years of AgeBNT162b2 20 mcg Dose, 65-85 Years of AgeBNT162b2 30 mcg Dose, 65-85 Years of AgePlacebo: 65-85 Years of Age for BNT162b2
Hemoglobin: Baseline Normal to Normal50.075.0100.0100.0100.0100.0100.0100.083.388.991.783.3100.0100.091.791.783.3100.0
Hemoglobin: Normal to Grade133.38.300000016.7008.300008.30
Hemoglobin: Grade1 to Normal16.70000000011.10000008.30
Hemoglobin: Grade1 to Grade1016.7000000008.30008.38.300
Hemoglobin: Grade1 to Grade2000000000008.3000000
Eosinophils: Baseline Normal to Normal100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.091.7100.0100.0100.0100.0100.0
Eosinophils: Baseline Normal to Grade 10000000000008.300000
Lymphocytes: Baseline Normal to Normal91.783.3100.088.9100.0100.0100.0100.0100.088.9100.083.3100.0100.091.7100.091.788.9
Lymphocytes: Normal to Grade18.316.7011.1000000016.7008.3000
Lymphocytes: Grade1 to Grade100000000011.10000008.311.1
Platelets Decrease: Baseline Normal to Normal100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.091.7100.091.7100.0100.088.9
Platelets Decrease: Grade 1 to Grade10000000000008.300000
Platelets Decrease: Normal to Grade2000000000000008.3000
Platelets Decrease: Grade1 to Grade20000000000000000011.1
Urea Nitrogen: Baseline Normal to Normal100.091.7100.0100.0100.0100.0100.0100.091.788.991.7100.0100.077.8100.0100.083.3100.0
Urea Nitrogen: Normal to Grade 1000000008.3000022.20016.70
Urea Nitrogen: Normal to Grade200000000008.30000000
Urea Nitrogen: Grade1 to Normal08.30000000000000000
Urea Nitrogen: Grade 1 to Grade 200000000011.100000000
WBC Decrease: Baseline Normal to Normal100.091.7100.088.9100.0100.091.7100.0100.077.8100.091.7100.0100.075.0100.091.7100.0
WBC Decrease: Normal to Grade108.3011.1008.30022.208.30016.7000
WBC Decrease: Grade1 to Normal000000000000008.3000
WBC Decrease: Grade 1 to Grade 100000000000000008.30
PrimaryPercentage of Participants With Grade Shift in Hematology Parameters 7 Days After Dose 2: Phase 1

Percentage of participants with grade shift in hematology parameters reported in this outcome measure. Grade(G)1: Mild, G2:Moderate, G3:Severe, G4:potentially life threatening. Hemoglobin(Female): G1: 11.0 - 12.0grams per deciliter(g/dL), G2: 9.5 - 10.9, G3: 8.0 - 9.4, G4: \<8.0. Hemoglobin(Male): G1: 12.5 - 13.5, G2: 10.5 - 12.4, G3: 8.5 - 10.4, G4: \<8.5. WBC decrease(cells/mm3):G1: 2,500 - 3,500, G2: 1,500 - 2,499, G3: 1,000 - 1,499, G4: \<1,000 Lymphocytes decrease(cells/mm3): G1: 750 - 1,000, G2: 500 - 749, G3: 250 - 499, G4: \<250. Eosinophils(cells/mm3):G1: 650 - 1500, G2: 1501 - 5000, G3: \>5000, G4:Hypereosinophilic. Platelets decreased(cells/mm3): G1: 125,000 - 140,000, G2: 100,000 - 124,000, G3: 25,000 - 99,000, G4: \<25,000. Urea Nitrogen (mg/dl): G1: 23-26; G2:27-31; G3: \>31; G4: requires dialysis. Only parameters where grade shift was observed were reported.

Time frame:
7 Days After Dose 2
Reported as:
Number · Percentage of participants
Percentage of Participants With Grade Shift in Hematology Parameters 7 Days After Dose 2: Phase 1
Percentage of participantsBNT162b1 10 mcg Dose: 18-55 Years of AgeBNT162b1 20 mcg Dose: 18-55 Years of AgeBNT162b1 30 mcg Dose: 18-55 Years of AgePlacebo: 18-55 Years of Age for BNT162b1BNT162b2 10 mcg Dose, 18-55 Years of AgeBNT162b2 20 mcg Dose, 18-55 Years of AgeBNT162b2 30 mcg Dose, 18-55 Years of AgeBNT162b1 10 mcg Dose, 65-85 Years of AgeBNT162b1 20 mcg Dose, 65-85 Years of AgeBNT162b1 30 mcg Dose, 65-85 Years of AgePlacebo, 65-85 Years of Age for BNT162b1BNT162b2 10 mcg Dose, 65-85 Years of AgeBNT162b2 20 mcg Dose, 65-85 Years of AgeBNT162b2 30 mcg Dose, 65-85 Years of AgePlacebo: 65-85 Years of Age for BNT162b2Placebo: 18-55 Years of Age for BNT162b2
Hemoglobin: Baseline Normal to Normal58.366.791.788.991.7100.066.788.983.383.383.388.983.391.791.7100.0
Hemoglobin: Normal to Grade 18.38.38.311.18.3016.711.18.3016.711.18.3000
Hemoglobin: Grade 1 to Normal25.00000016.7008.300008.30
Hemoglobin: Grade 1 to Grade 18.325.000000008.3008.38.300
Hemoglobin: Grade 2 to Grade 2000000008.30000000
Eosinophils: Baseline Normal to Normal100.0100.0100.0100.0100.0100.0100.0100.0100.0100.091.7100.0100.0100.0100.0100.0
Eosinophils: Baseline Normal to Grade 100000000008.300000
Eosinophils: Grade 1 to Normal0000000000000000
Lymphocytes: Baseline Normal to Normal91.783.3100.088.9100.0100.0100.077.8100.083.3100.0100.0100.0100.091.788.9
Lymphocytes: Normal to Grade 1000000011.100000000
Lymphocytes: Grade 1 to Normal000000011.1016.7000000
Lymphocytes: Grade 1 to Grade 18.316.7011.1000000000000
Lymphocytes: Grade 1 to Grade 2000000000000008.311.1
Platelets Decrease: Baseline Normal to Normal100.0100.091.7100.0100.0100.0100.0100.0100.0100.0100.0100.0100.0100.088.9100.0
Platelets Decrease: Normal to Grade 1008.30000000000000
Platelets Decrease: Grade 1 to Grade 10000000000000000
Platelets Decrease: Grade 2 to Grade 10000000000000011.10
Urea Nitrogen: Baseline Normal to Normal100.0100.0100.0100.0100.091.791.791.791.7100.077.891.783.375.0100.088.9
Urea Nitrogen: Normal to Grade 1000008.3000008.316.78.300
Urea Nitrogen: Grade 1 to Normal0000008.300011.100000
Urea Nitrogen: Grade 2 to Grade 200000000000000011.1
Urea Nitrogen: Grade 1 to Grade 1000000000000016.700
Urea Nitrogen: Grade 2 to Normal00000008.300000000
Urea Nitrogen: Normal to Grade 2000000008.30000000
Urea Nitrogen: Grade 1 to Grade 2000000000011.100000
WBC Decrease: Baseline Normal to Normal91.783.391.788.991.7100.0100.0100.083.3100.0100.075.0100.091.7100.077.8
WBC Decrease: Normal to Grade 18.38.38.3000008.3008.30000
WBC Decrease: Grade 1 to Normal08.3011.100008.300000022.2
WBC Decrease: Grade 1 to Grade 100008.300000016.708.300
PrimaryPercentage of Participants With Grade Shift in Chemistry Parameters 1 Day After Dose 1: Phase 1

Percentage of participants with grade shift in chemistry were reported in this outcome measure. G1: Mild, G2: Moderate, G3: Severe, G4: potentially life threatening. BUN(milligram per deciliter \[mg/dL\]): G1: 23 - 26, G2: 27 - 31, G3: \>31, G4: required dialysis. Creatinine(mg/dL): G1: 1.5 - 1.7, G2: 1.8 - 2.0, G3: 2.1 - 2.5, G4: \> 2.5 or required dialysis. Alkaline phosphate(increase by factor): G1: 1.1 - 2.0 x ULN G2: 2.1 - 3.0 x ULN G3: 3.1 -10 x ULN, G4: \>10 x ULN. Liver function tests(ALT, AST increase by factor): G1: 1.1 - 2.5 x ULN G2: 2.6 - 5.0 x ULN G3: 5.1 - 10 x ULN, G4: \>10 x ULN. Bilirubin(when accompanied by any increase in liver function test - increase by factor): G1: 1.1 - 1.25 x ULN G2: 1.26 - 1.5 x ULN G3: 1.51 - 1.75 x ULN, G4: \>1.75 x ULN. Bilirubin(when liver function test is normal - increase by factor): G1: 1.1 - 1.5 x ULN, G2: 1.6 - 2.0 x ULN, G3: 2.0 - 3.0 x ULN, G4: \>3.0 x ULN. Only parameters where grade shift was observed were reported.

Time frame:
1 Day After Dose 1
Reported as:
Number · Percentage of participants
Percentage of Participants With Grade Shift in Chemistry Parameters 1 Day After Dose 1: Phase 1
Percentage of participantsBNT162b1 10 mcg Dose: 18-55 Years of AgeBNT162b1 20 mcg Dose: 18-55 Years of AgeBNT162b1 30 mcg Dose: 18-55 Years of AgePlacebo: 18-55 Years of Age for BNT162b1BNT162b1 100 mcg Dose, 18-55 Years of AgePlacebo 18-55 Years of Age for BNT162b1 100 mcgBNT162b2 10 mcg Dose, 18-55 Years of AgeBNT162b2 20 mcg Dose, 18-55 Years of AgeBNT162b2 30 mcg Dose, 18-55 Years of AgePlacebo: 18-55 Years of Age for BNT162b2BNT162b1 10 mcg Dose, 65-85 Years of AgeBNT162b1 20 mcg Dose, 65-85 Years of AgeBNT162b1 30 mcg Dose, 65-85 Years of AgePlacebo, 65-85 Years of Age for BNT162b1BNT162b2 10 mcg Dose, 65-85 Years of AgeBNT162b2 20 mcg Dose, 65-85 Years of AgeBNT162b2 30 mcg Dose, 65-85 Years of AgePlacebo: 65-85 Years of Age for BNT162b2
ALT Increased: Baseline Normal to Normal000000091.791.7000088.90000
ALT Increased: Normal to Grade 100000008.30000011.10000
ALT Increased: Grade 1 to Grade 1000000008.3000000000
ALP Increased: Baseline Normal to Normal00000000000091.788.90000
ALP Increased: Grade 1 to Grade 10000000000008.300000
ALP Increased: Grade 1 to Normal000000000000011.10000
AST Increased: Baseline Normal to Normal000000000000000091.70
AST Increased: Normal to Grade 100000000000000008.30
Bilirubin: Baseline Normal to Normal000091.7091.70088.900000000
Bilirubin: Grade 2 to Grade 300008.308.300000000000
Bilirubin: Grade 1 to Grade 100000000011.100000000
PrimaryPercentage of Participants With Grade Shift in Chemistry Parameters 7 Days After Dose 1: Phase 1

Percentage of participants with grade shift in chemistry were reported in this outcome measure. G1: Mild, G2: Moderate, G3: Severe, G4: potentially life threatening. BUN(mg/dL): G1: 23 - 26, G2: 27 - 31, G3: \>31, G4: required dialysis. Creatinine(mg/dL): G1: 1.5 - 1.7, G2: 1.8 - 2.0, G3: 2.1 - 2.5, G4: \> 2.5 or required dialysis. Alkaline phosphate(increase by factor): G1: 1.1 - 2.0 x ULN G2: 2.1 - 3.0 x ULN G3: 3.1 -10 x ULN, G4: \>10 x ULN. Liver function tests(ALT, AST increase by factor): G1: 1.1 - 2.5 x ULN G2: 2.6 - 5.0 x ULN G3: 5.1 - 10 x ULN, G4: \>10 x ULN. Bilirubin(when accompanied by any increase in liver function test - increase by factor): G1: 1.1 - 1.25 x ULN G2: 1.26 - 1.5 x ULN G3: 1.51 - 1.75 x ULN, G4: \>1.75 x ULN. Bilirubin(when liver function test is normal - increase by factor): G1: 1.1 - 1.5 x ULN, G2: 1.6 - 2.0 x ULN, G3: 2.0 - 3.0 x ULN, G4: \>3.0 x ULN. Only parameters where grade shift was observed were reported.

Time frame:
7 Days After Dose 1
Reported as:
Number · Percentage of participants
Percentage of Participants With Grade Shift in Chemistry Parameters 7 Days After Dose 1: Phase 1
Percentage of participantsBNT162b1 10 mcg Dose: 18-55 Years of AgeBNT162b1 20 mcg Dose: 18-55 Years of AgeBNT162b1 30 mcg Dose: 18-55 Years of AgePlacebo: 18-55 Years of Age for BNT162b1BNT162b1 100 mcg Dose, 18-55 Years of AgePlacebo 18-55 Years of Age for BNT162b1 100 mcgBNT162b2 10 mcg Dose, 18-55 Years of AgeBNT162b2 20 mcg Dose, 18-55 Years of AgeBNT162b2 30 mcg Dose, 18-55 Years of AgePlacebo: 18-55 Years of Age for BNT162b2BNT162b1 10 mcg Dose, 65-85 Years of AgeBNT162b1 20 mcg Dose, 65-85 Years of AgeBNT162b1 30 mcg Dose, 65-85 Years of AgePlacebo, 65-85 Years of Age for BNT162b1BNT162b2 10 mcg Dose, 65-85 Years of AgeBNT162b2 20 mcg Dose, 65-85 Years of AgeBNT162b2 30 mcg Dose, 65-85 Years of AgePlacebo: 65-85 Years of Age for BNT162b2
ALT Increased: Baseline Normal to Normal000000091.791.7000000000
ALT Increased: Normal to Grade 100000008.30000000000
ALT Increased: Grade 1 to Grade 1000000008.3000000000
ALP Increased: Baseline Normal to Normal00000000000091.788.90000
ALP Increased: Grade 1 to Grade 10000000000008.311.10000
Bilirubin: Baseline Normal to Normal0091.700091.700000000091.70
Bilirubin: Normal to Grade 1008.300000000000008.30
Bilirubin: Grade 2 to Grade 10000008.300000000000
Bilirubin: Grade 1 to Grade 200000000011.100000000
Creatinine Increased: Baseline Normal to Normal00000000088.900000000
Creatinine Increased: Normal to Grade 100000000011.100000000
PrimaryPercentage of Participants With Grade Shift in Chemistry Parameters Before Dose 2: Phase 1

Percentage of participants with grade shift in chemistry were reported in this outcome measure. G1: Mild, G2: Moderate, G3: Severe, G4: potentially life threatening. BUN(mg/dL): G1: 23 - 26, G2: 27 - 31, G3: \>31, G4: required dialysis. Creatinine(mg/dL): G1: 1.5 - 1.7, G2: 1.8 - 2.0, G3: 2.1 - 2.5, G4: \> 2.5 or required dialysis. Alkaline phosphate(increase by factor): G1: 1.1 - 2.0 x ULN G2: 2.1 - 3.0 x ULN G3: 3.1 -10 x ULN, G4: \>10 x ULN. Liver function tests(ALT, AST increase by factor): G1: 1.1 - 2.5 x ULN G2: 2.6 - 5.0 x ULN G3: 5.1 - 10 x ULN, G4: \>10 x ULN. Bilirubin(when accompanied by any increase in liver function test - increase by factor): G1: 1.1 - 1.25 x ULN G2: 1.26 - 1.5 x ULN G3: 1.51 - 1.75 x ULN, G4: \>1.75 x ULN. Bilirubin(when liver function test is normal - increase by factor): G1: 1.1 - 1.5 x ULN, G2: 1.6 - 2.0 x ULN, G3: 2.0 - 3.0 x ULN, G4: \>3.0 x ULN. Only parameters where grade shift was observed were reported.

Time frame:
Before Dose 2
Reported as:
Number · Percentage of participants
Percentage of Participants With Grade Shift in Chemistry Parameters Before Dose 2: Phase 1
Percentage of participantsBNT162b1 10 mcg Dose: 18-55 Years of AgeBNT162b1 20 mcg Dose: 18-55 Years of AgeBNT162b1 30 mcg Dose: 18-55 Years of AgePlacebo: 18-55 Years of Age for BNT162b1BNT162b1 100 mcg Dose, 18-55 Years of AgePlacebo 18-55 Years of Age for BNT162b1 100 mcgBNT162b2 10 mcg Dose, 18-55 Years of AgeBNT162b2 20 mcg Dose, 18-55 Years of AgeBNT162b2 30 mcg Dose, 18-55 Years of AgePlacebo: 18-55 Years of Age for BNT162b2BNT162b1 10 mcg Dose, 65-85 Years of AgeBNT162b1 20 mcg Dose, 65-85 Years of AgeBNT162b1 30 mcg Dose, 65-85 Years of AgePlacebo, 65-85 Years of Age for BNT162b1BNT162b2 10 mcg Dose, 65-85 Years of AgeBNT162b2 20 mcg Dose, 65-85 Years of AgeBNT162b2 30 mcg Dose, 65-85 Years of AgePlacebo: 65-85 Years of Age for BNT162b2
ALT Increased: Baseline Normal to Normal091.70000091.791.7000000000
ALT Increased: Normal to Grade 108.3000008.30000000000
ALT Increased: Grade 1 to Normal000000008.3000000000
ALP Increased: Baseline Normal to Normal00000000000091.788.90000
ALP Increased: Grade 1 to Grade 10000000000008.311.10000
AST Increased: Baseline Normal to Normal090.990.9000000000085.70000
AST Increased: Normal to Grade 109.19.1000000000014.30000
Bilirubin: Baseline Normal to Normal0091.700091.7091.788.900000000
Bilirubin: Normal to Grade 1008.3000008.3000000000
Bilirubin: Grade 2 to Grade 10000008.300000000000
Bilirubin: Grade 1 to Grade 100000000011.100000000
Creatinine Increased: Baseline Normal to Normal00000000088.900000000
Creatinine Increased: Normal to Grade 100000000011.100000000
PrimaryPercentage of Participants With Grade Shift in Chemistry Parameters 7 Days After Dose 2: Phase 1

Percentage of participants with grade shift in chemistry were reported in this outcome measure. G1: Mild, G2: Moderate, G3: Severe, G4: potentially life threatening. BUN(mg/dL): G1: 23 - 26, G2: 27 - 31, G3: \>31, G4: required dialysis. Creatinine(mg/dL): G1: 1.5 - 1.7, G2: 1.8 - 2.0, G3: 2.1 - 2.5, G4: \> 2.5 or required dialysis. Alkaline phosphate(increase by factor): G1: 1.1 - 2.0 x ULN G2: 2.1 - 3.0 x ULN G3: 3.1 -10 x ULN, G4: \>10 x ULN. Liver function tests(ALT, AST increase by factor): G1: 1.1 - 2.5 x ULN G2: 2.6 - 5.0 x ULN G3: 5.1 - 10 x ULN, G4: \>10 x ULN. Bilirubin(when accompanied by any increase in liver function test - increase by factor): G1: 1.1 - 1.25 x ULN G2: 1.26 - 1.5 x ULN G3: 1.51 - 1.75 x ULN, G4: \>1.75 x ULN. Bilirubin(when liver function test is normal - increase by factor): G1: 1.1 - 1.5 x ULN, G2: 1.6 - 2.0 x ULN, G3: 2.0 - 3.0 x ULN, G4: \>3.0 x ULN. Only parameters where grade shift was observed were reported.

Time frame:
7 Days After Dose 2
Reported as:
Number · Percentage of participants
Percentage of Participants With Grade Shift in Chemistry Parameters 7 Days After Dose 2: Phase 1
Percentage of participantsBNT162b1 10 mcg Dose: 18-55 Years of AgeBNT162b1 20 mcg Dose: 18-55 Years of AgeBNT162b1 30 mcg Dose: 18-55 Years of AgePlacebo: 18-55 Years of Age for BNT162b1BNT162b2 10 mcg Dose, 18-55 Years of AgeBNT162b2 20 mcg Dose, 18-55 Years of AgeBNT162b2 30 mcg Dose, 18-55 Years of AgePlacebo: 18-55 Years of Age for BNT162b2BNT162b1 10 mcg Dose, 65-85 Years of AgeBNT162b1 20 mcg Dose, 65-85 Years of AgeBNT162b1 30 mcg Dose, 65-85 Years of AgePlacebo, 65-85 Years of Age for BNT162b1BNT162b2 10 mcg Dose, 65-85 Years of AgeBNT162b2 20 mcg Dose, 65-85 Years of AgeBNT162b2 30 mcg Dose, 65-85 Years of AgePlacebo: 65-85 Years of Age for BNT162b2
ALT Increased: Baseline Normal to Normal091.791.70091.783.3000000000
ALT Increased: Grade 1 to Normal08.3000016.7000000000
ALT Increased: Normal to Grade 1008.30000000000000
ALT Increased: Grade 1 to Grade 1000008.30000000000
ALP Increased: Baseline Normal to Normal00000000091.791.788.90000
ALP Increased: Normal to Grade 10000000008.3000000
ALP Increased: Grade 1 to Grade 100000000008.311.10000
AST Increased: Baseline Normal to Normal090.991.700090.9000085.70091.70
AST Increased: Grade 1 to Normal09.100000000014.30000
AST Increased: Grade 1 to Grade 1008.30000000000000
AST Increased: Normal to Grade 10000009.100000008.30
Bilirubin: Baseline Normal to Normal0091.7091.7091.788.900000000
Bilirubin: Grade 1 to Normal008.30008.3000000000
Bilirubin: Grade 1 to Grade 100008.300000000000
Bilirubin: Grade 1 to Grade 2000000011.100000000
Creatinine Increased: Baseline Normal to Normal000000088.900000000
Creatinine Increased: Grade 1 to Normal000000011.100000000
PrimaryPercentage of Participants With Local Reactions Within 7 Days After Dose 1: Phase 2/3

Local reactions included redness, swelling and, pain at the injection site, recorded by participants or parents/legal guardians in an e-diary. Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 cm. Redness and swelling were graded as mild (\> 2.0 to 5.0 cm), moderate (\> 5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis or exfoliative dermatitis for redness and necrosis for swelling). Pain at injection site was graded as mild (does not interfere with activity), moderate (interferes with activity), severe (prevents daily activity) and Grade 4 (emergency room visit or hospitalization for severe pain).

Time frame:
Within 7 Days after Dose 1
Reported as:
Number · Percentage of participants
Percentage of Participants With Local Reactions Within 7 Days After Dose 1: Phase 2/3
Percentage of participantsBNT162b2 (30 mcg): 16-55 YearsBNT162b2 (30 mcg): 56-85 YearsPlacebo: 16-55 YearsPlacebo: 56 to 85 YearsBNT162b2 (30 mcg): 12-15 Years of AgePlacebo: 12-15 Years of Age
Redness: Mild3.9 (3.2 to 4.7)3.5 (2.8 to 4.4)0.7 (0.4 to 1.0)0.7 (0.3 to 1.1)3.9 (2.9 to 5.2)1.0 (0.5 to 1.7)
Redness: Moderate1.2 (0.9 to 1.7)1.5 (1.0 to 2.1)0.2 (0.1 to 0.4)0.3 (0.1 to 0.6)1.8 (1.1 to 2.7)0.1 (0.0 to 0.5)
Redness: Severe0.2 (0.1 to 0.5)0.2 (0.1 to 0.6)0.1 (0.0 to 0.3)0.1 (0.0 to 0.4)0.1 (0.0 to 0.5)0.0 (0.0 to 0.3)
Redness: Grade 40 (0.0 to 0.1)0.0 (0.0 to 0.2)0.0 (0.0 to 0.1)0.0 (0.0 to 0.2)0.0 (0.0 to 0.3)0.0 (0.0 to 0.3)
Swelling: Mild4.3 (3.6 to 5.1)4.3 (3.5 to 5.3)0.2 (0.1 to 0.4)0.6 (0.3 to 1.0)4.9 (3.7 to 6.3)0.8 (0.4 to 1.5)
Swelling: Moderate1.9 (1.4 to 2.4)2.6 (1.9 to 3.4)0.3 (0.1 to 0.5)0.6 (0.3 to 1.1)2.0 (1.3 to 3.0)0.2 (0.0 to 0.6)
Swelling: Severe0.2 (0.1 to 0.4)0.1 (0.0 to 0.4)0.1 (0.0 to 0.2)0 (0.0 to 0.2)0.0 (0.0 to 0.3)0.0 (0.0 to 0.3)
Swelling: Grade 40 (0.0 to 0.1)0.0 (0.0 to 0.2)0 (0.0 to 0.1)0 (0.0 to 0.2)0.0 (0.0 to 0.3)0 (0.0 to 0.3)
Pain at injection site: Mild50.5 (48.7 to 52.3)55.2 (53.0 to 57.4)13.4 (12.2 to 14.7)8.9 (7.7 to 10.2)41.4 (38.5 to 44.4)20.1 (17.8 to 22.6)
Pain at injection site: Moderate31.8 (30.1 to 33.6)14.7 (13.2 to 16.4)0.7 (0.4 to 1.1)0.4 (0.2 to 0.8)43.7 (40.8 to 46.7)3.2 (2.2 to 4.4)
Pain at injection site: Severe1.3 (1.0 to 1.8)0.2 (0.1 to 0.5)0.1 (0.0 to 0.3)0.0 (0.0 to 0.2)1.0 (0.5 to 1.7)0.0 (0.0 to 0.3)
Pain at injection site: Grade 40.0 (0.0 to 0.1)0.0 (0.0 to 0.2)0.0 (0.0 to 0.1)0.0 (0.0 to 0.2)0.0 (0.0 to 0.3)0.0 (0.0 to 0.3)
PrimaryPercentage of Participants With Local Reactions Within 7 Days After Dose 2: Phase 2/3

Local reactions included redness, swelling and, pain at the injection site, recorded by participants or parents/legal guardians in an e-diary. Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 cm. Redness and swelling were graded as mild (\> 2.0 to 5.0 cm), moderate (\> 5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis or exfoliative dermatitis for redness and necrosis for swelling). Pain at injection site was graded as mild (does not interfere with activity), moderate (interferes with activity), severe (prevents daily activity) and Grade 4 (emergency room visit or hospitalization for severe pain).

Time frame:
Within 7 Days after Dose 2
Reported as:
Number · Percentage of participants
Percentage of Participants With Local Reactions Within 7 Days After Dose 2: Phase 2/3
Percentage of participantsBNT162b2 (30 mcg): 16-55 YearsBNT162b2 (30 mcg): 56-85 YearsPlacebo: 16-55 YearsPlacebo: 56 to 85 YearsBNT162b2 (30 mcg): 12-15 Years of AgePlacebo: 12-15 Years of Age
Redness: Mild3.4 (2.7 to 4.1)3.5 (2.7 to 4.4)0.4 (0.2 to 0.8)0.5 (0.3 to 1.0)2.6 (1.8 to 3.8)0.7 (0.3 to 1.5)
Redness: Moderate1.9 (1.4 to 2.5)3.1 (2.4 to 4.0)0.2 (0.1 to 0.5)0.2 (0.0 to 0.5)2.4 (1.6 to 3.5)0.2 (0.0 to 0.7)
Redness: Severe0.4 (0.2 to 0.7)0.5 (0.3 to 1.0)0.0 (0.0 to 0.1)0.1 (0.0 to 0.3)0.1 (0.0 to 0.3)0.0 (0.0 to 0.3)
Redness: Grade 40 (0.0 to 0.1)0.0 (0.0 to 0.2)0.0 (0.0 to 0.1)0.0 (0.0 to 0.2)0.0 (0.0 to 0.3)0.0 (0.0 to 0.3)
Swelling: Mild4.1 (3.4 to 4.9)4.3 (3.4 to 5.3)0.1 (0.0 to 0.3)0.3 (0.1 to 0.6)3.3 (2.3 to 4.5)0.4 (0.1 to 1.9)
Swelling: Moderate2.5 (1.9 to 3.1)3.3 (2.5 to 4.2)0.1 (0.0 to 0.3)0.4 (0.2 to 0.8)1.6 (1.0 to 2.6)0.2 (0.0 to 0.7)
Swelling: Severe0.3 (0.1 to 0.5)0.2 (0.1 to 0.5)0.0 (0.0 to 0.1)0.1 (0.0 to 0.3)0.0 (0.0 to 0.3)0.0 (0.0 to 0.3)
Swelling: Grade 40 (0.0 to 0.1)0.0 (0.0 to 0.2)0 (0.0 to 0.1)0 (0.0 to 0.2)0.0 (0.0 to 0.3)0 (0.0 to 0.3)
Pain at injection site: Mild47.5 (45.6 to 49.4)46.9 (44.6 to 49.2)10.6 (9.4 to 11.8)7.5 (6.4 to 8.8)42.5 (39.5 to 45.5)15.2 (13.1 to 17.5)
Pain at injection site: Moderate29.4 (27.7 to 31.1)18.7 (16.9 to 20.5)1.0 (0.7 to 1.5)0.3 (0.1 to 0.6)35.8 (33.0 to 38.7)2.7 (1.8 to 3.8)
Pain at injection site: Severe1.5 (1.0 to 2.0)0.5 (0.3 to 1.0)0.0 (0.0 to 0.1)0.0 (0.0 to 0.2)0.6 (0.3 to 1.3)0.0 (0.0 to 0.3)
Pain at injection site: Grade 40.0 (0.0 to 0.1)0.0 (0.0 to 0.2)0.0 (0.0 to 0.1)0.0 (0.0 to 0.2)0.0 (0.0 to 0.3)0.0 (0.0 to 0.3)
PrimaryPercentage of Participants With Systemic Events Within 7 Days After Dose 1: Phase 2/3

Systemic events included fever, fatigue, headache, chills, vomiting, diarrhea, new or worsened muscle pain, new or worsened joint pain recorded by participants or parents/legal guardians of participants using e-diary. Fever=temperature \>=38.0 deg C categorized as \>=38.0 to 38.4, \>38.4 to 38.9, \>38.9 to 40.0 and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain, new or worsened joint pain graded as mild (does not interfere with activity), moderate (some interference with activity), severe (prevents daily routine activity), Grade 4 (Emergency room visit/hospitalization). Vomiting: mild (1-2 times in 24 h), moderate (\>2 times in 24 h), severe (requires IV hydration), Grade 4 (emergency room visit/hospitalization for hypotensive shock). Diarrhea: mild (2-3 loose stools in 24h), moderate (4-5 loose stools in 24 h), severe (\>=6 loose stools in 24 h) and Grade 4 (emergency room visit/hospitalization).

Time frame:
Within 7 Days after Dose 1
Reported as:
Number · Percentage of participants
Percentage of Participants With Systemic Events Within 7 Days After Dose 1: Phase 2/3
Percentage of participantsBNT162b2 (30 mcg): 16-55 YearsPlacebo: 16-55 YearsBNT162b2 (30 mcg): 56-85 YearsPlacebo: 56 to 85 YearsBNT162b2 (30 mcg): 12-15 Years of AgePlacebo: 12-15 Years of Age
Fever: 38.0°C to 38.4°C3.0 (2.4 to 3.7)0.6 (0.3 to 0.9)1.1 (0.7 to 1.7)0.4 (0.2 to 0.8)6.6 (5.2 to 8.2)0.7 (0.3 to 1.4)
Fever: >38.4°C to 38.9°C0.9 (0.6 to 1.3)0.2 (0.1 to 0.4)0.1 (0.0 to 0.4)0.2 (0.0 to 0.4)2.6 (1.7 to 3.7)0.2 (0.0 to 0.6)
Fever: >38.9°C to 40.0°C0.3 (0.1 to 0.5)0.1 (0.0 to 0.4)0.0 (0.0 to 0.3)0.2 (0.0 to 0.4)0.9 (0.4 to 1.6)0.2 (0.0 to 0.6)
Fever: >40.0°C0 (0.0 to 0.1)0.0 (0.0 to 0.1)0.0 (0.0 to 0.2)0 (0.0 to 0.2)0.1 (0.0 to 0.5)0.0 (0.0 to 0.3)
Fatigue: Mild26.2 (24.6 to 27.9)19.6 (18.2 to 21.1)20.7 (18.9 to 22.5)14.1 (12.6 to 15.7)24.7 (22.2 to 27.3)22.2 (19.8 to 24.7)
Fatigue: Moderate21.7 (20.2 to 23.3)12.8 (11.6 to 14.1)12.9 (11.5 to 14.4)8.2 (7.0 to 9.5)34.1 (31.3 to 36.9)17.7 (15.5 to 20.0)
Fatigue: Severe1.4 (1.0 to 1.9)0.6 (0.4 to 1.0)0.1 (0.0 to 0.4)0.2 (0.0 to 0.4)1.3 (0.7 to 2.2)0.7 (0.3 to 1.4)
Fatigue: Grade 40 (0.0 to 0.1)0 (0.0 to 0.1)0 (0.0 to 0.2)0 (0.0 to 0.2)0 (0.0 to 0.3)0 (0.0 to 0.3)
Headache: Mild27.1 (25.5 to 28.7)21.8 (20.3 to 23.3)19.0 (17.3 to 20.8)13.4 (12.0 to 15.0)32.0 (29.3 to 34.8)22.7 (20.3 to 25.3)
Headache: Moderate15.3 (14.0 to 16.7)10.9 (9.8 to 12.1)6.0 (5.0 to 7.1)4.7 (3.8 to 5.7)22.3 (19.9 to 24.8)11.6 (9.8 to 13.6)
Headache: Severe1.1 (0.8 to 1.6)0.8 (0.5 to 1.2)0.1 (0.0 to 0.4)0.2 (0.0 to 0.4)1.0 (0.5 to 1.7)0.8 (0.4 to 1.5)
Headache: Grade 40.0 (0.0 to 0.1)0.0 (0.0 to 0.1)0.0 (0.0 to 0.2)0.0 (0.0 to 0.2)0.0 (0.0 to 0.3)0.0 (0.0 to 0.3)
Chills: Mild11.7 (10.5 to 12.9)5.1 (4.3 to 6.0)5.1 (4.2 to 6.1)2.5 (1.8 to 3.2)17.3 (15.1 to 19.6)7.3 (5.8 to 9.0)
Chills: Moderate4.3 (3.6 to 5.2)1.7 (1.2 to 2.2)1.4 (0.9 to 2.0)1.0 (0.6 to 1.5)9.8 (8.2 to 11.7)2.2 (1.4 to 3.3)
Chills: Severe0.5 (0.3 to 0.9)0.1 (0.0 to 0.2)0.0 (0.0 to 0.2)0.0 (0.0 to 0.2)0.4 (0.1 to 1.0)0.2 (0.0 to 0.6)
Chills: Grade 40.0 (0.0 to 0.1)0.0 (0.0 to 0.1)0.0 (0.0 to 0.2)0.0 (0.0 to 0.2)0.0 (0.0 to 0.3)0.0 (0.0 to 0.3)
Vomiting: Mild1.0 (0.7 to 1.4)1.0 (0.7 to 1.5)0.4 (0.2 to 0.8)0.5 (0.2 to 0.9)2.7 (1.8 to 3.8)0.7 (0.3 to 1.4)
Vomiting: Moderate0.2 (0.1 to 0.4)0.2 (0.1 to 0.4)0.0 (0.0 to 0.3)0.0 (0.0 to 0.2)0.0 (0.0 to 0.3)0.2 (0.0 to 0.6)
Vomiting: Severe0.0 (0.0 to 0.1)0.0 (0.0 to 0.2)0.0 (0.0 to 0.2)0.0 (0.0 to 0.2)0.1 (0.0 to 0.5)0.0 (0.0 to 0.3)
Vomiting: Grade 40.0 (0.0 to 0.1)0.0 (0.0 to 0.1)0.0 (0.0 to 0.2)0.0 (0.0 to 0.2)0.0 (0.0 to 0.3)0.0 (0.0 to 0.3)
Diarrhea: Mild8.7 (7.7 to 9.7)9.1 (8.1 to 10.2)6.8 (5.8 to 8.0)5.5 (4.5 to 6.6)6.8 (5.4 to 8.5)6.4 (5.0 to 8.0)
Diarrhea: Moderate1.9 (1.4 to 2.5)2.0 (1.5 to 2.6)1.3 (0.9 to 2.0)1.0 (0.6 to 1.5)1.2 (0.6 to 2.0)0.9 (0.4 to 1.6)
Diarrhea: Severe0.1 (0.0 to 0.3)0.0 (0.0 to 0.2)0.2 (0.1 to 0.5)0.1 (0.0 to 0.3)0.0 (0.0 to 0.3)0.0 (0.0 to 0.3)
Diarrhea: Grade 40.0 (0.0 to 0.1)0.0 (0.0 to 0.1)0.0 (0.0 to 0.2)0.0 (0.0 to 0.2)0.0 (0.0 to 0.3)0.0 (0.0 to 0.3)
New or worsened muscle pain: Mild12.2 (11.0 to 13.4)7.9 (7.0 to 9.0)9.1 (7.9 to 10.5)5.6 (4.6 to 6.7)11.1 (9.3 to 13.1)7.8 (6.3 to 9.5)
New or worsened muscle pain: Moderate10.2 (9.1 to 11.4)3.3 (2.7 to 4.0)4.5 (3.6 to 5.5)2.6 (1.9 to 3.4)12.9 (11.0 to 15.0)5.3 (4.1 to 6.8)
New or worsened muscle pain: Severe0.5 (0.3 to 0.9)0.1 (0.0 to 0.2)0.0 (0.0 to 0.3)0.2 (0.0 to 0.4)0.2 (0.0 to 0.6)0.0 (0.0 to 0.3)
New or worsened muscle pain: Grade 40.0 (0.0 to 0.1)0.0 (0.0 to 0.1)0.0 (0.0 to 0.2)0.0 (0.0 to 0.2)0.0 (0.0 to 0.3)0.0 (0.0 to 0.3)
New or worsened joint pain: Mild6.9 (6.0 to 7.9)3.9 (3.2 to 4.6)5.9 (4.9 to 7.0)3.9 (3.1 to 4.9)5.9 (4.6 to 7.4)4.4 (3.3 to 5.8)
New or worsened joint pain: Moderate4.7 (4.0 to 5.6)1.9 (1.4 to 2.5)2.6 (2.0 to 3.4)2.3 (1.7 to 3.0)3.7 (2.7 to 5.0)2.4 (1.6 to 3.5)
New or worsened joint pain: Severe0.2 (0.1 to 0.4)0.0 (0.0 to 0.2)0.1 (0.0 to 0.4)0.1 (0.0 to 0.3)0.1 (0.0 to 0.5)0 (0.0 to 0.3)
New or worsened joint pain: Grade 40.0 (0.0 to 0.1)0.0 (0.0 to 0.1)0.0 (0.0 to 0.2)0.0 (0.0 to 0.2)0 (0.0 to 0.3)0 (0.0 to 0.3)
PrimaryPercentage of Participants With Systemic Events Within 7 Days After Dose 2: Phase 2/3

Systemic events included fever, fatigue, headache, chills, vomiting, diarrhea, new or worsened muscle pain, new or worsened joint pain recorded by participants or parents/legal guardians of participants using e-diary. Fever=temperature \>=38.0 deg C categorized as \>=38.0 to 38.4, \>38.4 to 38.9, \>38.9 to 40.0 and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain, new or worsened joint pain graded as mild (does not interfere with activity), moderate (some interference with activity), severe (prevents daily routine activity), Grade 4 (Emergency room visit/hospitalization). Vomiting: mild (1-2 times in 24 h), moderate (\>2 times in 24 h), severe (requires IV hydration), Grade 4 (emergency room visit/hospitalization for hypotensive shock). Diarrhea: mild (2-3 loose stools in 24h), moderate (4-5 loose stools in 24 h), severe (\>=6 loose stools in 24 h) and Grade 4 (emergency room visit/hospitalization).

Time frame:
Within 7 Days after Dose 2
Reported as:
Number · Percentage of participants
Percentage of Participants With Systemic Events Within 7 Days After Dose 2: Phase 2/3
Percentage of participantsBNT162b2 (30 mcg): 16-55 YearsBNT162b2 (30 mcg): 56-85 YearsPlacebo: 16-55 YearsPlacebo: 56 to 85 YearsBNT162b2 (30 mcg): 12-15 Years of AgePlacebo: 12-15 Years of Age
Fever: 38.0°C to 38.4°C9.5 (8.4 to 10.6)8.5 (7.3 to 9.9)0.2 (0.1 to 0.4)0.1 (0.0 to 0.4)9.8 (8.1 to 11.7)0.5 (0.2 to 1.1)
Fever: >38.4°C to 38.9°C5.4 (4.6 to 6.4)2.9 (2.2 to 3.8)0.1 (0.0 to 0.4)0.1 (0.0 to 0.3)7.6 (6.1 to 9.3)0.1 (0.0 to 0.5)
Fever: >38.9°C to 40.0°C1.5 (1.0 to 2.0)0.4 (0.2 to 0.8)0.1 (0.0 to 0.3)0.0 (0.0 to 0.2)2.3 (1.5 to 3.3)0.1 (0.0 to 0.5)
Fever: >40.0°C0.0 (0.0 to 0.2)0.0 (0.0 to 0.2)0.0 (0.0 to 0.1)0 (0.0 to 0.2)0.0 (0.0 to 0.3)0.0 (0.0 to 0.3)
Fatigue: Mild20.8 (19.3 to 22.4)21.0 (19.2 to 22.9)11.8 (10.6 to 13.1)10.0 (8.6 to 11.4)21.1 (18.8 to 23.7)12.3 (10.4 to 14.5)
Fatigue: Moderate35.4 (33.6 to 37.2)26.7 (24.7 to 28.8)10.5 (9.4 to 11.8)6.6 (5.5 to 7.8)42.7 (39.7 to 45.7)11.8 (9.9 to 13.9)
Fatigue: Severe5.3 (4.5 to 6.2)3.2 (2.5 to 4.1)0.5 (0.3 to 0.9)0.1 (0.0 to 0.4)2.4 (1.6 to 3.5)0.4 (0.1 to 0.9)
Fatigue: Grade 40.0 (0.0 to 0.1)0.1 (0.0 to 0.3)0.0 (0.0 to 0.1)0.0 (0.0 to 0.2)0 (0.0 to 0.3)0 (0.0 to 0.3)
Headache: Mild26.1 (24.4 to 27.8)24.9 (23.0 to 27.0)15.1 (13.7 to 16.5)10.3 (9.0 to 11.8)27.5 (24.9 to 30.3)15.7 (13.6 to 18.0)
Headache: Moderate24.5 (22.9 to 26.2)26.7 (24.7 to 28.8)8.6 (7.5 to 9.7)3.5 (2.7 to 4.5)35.0 (32.2 to 37.9)8.6 (7.0 to 10.5)
Headache: Severe3.4 (2.7 to 4.1)3.2 (2.5 to 4.1)0.7 (0.4 to 1.1)0.3 (0.1 to 0.6)2.0 (1.3 to 3.0)0.1 (0.0 to 0.5)
Headache: Grade 40.0 (0.0 to 0.1)0.1 (0.0 to 0.3)0.0 (0.0 to 0.1)0.0 (0.0 to 0.2)0.0 (0.0 to 0.3)0.0 (0.0 to 0.3)
Chills: Mild17.8 (16.4 to 19.3)12.3 (10.9 to 13.9)3.3 (2.7 to 4.1)2.5 (1.8 to 3.3)20.1 (17.8 to 22.6)4.8 (3.6 to 6.3)
Chills: Moderate17.5 (16.1 to 19.0)9.9 (8.6 to 11.4)0.9 (0.5 to 1.3)0.0 (0.0 to 0.2)19.5 (17.2 to 22.0)1.9 (1.2 to 3.0)
Chills: Severe2.6 (2.0 to 3.2)1.1 (0.7 to 1.7)0.1 (0.0 to 0.3)0.0 (0.0 to 0.2)1.8 (1.1 to 2.8)0.0 (0.0 to 0.3)
Chills: Grade 40.0 (0.0 to 0.1)0.0 (0.0 to 0.2)0.0 (0.0 to 0.1)0.0 (0.0 to 0.2)0.0 (0.0 to 0.3)0.0 (0.0 to 0.3)
Vomiting: Mild1.6 (1.1 to 2.1)0.5 (0.3 to 1.0)0.7 (0.5 to 1.1)0.3 (0.1 to 0.6)2.3 (1.5 to 3.3)1.0 (0.5 to 1.8)
Vomiting: Moderate0.4 (0.2 to 0.8)0.1 (0.0 to 0.3)0.4 (0.2 to 0.7)0.0 (0.0 to 0.2)0.4 (0.1 to 1.9)0.1 (0.0 to 0.5)
Vomiting: Severe0.1 (0.0 to 0.4)0.1 (0.0 to 0.4)0.0 (0.0 to 0.1)0.0 (0.0 to 0.2)0.0 (0.0 to 0.3)0.0 (0.0 to 0.3)
Vomiting: Grade 40.0 (0.0 to 0.1)0.0 (0.0 to 0.2)0.0 (0.0 to 0.1)0.0 (0.0 to 0.2)0.0 (0.0 to 0.3)0.0 (0.0 to 0.3)
Diarrhea: Mild8.2 (7.2 to 9.3)6.7 (5.6 to 8.0)6.3 (5.4 to 7.3)4.1 (3.3 to 5.2)5.4 (4.1 to 6.9)3.5 (2.5 to 4.8)
Diarrhea: Moderate1.6 (1.2 to 2.2)1.3 (0.9 to 2.0)1.3 (0.9 to 1.8)1.2 (0.8 to 1.8)0.5 (0.2 to 1.2)0.5 (0.2 to 1.1)
Diarrhea: Severe0.2 (0.1 to 0.5)0.1 (0.1 to 0.4)0.0 (0.0 to 0.2)0.2 (0.1 to 0.6)0.0 (0.0 to 0.3)0.0 (0.0 to 0.3)
Diarrhea: Grade 40.0 (0.0 to 0.1)0.0 (0.0 to 0.2)0.0 (0.0 to 0.1)0.0 (0.0 to 0.2)0.0 (0.0 to 0.3)0.0 (0.0 to 0.3)
New or worsened muscle pain: Mild16.4 (15.1 to 17.9)12.3 (10.9 to 13.9)5.6 (4.7 to 6.5)3.5 (2.7 to 4.5)13.9 (11.9 to 16.0)4.7 (3.5 to 6.2)
New or worsened muscle pain: Moderate20.6 (19.1 to 22.2)15.5 (13.9 to 17.2)3.1 (2.5 to 3.9)1.8 (1.2 to 2.5)18.0 (15.7 to 20.4)3.4 (2.4 to 4.7)
New or worsened muscle pain: Severe2.3 (1.8 to 3.0)1.1 (0.7 to 1.7)0.1 (0.0 to 0.3)0.1 (0.0 to 0.3)0.5 (0.2 to 1.2)0.2 (0.0 to 0.7)
New or worsened muscle pain: Grade 40.0 (0.0 to 0.1)0.0 (0.0 to 0.2)0.0 (0.0 to 0.1)0.0 (0.0 to 0.2)0.0 (0.0 to 0.3)0.0 (0.0 to 0.3)
New or worsened joint pain: Mild10.9 (9.7 to 12.1)9.8 (8.5 to 11.3)3.1 (2.4 to 3.8)2.4 (1.7 to 3.2)8.3 (6.7 to 10.1)2.8 (1.9 to 3.9)
New or worsened joint pain: Moderate11.9 (10.7 to 13.2)8.7 (7.4 to 10.0)2.3 (1.7 to 2.9)1.5 (1.0 to 2.1)7.1 (5.7 to 8.8)1.9 (1.2 to 3.0)
New or worsened joint pain: Severe1.0 (0.7 to 1.5)0.5 (0.2 to 0.9)0.1 (0.0 to 0.4)0.1 (0.0 to 0.3)0.4 (0.1 to 0.9)0 (0.0 to 0.3)
New or worsened joint pain: Grade 40.0 (0.0 to 0.1)0.0 (0.0 to 0.2)0.0 (0.0 to 0.1)0.0 (0.0 to 0.2)0 (0.0 to 0.3)0 (0.0 to 0.3)
PrimaryPercentage of Participants Reporting Adverse Events From Dose 1 to 1 Month After Dose 2: Phase 2/3

An AE was any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. HIV positive participants were excluded from this analysis.

Time frame:
From Dose 1 to 1 Month After Dose 2
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting Adverse Events From Dose 1 to 1 Month After Dose 2: Phase 2/3
Percentage of participantsBNT162b2 (30 mcg): >=16 Years of AgePlacebo: >=16 Years of AgeBNT162b2 (30 mcg): 12-15 Years of AgePlacebo: 12-15 Years of Age
Percentage of Participants Reporting Adverse Events From Dose 1 to 1 Month After Dose 2: Phase 2/330.2 (29.6 to 30.8)13.9 (13.4 to 14.4)6.0 (4.7 to 7.6)5.9 (4.6 to 7.5)
PrimaryPercentage of Participants Reporting Serious Adverse Events From Dose 1 to 6 Months After Dose 2: Phase 2/3

An SAE was any untoward medical occurrence that occurred, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent or significant disability/ incapacity; was a congenital anomaly/birth defect and other important medical events. HIV positive participants were excluded from this analysis.

Time frame:
From Dose 1 to 6 Months After Dose 2
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting Serious Adverse Events From Dose 1 to 6 Months After Dose 2: Phase 2/3
Percentage of participantsBNT162b2 (30 mcg): 12-15 Years of AgePlacebo/BNT162b2 30 mcg: 12-15 Years of AgePlacebo: 12-15 Years of AgeBNT162b2 30 mcg: >=16 Years of AgePlacebo/BNT162b2 30 mcg: >=16 Years of AgePlacebo: >=16 Years of Age
Percentage of Participants Reporting Serious Adverse Events From Dose 1 to 6 Months After Dose 2: Phase 2/31.1 (0.6 to 2.0)1.3 (0.7 to 2.2)0.2 (0.0 to 0.6)2.0 (1.8 to 2.1)1.7 (1.6 to 1.9)1.3 (1.2 to 1.5)
PrimaryPercentage of Participants With Local Reactions Within 7 Days After Dose 1: Phase 2

Local reactions included redness, swelling and, pain at the injection site, recorded by participants in an e-diary. Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 cm. Redness and swelling were graded as mild (\> 2.0 to 5.0 cm), moderate (\> 5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis or exfoliative dermatitis for redness and necrosis for swelling). Pain at injection site was graded as mild (does not interfere with activity), moderate (interferes with activity), severe (prevents daily activity) and Grade 4 (emergency room visit or hospitalization for severe pain).

Time frame:
Within 7 Days after Dose 1
Reported as:
Number · Percentage of participants
Percentage of Participants With Local Reactions Within 7 Days After Dose 1: Phase 2
Percentage of participantsBNT162b2 (30 mcg): 18-55 Years of AgePlacebo:18-55 Years of AgeBNT162b2 (30 mcg): 56-85 Years of AgePlacebo: 56 to 85 Years of Age
Redness: Mild1.1 (0.0 to 6.2)1.7 (0.3 to 4.8)2.2 (0.3 to 7.6)0.6 (0.0 to 3.1)
Redness: Moderate2.3 (0.3 to 8.0)2.2 (0.6 to 5.6)2.2 (0.3 to 7.6)0 (0.0 to 2.0)
Redness: Severe0 (0.0 to 4.1)0 (0.0 to 2.0)0 (0.0 to 3.9)0 (0.0 to 2.0)
Redness: Grade 40 (0.0 to 4.1)0 (0.0 to 2.0)0 (0.0 to 3.9)0 (0.0 to 2.0)
Swelling: Mild2.3 (0.3 to 8.0)2.2 (0.6 to 5.6)2.2 (0.3 to 7.6)0 (0.0 to 2.0)
Swelling: Moderate4.5 (1.3 to 11.2)4.4 (1.9 to 8.6)4.3 (1.2 to 10.8)0 (0.0 to 2.0)
Swelling: Severe0 (0.0 to 4.1)0 (0.0 to 4.1)0 (0.0 to 3.9)0 (0.0 to 2.0)
Swelling: Grade 40 (0.0 to 4.1)0 (0.0 to 4.1)0 (0.0 to 3.9)0 (0.0 to 2.0)
Pain at injection site: Mild56.8 (45.8 to 67.3)55.0 (47.4 to 62.4)53.3 (42.6 to 63.7)8.9 (5.2 to 14.0)
Pain at injection site: Moderate28.4 (19.3 to 39.0)22.2 (16.4 to 29.0)16.3 (9.4 to 25.5)0 (0.0 to 2.0)
Pain at injection site: Severe0 (0.0 to 4.1)0.6 (0.0 to 3.1)1.1 (0.0 to 5.9)0 (0.0 to 2.0)
Pain at injection site: Grade 40 (0.0 to 4.1)0 (0.0 to 2.0)0 (0.0 to 3.9)0 (0.0 to 2.0)
PrimaryPercentage of Participants With Local Reactions Within 7 Days After Dose 2: Phase 2

Local reactions included redness, swelling and, pain at the injection site, recorded by participants in an e-diary. Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 cm. Redness and swelling were graded as mild (\> 2.0 to 5.0 cm), moderate (\> 5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis or exfoliative dermatitis for redness and necrosis for swelling). Pain at injection site was graded as mild (does not interfere with activity), moderate (interferes with activity), severe (prevents daily activity) and Grade 4 (emergency room visit or hospitalization for severe pain).

Time frame:
Within 7 Days after Dose 2
Reported as:
Number · Percentage of participants
Percentage of Participants With Local Reactions Within 7 Days After Dose 2: Phase 2
Percentage of participantsBNT162b2 (30 mcg): 18-55 Years of AgePlacebo:18-55 Years of AgeBNT162b2 (30 mcg): 56-85 Years of AgePlacebo: 56 to 85 Years of Age
Redness: Mild2.3 (0.3 to 8.1)2.3 (0.6 to 5.7)2.2 (0.3 to 7.7)0 (0.0 to 2.1)
Redness: Moderate1.2 (0.0 to 6.3)2.8 (0.9 to 6.5)4.4 (1.2 to 10.9)0 (0.0 to 2.1)
Redness: Severe0 (0.0 to 4.2)0.6 (0.0 to 3.1)1.1 (0.0 to 6.0)0 (0.0 to 2.1)
Redness: Grade 40 (0.0 to 4.2)0 (0.0 to 2.1)0 (0.0 to 4.0)0 (0.0 to 2.1)
Swelling: Mild3.5 (0.7 to 9.9)4.5 (2.0 to 8.7)5.5 (1.8 to 12.4)0 (0.0 to 2.1)
Swelling: Moderate0 (0.0 to 4.2)0 (0.0 to 4.2)0 (0.0 to 4.2)0 (0.0 to 2.1)
Swelling: Severe0 (0.0 to 4.2)0 (0.0 to 2.1)0 (0.0 to 4.0)0 (0.0 to 2.1)
Swelling: Grade 40 (0.0 to 4.2)0 (0.0 to 2.1)0 (0.0 to 4.0)0 (0.0 to 2.1)
Pain at injection site: Mild53.5 (42.4 to 64.3)54.2 (46.6 to 61.7)54.9 (44.2 to 65.4)8.5 (4.8 to 13.7)
Pain at injection site: Moderate25.6 (16.8 to 36.1)21.5 (15.7 to 28.3)17.6 (10.4 to 27.0)1.1 (0.1 to 4.0)
Pain at injection site: Severe1.2 (0.0 to 6.3)0.6 (0.0 to 3.1)0 (0.0 to 4.0)0 (0.0 to 2.1)
Pain at injection site: Grade 40 (0.0 to 4.2)0 (0.0 to 2.1)0 (0.0 to 4.0)0 (0.0 to 2.1)
PrimaryPercentage of Participants With Systemic Events Within 7 Days After Dose 1: Phase 2

Systemic events included fever, fatigue, headache, chills, vomiting, diarrhea, new or worsened muscle pain, new or worsened joint pain recorded by participants or parents/legal guardians of participants using e-diary. Fever=temperature \>=38.0 deg C categorized as \>=38.0 to 38.4, \>38.4 to 38.9, \>38.9 to 40.0 and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain, new or worsened joint pain graded as mild (does not interfere with activity), moderate (some interference with activity), severe (prevents daily routine activity), Grade 4 (Emergency room visit/hospitalization). Vomiting: mild (1-2 times in 24 h), moderate (\>2 times in 24 h), severe (requires IV hydration), Grade 4 (emergency room visit/hospitalization for hypotensive shock). Diarrhea: mild (2-3 loose stools in 24h), moderate (4-5 loose stools in 24 h), severe (\>=6 loose stools in 24 h) and Grade 4 (emergency room visit/hospitalization).

Time frame:
Within 7 Days after Dose 1
Reported as:
Number · Percentage of participants
Percentage of Participants With Systemic Events Within 7 Days After Dose 1: Phase 2
Percentage of participantsBNT162b2 (30 mcg): 18-55 Years of AgePlacebo: 18-55 Years of AgeBNT162b2 (30 mcg): 56-85 Years of AgePlacebo: 56 to 85 Years of Age
Fever: 38.0°C to 38.4°C0 (0.0 to 4.1)0 (0.0 to 2.0)0 (0.0 to 3.9)0 (0.0 to 2.0)
Fever: >38.4°C to 38.9°C3.4 (0.7 to 9.6)1.7 (0.3 to 4.8)0 (0.0 to 3.9)0 (0.0 to 2.0)
Fever: >38.9°C to 40.0°C0 (0.0 to 4.1)0 (0.0 to 2.0)0 (0.0 to 3.9)0 (0.0 to 2.0)
Fever: >40.0°C0 (0.0 to 4.1)0 (0.0 to 2.0)0 (0.0 to 3.9)0 (0.0 to 2.0)
Fatigue: Mild29.5 (20.3 to 40.2)23.3 (17.4 to 30.2)17.4 (10.3 to 26.7)17.8 (12.5 to 24.2)
Fatigue: Moderate20.5 (12.6 to 30.4)19.4 (13.9 to 26.0)18.5 (11.1 to 27.9)9.4 (5.6 to 14.7)
Fatigue: Severe0 (0.0 to 4.1)0 (0.0 to 2.0)0 (0.0 to 3.9)0 (0.0 to 2.0)
Fatigue: Grade 40 (0.0 to 4.1)0 (0.0 to 2.0)0 (0.0 to 3.9)0 (0.0 to 2.0)
Headache: Mild20.5 (12.6 to 30.4)21.7 (15.9 to 28.4)22.8 (14.7 to 32.8)15.6 (10.6 to 21.7)
Headache: Moderate11.4 (5.6 to 19.9)7.8 (4.3 to 12.7)4.3 (1.2 to 10.8)8.3 (4.7 to 13.4)
Headache: Severe0 (0.0 to 4.1)0 (0.0 to 2.0)0 (0.0 to 3.9)0.6 (0.0 to 3.1)
Headache: Grade 40 (0.0 to 4.1)0 (0.0 to 2.0)0 (0.0 to 3.9)0 (0.0 to 2.0)
Chills: Mild6.8 (2.5 to 14.3)6.1 (3.1 to 10.7)5.4 (1.8 to 12.2)3.9 (1.6 to 7.8)
Chills: Moderate2.3 (0.3 to 8.0)2.2 (0.6 to 5.6)2.2 (0.3 to 7.6)0 (0.0 to 2.0)
Chills: Severe0 (0.0 to 4.1)0 (0.0 to 2.0)0 (0.0 to 3.9)0 (0.0 to 2.0)
Chills: Grade 40 (0.0 to 4.1)0 (0.0 to 2.0)0 (0.0 to 3.9)0 (0.0 to 2.0)
Vomiting: Mild0 (0.0 to 4.1)0 (0.0 to 2.0)0 (0.0 to 3.9)0 (0.0 to 2.0)
Vomiting: Moderate0 (0.0 to 4.1)0 (0.0 to 2.0)0 (0.0 to 3.9)0 (0.0 to 2.0)
Vomiting: Severe0 (0.0 to 4.1)0 (0.0 to 2.0)0 (0. to 03.9)0 (0.0 to 2.0)
Vomiting: Grade 40 (0.0 to 4.1)0 (0.0 to 2.0)0 (0.0 to 3.9)0 (0.0 to 2.0)
Diarrhea: Mild10.2 (4.8 to 18.5)10.0 (6.0 to 15.3)9.8 (4.6 to 17.8)10.6 (6.5 to 16.0)
Diarrhea: Moderate6.8 (2.5 to 14.3)4.4 (1.9 to 8.6)2.2 (0.3 to 7.6)1.7 (0.3 to 4.8)
Diarrhea: Severe0 (0.0 to 4.1)0 (0.0 to 2.0)0 (0.0 to 3.9)0 (0.0 to 2.0)
Diarrhea: Grade 40 (0.0 to 4.1)0 (0.0 to 2.0)0 (0.0 to 3.9)0 (0.0 to 2.0)
New or worsened muscle pain: Mild13.6 (7.2 to 22.6)11.1 (6.9 to 16.6)8.7 (3.8 to 16.4)4.4 (1.9 to 8.6)
New or worsened muscle pain: Moderate10.2 (4.8 to 18.5)7.8 (4.3 to 12.7)5.4 (1.8 to 12.2)1.7 (0.3 to 4.8)
New or worsened muscle pain: Severe0 (0.0 to 4.1)0 (0.0 to 2.0)0 (0.0 to 3.9)0 (0.0 to 2.0)
New or worsened muscle pain: Grade 40 (0.0 to 4.1)0 (0.0 to 2.0)0 (0.0 to 3.9)0 (0.0 to 2.0)
New or worsened joint pain: Mild6.8 (2.5 to 14.3)5.0 (2.3 to 9.3)3.3 (0.7 to 9.2)2.2 (0.6 to 5.6)
New or worsened joint pain: Moderate2.3 (0.3 to 8.0)1.7 (0.3 to 4.8)1.1 (0.0 to 5.9)1.7 (0.3 to 4.8)
New or worsened joint pain: Severe0 (0.0 to 4.1)0 (0.0 to 2.0)0 (0.0 to 3.9)0 (0.0 to 2.0)
New or worsened joint pain: Grade 40 (0.0 to 4.1)0 (0.0 to 2.0)0 (0.0 to 3.9)0 (0.0 to 2.0)
PrimaryPercentage of Participants With Systemic Events Within 7 Days After Dose 2: Phase 2

Systemic events included fever, fatigue, headache, chills, vomiting, diarrhea, new or worsened muscle pain, new or worsened joint pain recorded by participants or parents/legal guardians of participants using e-diary. Fever=temperature \>=38.0 deg C categorized as \>=38.0 to 38.4, \>38.4 to 38.9, \>38.9 to 40.0 and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain, new or worsened joint pain graded as mild (does not interfere with activity), moderate (some interference with activity), severe (prevents daily routine activity), Grade 4 (Emergency room visit/hospitalization). Vomiting: mild (1-2 times in 24 h), moderate (\>2 times in 24 h), severe (requires IV hydration), Grade 4 (emergency room visit/hospitalization for hypotensive shock). Diarrhea: mild (2-3 loose stools in 24h), moderate (4-5 loose stools in 24 h), severe (\>=6 loose stools in 24 h) and Grade 4 (emergency room visit/hospitalization).

Time frame:
Within 7 Days After Dose 2
Reported as:
Number · Percentage of participants
Percentage of Participants With Systemic Events Within 7 Days After Dose 2: Phase 2
Percentage of participantsBNT162b2 (30 mcg): 18-55 Years of AgePlacebo:18-55 Years of AgeBNT162b2 (30 mcg): 56-85 Years of AgePlacebo: 56 to 85 Years of Age
Fever: 38.0°C to 38.4°C8.1 (3.3 to 16.1)7.9 (4.4 to 12.9)7.7 (3.1 to 15.2)0 (0.0 to 2.1)
Fever: >38.4°C to 38.9°C7.0 (2.6 to 14.6)5.1 (2.4 to 9.4)3.3 (0.7 to 9.3)0 (0.0 to 2.1)
Fever: >38.9°C to 40.0°C2.3 (0.3 to 8.1)1.1 (0.1 to 4.0)0 (0.0 to 4.0)0 (0.0 to 2.1)
Fever: >40.0°C0 (0.0 to 4.2)0 (0.0 to 2.1)0 (0.0 to 4.0)0 (0.0 to 2.1)
Fatigue: Mild16.3 (9.2 to 25.8)20.3 (14.7 to 27.0)24.2 (15.8 to 34.3)11.9 (7.5 to 17.7)
Fatigue: Moderate37.2 (27.0 to 48.3)31.6 (24.9 to 39.0)26.4 (17.7 to 36.7)8.5 (4.8 to 13.7)
Fatigue: Severe5.8 (1.9 to 13.0)4.0 (1.6 to 8.0)2.2 (0.3 to 7.7)0 (0.0 to 2.1)
Fatigue: Grade 40 (0.0 to 4.2)0 (0.0 to 2.1)0 (0.0 to 4.0)0 (0.0 to 2.1)
Headache: Mild22.1 (13.9 to 32.3)20.9 (15.2 to 27.6)19.8 (12.2 to 29.4)9.7 (5.7 to 15.0)
Headache: Moderate24.4 (15.8 to 34.9)19.8 (14.2 to 26.4)15.4 (8.7 to 24.5)6.3 (3.2 to 10.9)
Headache: Severe4.7 (1.3 to 11.5)2.8 (0.9 to 6.5)1.1 (0.0 to 6.0)0.6 (0.0 to 3.1)
Headache: Grade 40 (0.0 to 4.2)0 (0.0 to 2.1)0 (0.0 to 4.0)0 (0.0 to 2.1)
Chills: Mild22.1 (13.9 to 32.3)15.8 (10.8 to 22.0)9.9 (4.6 to 17.9)1.7 (0.4 to 4.9)
Chills: Moderate15.1 (8.3 to 24.5)12.4 (8.0 to 18.2)9.9 (4.6 to 17.9)0.6 (0.0 to 3.1)
Chills: Severe3.5 (0.7 to 9.9)2.3 (0.6 to 5.7)1.1 (0.0 to 6.0)0 (0.0 to 2.1)
Chills: Grade 40 (0.0 to 4.2)0 (0.0 to 2.1)0 (0.0 to 4.0)0 (0.0 to 2.1)
Vomiting: Mild2.3 (0.3 to 8.1)1.1 (0.1 to 4.0)0 (0.0 to 4.0)0.6 (0.0 to 3.1)
Vomiting: Moderate0 (0.0 to 4.2)0 (0.0 to 2.1)0 (0.0 to 4.0)0 (0.0 to 2.1)
Vomiting: Severe0 (0.0 to 4.2)0 (0.0 to 2.1)0 (0.0 to 4.0)0 (0.0 to 2.1)
Vomiting: Grade 40 (0.0 to 4.2)0 (0.0 to 2.1)0 (0.0 to 4.0)0 (0.0 to 2.1)
Diarrhea: Mild16.3 (9.2 to 25.8)11.3 (7.0 to 16.9)6.6 (2.5 to 13.8)6.8 (3.6 to 11.6)
Diarrhea: Moderate3.5 (0.7 to 9.9)2.8 (0.9 to 6.5)2.2 (0.3 to 7.7)1.1 (0.1 to 4.0)
Diarrhea: Severe0 (0.0 to 4.2)0 (0.0 to 2.1)0 (0.0 to 4.0)0 (0.0 to 2.1)
Diarrhea: Grade 40 (0.0 to 4.2)0 (0.0 to 2.1)0 (0.0 to 4.0)0 (0.0 to 2.1)
New or worsened muscle pain: Mild20.9 (12.9 to 31.0)16.4 (11.3 to 22.7)12.1 (6.2 to 20.6)2.3 (0.6 to 5.7)
New or worsened muscle pain: Moderate22.1 (13.9 to 32.3)18.6 (13.2 to 25.2)15.4 (8.7 to 24.5)1.1 (0.1 to 4.0)
New or worsened muscle pain: Severe0 (0.0 to 4.2)1.7 (0.4 to 4.9)1.1 (0.0 to 6.0)0 (0.0 to 2.1)
New or worsened muscle pain: Grade 40 (0.0 to 4.2)0 (0.0 to 2.1)0 (0.0 to 4.0)0 (0.0 to 2.1)
New or worsened joint pain: Mild9.3 (4.1 to 17.5)9.0 (5.3 to 14.3)8.8 (3.9 to 16.6)2.3 (0.6 to 5.7)
New or worsened joint pain: Moderate8.1 (3.3 to 16.1)7.9 (4.4 to 12.9)7.7 (3.1 to 15.2)2.3 (0.6 to 5.7)
New or worsened joint pain: Severe0 (0.0 to 4.2)0 (0.0 to 2.1)0 (0.0 to 4.0)0 (0.0 to 2.1)
New or worsened joint pain: Grade 40 (0.0 to 4.2)0 (0.0 to 2.1)0 (0.0 to 4.0)0 (0.0 to 2.1)
PrimaryPercentage of Participants Reporting Adverse Events From Dose 1 to 7 Days After Dose 2: Phase 2

An AE was any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment.

Time frame:
From Dose 1 to 7 Days After Dose 2
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting Adverse Events From Dose 1 to 7 Days After Dose 2: Phase 2
Percentage of participantsBNT162b2 (30 mcg): 18-55 Years of AgePlacebo:18-55 Years of AgeBNT162b2 (30 mcg): 56-85 Years of AgePlacebo: 56 to 85 Years of Age
Percentage of Participants Reporting Adverse Events From Dose 1 to 7 Days After Dose 2: Phase 29.1 (4.0 to 17.1)6.7 (3.5 to 11.4)4.3 (1.2 to 10.8)10.0 (6.0 to 15.3)
PrimaryPercentage of Participants Reporting Serious Adverse Events From Dose 1 to 7 Days After Dose 2: Phase 2

A SAE was any untoward medical occurrence that occurred, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent or significant disability/ incapacity; was a congenital anomaly/birth defect and other important medical events.

Time frame:
From Dose 1 to 7 Days After Dose 2
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting Serious Adverse Events From Dose 1 to 7 Days After Dose 2: Phase 2
Percentage of participantsBNT162b2 (30 mcg): 18-55 Years of AgePlacebo:18-55 Years of AgeBNT162b2 (30 mcg): 56-85 Years of AgePlacebo: 56 to 85 Years of Age
Percentage of Participants Reporting Serious Adverse Events From Dose 1 to 7 Days After Dose 2: Phase 21.1 (0.0 to 6.2)0.6 (0.0 to 3.1)0 (0.0 to 3.9)0 (0.0 to 2.0)
PrimaryPercentage of Participants With Local Reactions Within 7 Days After Booster Dose: BNT162b2 Experienced Participants Who Were Rerandomized to Receive 1 Booster Dose

Local reactions included redness, swelling and, pain at the injection site, recorded by participants or parents/legal guardians in an e-diary. Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 cm. Redness and swelling were graded as mild (\> 2.0 to 5.0 cm), moderate (\> 5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis or exfoliative dermatitis for redness and necrosis for swelling). Pain at injection site was graded as mild (does not interfere with activity), moderate (interferes with activity), severe (prevents daily activity) and Grade 4 (emergency room visit or hospitalization for severe pain). HIV positive participants were excluded.

Time frame:
Within 7 Days After Booster Dose
Reported as:
Number · Percentage of participants
Percentage of Participants With Local Reactions Within 7 Days After Booster Dose: BNT162b2 Experienced Participants Who Were Rerandomized to Receive 1 Booster Dose
Percentage of participantsBNT162b2 (30 mcg)BNT162b2SA (30 mcg)
Redness: Mild3.5 (1.7 to 6.3)1.7 (0.5 to 3.9)
Redness: Moderate2.4 (1.0 to 4.9)3.0 (1.4 to 5.7)
Redness: Severe0 (0.0 to 1.3)0.3 (0.0 to 1.9)
Redness: Grade 40 (0.0 to 1.3)0 (0.0 to 1.2)
Swelling: Mild4.5 (2.4 to 7.6)4.4 (2.3 to 7.3)
Swelling: Moderate3.1 (1.4 to 5.8)2.0 (0.7 to 4.3)
Swelling: Severe0.3 (0.0 to 1.9)0.3 (0.0 to 1.9)
Swelling: Grade 40 (0.0 to 1.3)0 (0.0 to 1.2)
Pain at injection site: Mild60.2 (54.3 to 65.9)53.0 (47.2 to 58.8)
Pain at injection site: Moderate22.5 (17.8 to 27.7)28.9 (23.8 to 34.4)
Pain at injection site: Severe0.3 (0.0 to 1.9)1.0 (0.2 to 2.9)
Pain at injection site: Grade 40 (0.0 to 1.3)0 (0.0 to 1.2)
PrimaryPercentage of Participants With Systemic Events Within 7 Days After Booster Dose 1: BNT162b2 Experienced Participants Who Were Rerandomized to Receive 1 Booster Dose

Systemic events included fever, fatigue, headache, chills, vomiting, diarrhea, new or worsened muscle pain, new or worsened joint pain recorded by participants or parents/legal guardians of participants using e-diary. Fever=temperature \>=38.0 deg C categorized as \>=38.0 to 38.4, \>38.4 to 38.9, \>38.9 to 40.0 and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain, new or worsened joint pain graded as mild (does not interfere with activity), moderate (some interference with activity), severe (prevents daily routine activity), Grade 4 (Emergency room visit/hospitalization). Vomiting: mild (1-2 times in 24 h), moderate (\>2 times in 24 h), severe (requires IV hydration), Grade 4 (emergency room visit/hospitalization for hypotensive shock). Diarrhea: mild (2-3 loose stools in 24h), moderate (4-5 loose stools in 24 h), severe (\>=6 loose stools in 24 h) and Grade 4 (emergency room visit/hospitalization). HIV positive participants were excluded.

Time frame:
Within 7 Days After Booster Dose
Reported as:
Number · Percentage of participants
Percentage of Participants With Systemic Events Within 7 Days After Booster Dose 1: BNT162b2 Experienced Participants Who Were Rerandomized to Receive 1 Booster Dose
Percentage of participantsBNT162b2 (30 mcg)BNT162b2SA (30 mcg)
Fever: 38.0°C to 38.4°C4.2 (2.2 to 7.1)4.0 (2.1 to 6.9)
Fever: >38.4°C to 38.9°C4.2 (2.2 to 7.1)4.0 (2.1 to 6.9)
Fever: >38.9°C to 40.0°C0.3 (0.0 to 1.9)4.0 (2.1 to 6.9)
Fever: >40.0°C0 (0.0 to 1.3)1.3 (0.4 to 3.4)
Fatigue: Mild23.5 (18.8 to 28.9)23.8 (19.1 to 29.1)
Fatigue: Moderate35.6 (30.1 to 41.5)41.3 (35.6 to 47.1)
Fatigue: Severe4.5 (2.4 to 7.6)4.7 (2.6 to 7.8)
Fatigue: Grade 40 (0.0 to 1.3)0 (0.0 to 1.2)
Headache: Mild28.7 (23.6 to 34.3)28.2 (23.2 to 33.7)
Headache: Moderate18.7 (14.4 to 23.7)23.5 (18.8 to 28.7)
Headache: Severe1.0 (0.2 to 3.0)2.0 (0.7 to 4.3)
Headache: Grade 40 (0.0 to 1.3)0 (0.0 to 1.2)
Chills: Mild12.8 (9.2 to 17.2)18.5 (14.2 to 23.3)
Chills: Moderate15.2 (11.3 to 19.9)16.1 (12.1 to 20.8)
Chills: Severe1.0 (0.2 to 3.0)2.0 (0.7 to 4.3)
Chills: Grade 40 (0.0 to 1.3)0 (0.0 to 1.2)
Vomiting: Mild1.7 (0.6 to 4.0)0.7 (0.1 to 2.4)
Vomiting: Moderate0 (0.0 to 1.3)0 (0.0 to 1.2)
Vomiting: Severe0 (0.0 to 1.3)0 (0.0 to 1.2)
Vomiting: Grade 40 (0.0 to 1.3)0 (0.0 to 1.2)
Diarrhea: Mild7.3 (4.6 to 10.9)8.1 (5.2 to 11.7)
Diarrhea: Moderate1.4 (0.4 to 3.5)1.3 (0.4 to 3.4)
Diarrhea: Severe0 (0.0 to 1.3)0.3 (0.0 to 1.9)
Diarrhea: Grade 40 (0.0 to 1.3)0 (0.0 to 1.2)
New or worsened muscle pain: Mild18.0 (13.7 to 22.9)14.8 (10.9 to 19.3)
New or worsened muscle pain: Moderate19.7 (15.3 to 24.8)21.8 (17.3 to 26.9)
New or worsened muscle pain: Severe1.4 (0.4 to 3.5)2.0 (0.7 to 4.3)
New or worsened muscle pain: Grade 40 (0.0 to 1.3)0 (0.0 to 1.2)
New or worsened joint pain: Mild12.5 (8.9 to 16.8)10.4 (7.2 to 14.4)
New or worsened joint pain: Moderate12.5 (8.9 to 16.8)11.4 (8.0 to 15.6)
New or worsened joint pain: Severe0.3 (0.0 to 1.9)0.7 (0.1 to 2.4)
New or worsened joint pain: Grade 40 (0.0 to 1.3)0 (0.0 to 1.2)
PrimaryPercentage of Participants Reporting Adverse Events From First Booster Dose to 1 Month After Booster Dose: BNT162b2 Experienced Participants Who Were Rerandomized to Receive 1 Booster Dose

An AE was any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. HIV positive participants were excluded.

Time frame:
From First Booster Dose to 1 Month After Booster Dose
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting Adverse Events From First Booster Dose to 1 Month After Booster Dose: BNT162b2 Experienced Participants Who Were Rerandomized to Receive 1 Booster Dose
Percentage of participantsBNT162b2 (30 mcg)BNT162b2SA (30 mcg)
Percentage of Participants Reporting Adverse Events From First Booster Dose to 1 Month After Booster Dose: BNT162b2 Experienced Participants Who Were Rerandomized to Receive 1 Booster Dose15.0 (11.2 to 19.5)10.8 (7.6 to 14.8)
PrimaryPercentage of Participants Reporting Serious Adverse Events From First Booster Dose to 6 Months After Booster Dose: BNT162b2 Experienced Participants Who Were Rerandomized to Receive 1 Booster Dose

A SAE was any untoward medical occurrence that occurred, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent or significant disability/ incapacity; was a congenital anomaly/birth defect and other important medical events. HIV positive participants were excluded.

Time frame:
From First Booster Dose to 6 Months After Booster Dose
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting Serious Adverse Events From First Booster Dose to 6 Months After Booster Dose: BNT162b2 Experienced Participants Who Were Rerandomized to Receive 1 Booster Dose
Percentage of participantsBNT162b2 (30 mcg)BNT162b2SA (30 mcg)
Percentage of Participants Reporting Serious Adverse Events From First Booster Dose to 6 Months After Booster Dose: BNT162b2 Experienced Participants Who Were Rerandomized to Receive 1 Booster Dose0.7 (0.1 to 2.3)0.6 (0.1 to 2.3)
PrimaryPercentage of Participants With Local Reactions Within 7 Days After Booster Dose 1: BNT162b2 Experienced Participants Assigned to Receive 2 Booster Doses of BNT162b2SA

Local reactions included redness, swelling and, pain at the injection site, recorded by participants in an e-diary. Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 cm. Redness and swelling were graded as mild (\> 2.0 to 5.0 cm), moderate (\> 5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis or exfoliative dermatitis for redness and necrosis for swelling). Pain at injection site was graded as mild (does not interfere with activity), moderate (interferes with activity), severe (prevents daily activity) and Grade 4 (emergency room visit or hospitalization for severe pain). HIV positive participants were excluded from this analysis.

Time frame:
Within 7 Days After Booster Dose 1
Reported as:
Number · Percentage of participants
Percentage of Participants With Local Reactions Within 7 Days After Booster Dose 1: BNT162b2 Experienced Participants Assigned to Receive 2 Booster Doses of BNT162b2SA
Percentage of participantsBNT162b2SA (30 mcg), 2 Doses
Redness: Mild0 (0.0 to 11.6)
Redness: Moderate0 (0.0 to 11.6)
Redness: Severe0 (0.0 to 11.6)
Redness: Grade 40 (0.0 to 11.6)
Swelling: Mild0 (0.0 to 11.6)
Swelling: Moderate0 (0.0 to 11.6)
Swelling: Severe0 (0.0 to 11.6)
Swelling: Grade 40 (0.0 to 11.6)
Pain at injection site: Mild56.7 (37.4 to 74.5)
Pain at injection site: Moderate20.0 (7.7 to 38.6)
Pain at injection site: Severe0 (0.0 to 11.6)
Pain at injection site: Grade 40 (0.0 to 11.6)
PrimaryPercentage of Participants With Local Reactions Within 7 Days After Booster Dose 2: BNT162b2 Experienced Participants Assigned to Receive 2 Booster Doses of BNT162b2SA

Local reactions included redness, swelling and, pain at the injection site, recorded by participants in an e-diary. Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 cm. Redness and swelling were graded as mild (\> 2.0 to 5.0 cm), moderate (\> 5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis or exfoliative dermatitis for redness and necrosis for swelling). Pain at injection site was graded as mild (does not interfere with activity), moderate (interferes with activity), severe (prevents daily activity) and Grade 4 (emergency room visit or hospitalization for severe pain). HIV positive participants were excluded from this analysis.

Time frame:
Within 7 Days after Booster Dose 2
Reported as:
Number · Percentage of participants
Percentage of Participants With Local Reactions Within 7 Days After Booster Dose 2: BNT162b2 Experienced Participants Assigned to Receive 2 Booster Doses of BNT162b2SA
Percentage of participantsBNT162b2SA (30 mcg), 2 Doses
Redness: Mild0 (0.0 to 12.3)
Redness: Moderate0 (0.0 to 12.3)
Redness: Severe0 (0.0 to 12.3)
Redness: Grade 40 (0.0 to 12.3)
Swelling: Mild0 (0.0 to 12.3)
Swelling: Moderate0 (0.0 to 12.3)
Swelling: Severe0 (0.0 to 12.3)
Swelling: Grade 40 (0.0 to 12.3)
Pain at injection site: Mild50.0 (30.6 to 69.4)
Pain at injection site: Moderate17.9 (6.1 to 36.9)
Pain at injection site: Severe0 (0.0 to 12.3)
Pain at injection site: Grade 40 (0.0 to 12.3)
PrimaryPercentage of Participants With Systemic Events Within 7 Days After Booster Dose 1: BNT162b2 Experienced Participants Assigned to Receive 2 Booster Doses of BNT162b2SA

Systemic events included fever, fatigue, headache, chills, vomiting, diarrhea, new or worsened muscle pain, new or worsened joint pain recorded by participants or parents/legal guardians of participants using e-diary. Fever=temperature \>=38.0 deg C categorized as \>=38.0 to 38.4, \>38.4 to 38.9, \>38.9 to 40.0 and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain, new or worsened joint pain graded as mild (does not interfere with activity), moderate (some interference with activity), severe (prevents daily routine activity), Grade 4 (Emergency room visit/hospitalization). Vomiting: mild (1-2 times in 24 h), moderate (\>2 times in 24 h), severe (requires IV hydration), Grade 4 (emergency room visit/hospitalization for hypotensive shock). Diarrhea: mild (2-3 loose stools in 24h), moderate (4-5 loose stools in 24 h), severe (\>=6 loose stools in 24 h) and Grade 4 (emergency room visit/hospitalization). HIV positive participants excluded.

Time frame:
Within 7 Days After Booster Dose 1
Reported as:
Number · Percentage of participants
Percentage of Participants With Systemic Events Within 7 Days After Booster Dose 1: BNT162b2 Experienced Participants Assigned to Receive 2 Booster Doses of BNT162b2SA
Percentage of participantsBNT162b2SA (30 mcg), 2 Doses
Fever: 38.0°C to 38.4°C3.3 (0.1 to 17.2)
Fever: >38.4°C to 38.9°C6.7 (0.8 to 22.1)
Fever: >38.9°C to 40.0°C0 (0.0 to 11.6)
Fever: >40.0°C0 (0.0 to 11.6)
Fatigue: Mild26.7 (12.3 to 45.9)
Fatigue: Moderate33.3 (17.3 to 52.8)
Fatigue: Severe3.3 (0.1 to 17.2)
Fatigue: Grade 40 (0.0 to 11.6)
Headache: Mild3.3 (0.1 to 17.2)
Headache: Moderate20.0 (7.7 to 38.6)
Headache: Severe0 (0.0 to 11.6)
Headache: Grade 40 (0.0 to 11.6)
Chills: Mild13.3 (3.8 to 30.7)
Chills: Moderate16.7 (5.6 to 34.7)
Chills: Severe3.3 (0.1 to 17.2)
Chills: Grade 40 (0.0 to 11.6)
Vomiting: Mild3.3 (0.1 to 17.2)
Vomiting: Moderate0 (0.0 to 11.6)
Vomiting: Severe0 (0.0 to 11.6)
Vomiting: Grade 40 (0.0 to 11.6)
Diarrhea: Mild6.7 (0.8 to 22.1)
Diarrhea: Moderate3.3 (0.1 to 17.2)
Diarrhea: Severe0 (0.0 to 11.6)
Diarrhea: Grade 40 (0.0 to 11.6)
New or worsened muscle pain: Mild20.0 (7.0 to 38.6)
New or worsened muscle pain: Moderate20.0 (7.0 to 38.6)
New or worsened muscle pain: Severe0 (0.0 to 11.6)
New or worsened muscle pain: Grade 40 (0.0 to 11.6)
New or worsened joint pain: Mild13.3 (3.3 to 38.7)
New or worsened joint pain: Moderate20.0 (7.7 to 38.6)
New or worsened joint pain: Severe0 (0.0 to 11.6)
New or worsened joint pain: Grade 40 (0.0 to 11.6)
PrimaryPercentage of Participants With Systemic Events Within 7 Days After Booster Dose 2: BNT162b2 Experienced Participants Assigned to Receive 2 Booster Doses of BNT162b2SA

Systemic events included fever, fatigue, headache, chills, vomiting, diarrhea, new or worsened muscle pain, new or worsened joint pain recorded by participants or parents/legal guardians of participants using e-diary. Fever=temperature \>=38.0 deg C categorized as \>=38.0 to 38.4, \>38.4 to 38.9, \>38.9 to 40.0 and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain, new or worsened joint pain graded as mild (does not interfere with activity), moderate (some interference with activity), severe (prevents daily routine activity), Grade 4 (Emergency room visit/hospitalization). Vomiting: mild (1-2 times in 24 h), moderate (\>2 times in 24 h), severe (requires IV hydration), Grade 4 (emergency room visit/hospitalization for hypotensive shock). Diarrhea: mild (2-3 loose stools in 24h), moderate (4-5 loose stools in 24 h), severe (\>=6 loose stools in 24 h) and Grade 4 (emergency room visit/hospitalization). HIV positive participants excluded.

Time frame:
Within 7 Days After Booster Dose 2
Reported as:
Number · Percentage of participants
Percentage of Participants With Systemic Events Within 7 Days After Booster Dose 2: BNT162b2 Experienced Participants Assigned to Receive 2 Booster Doses of BNT162b2SA
Percentage of participantsBNT162b2SA (30 mcg), 2 Doses
Fever: 38.0°C to 38.4°C3.6 (0.1 to 18.3)
Fever: >38.4°C to 38.9°C3.6 (0.1 to 18.3)
Fever: >38.9°C to 40.0°C3.6 (0.1 to 18.3)
Fever: >40.0°C0 (0.0 to 12.3)
Fatigue: Mild32.1 (15.9 to 52.4)
Fatigue: Moderate21.4 (8.3 to 41.0)
Fatigue: Severe0 (0.0 to 12.3)
Fatigue: Grade 40 (0.0 to 12.3)
Headache: Mild25.0 (10.7 to 44.9)
Headache: Moderate17.9 (6.1 to 36.9)
Headache: Severe0 (0.0 to 12.3)
Headache: Grade 40 (0.0 to 12.3)
Chills: Mild14.3 (4.0 to 32.7)
Chills: Moderate14.3 (4.0 to 32.7)
Chills: Severe0 (0.0 to 12.3)
Chills: Grade 40 (0.0 to 12.3)
Vomiting: Mild0 (0.0 to 12.3)
Vomiting: Moderate0 (0.0 to 12.3)
Vomiting: Severe0 (0.0 to 12.3)
Vomiting: Grade 40 (0.0 to 12.3)
Diarrhea: Mild14.3 (4.0 to 32.7)
Diarrhea: Moderate0 (0.0 to 12.3)
Diarrhea: Severe0 (0.0 to 12.3)
Diarrhea: Grade 40 (0.0 to 12.3)
New or worsened muscle pain: Mild14.3 (4.0 to 32.7)
New or worsened muscle pain: Moderate21.4 (8.3 to 41.0)
New or worsened muscle pain: Severe0 (0.0 to 12.3)
New or worsened muscle pain: Grade 40 (0.0 to 12.3)
New or worsened joint pain: Mild17.9 (6.1 to 36.9)
New or worsened joint pain: Moderate10.7 (2.3 to 28.2)
New or worsened joint pain: Severe0 (0.0 to 12.3)
New or worsened joint pain: Grade 40 (0.0 to 12.3)
PrimaryPercentage of Participants Reporting Adverse Events From First Booster Dose to 1 Month After Second Booster Dose: BNT162b2 Experienced Participants Assigned to Receive 2 Booster Doses of BNT162b2SA

An AE was any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. HIV positive participants were excluded.

Time frame:
From First Booster Dose to 1 Month After Second Booster Dose
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting Adverse Events From First Booster Dose to 1 Month After Second Booster Dose: BNT162b2 Experienced Participants Assigned to Receive 2 Booster Doses of BNT162b2SA
Percentage of participantsBNT162b2SA (30 mcg), 2 Doses
Percentage of Participants Reporting Adverse Events From First Booster Dose to 1 Month After Second Booster Dose: BNT162b2 Experienced Participants Assigned to Receive 2 Booster Doses of BNT162b2SA20.0 (7.7 to 38.6)
PrimaryPercentage of Participants Reporting Serious Adverse Events From First Booster Dose to 5 Months After Second Booster Dose: BNT162b2 Experienced Participants Assigned to Receive 2 Booster Doses of BNT162b2SA

An SAE was any untoward medical occurrence that occurred, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent or significant disability/ incapacity; was a congenital anomaly/birth defect and other important medical events. HIV positive participants were excluded.

Time frame:
From First Booster Dose to 5 Months After Second Booster Dose
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting Serious Adverse Events From First Booster Dose to 5 Months After Second Booster Dose: BNT162b2 Experienced Participants Assigned to Receive 2 Booster Doses of BNT162b2SA
Percentage of participantsBNT162b2SA (30 mcg), 2 Doses
Percentage of Participants Reporting Serious Adverse Events From First Booster Dose to 5 Months After Second Booster Dose: BNT162b2 Experienced Participants Assigned to Receive 2 Booster Doses of BNT162b2SA3.3 (0.1 to 17.2)
PrimaryPercentage of Participants With Local Reactions Within 7 Days After Dose 1: BNT162b2 Naive Participants Who Were Enrolled to Receive BNT162b2SA

Local reactions included redness, swelling and, pain at the injection site, recorded by participants in an e-diary. Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 cm. Redness and swelling were graded as mild (\> 2.0 to 5.0 cm), moderate (\> 5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis or exfoliative dermatitis for redness and necrosis for swelling). Pain at injection site was graded as mild (does not interfere with activity), moderate (interferes with activity), severe (prevents daily activity) and Grade 4 (emergency room visit or hospitalization for severe pain). HIV positive participants were excluded.

Time frame:
Within 7 Days After Dose 1
Reported as:
Number · Percentage of participants
Percentage of Participants With Local Reactions Within 7 Days After Dose 1: BNT162b2 Naive Participants Who Were Enrolled to Receive BNT162b2SA
Percentage of participantsBNT162b2SA (30 mcg)
Redness: Mild1.6 (0.5 to 3.7)
Redness: Moderate0.3 (0.0 to 1.8)
Redness: Severe0 (0.0 to 1.2)
Redness: Grade 40 (0.0 to 1.2)
Swelling: Mild1.9 (0.7 to 4.1)
Swelling: Moderate1.6 (0.5 to 3.7)
Swelling: Severe0 (0.0 to 1.2)
Swelling: Grade 40 (0.0 to 1.2)
Pain at injection site: Mild68.1 (62.6 to 73.2)
Pain at injection site: Moderate14.7 (11.0 to 19.1)
Pain at injection site: Severe0.3 (0.0 to 1.8)
Pain at injection site: Grade 40 (0.0 to 1.2)
PrimaryPercentage of Participants With Local Reactions Within 7 Days After Dose 2: BNT162b2 Naive Participants Who Were Enrolled to Receive BNT162b2SA

Local reactions included redness, swelling and, pain at the injection site, recorded by participants in an e-diary. Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 cm. Redness and swelling were graded as mild (\> 2.0 to 5.0 cm), moderate (\> 5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis or exfoliative dermatitis for redness and necrosis for swelling). Pain at injection site was graded as mild (does not interfere with activity), moderate (interferes with activity), severe (prevents daily activity) and Grade 4 (emergency room visit or hospitalization for severe pain). HIV positive participants were excluded.

Time frame:
Within 7 Days After Dose 2
Reported as:
Number · Percentage of participants
Percentage of Participants With Local Reactions Within 7 Days After Dose 2: BNT162b2 Naive Participants Who Were Enrolled to Receive BNT162b2SA
Percentage of participantsBNT162b2SA (30 mcg)
Redness: Mild2.8 (1.3 to 5.3)
Redness: Moderate1.9 (0.7 to 4.1)
Redness: Severe0.3 (0.0 to 1.8)
Redness: Grade 40 (0.0 to 1.2)
Swelling: Mild2.8 (1.3 to 5.3)
Swelling: Moderate2.2 (0.9 to 4.5)
Swelling: Severe0 (0.0 to 1.2)
Swelling: Grade 40 (0.0 to 1.2)
Pain at injection site: Mild53.5 (47.8 to 59.1)
Pain at injection site: Moderate19.3 (15.1 to 24.1)
Pain at injection site: Severe0.3 (0.0 to 1.8)
Pain at injection site: Grade 40 (0.0 to 1.2)
PrimaryPercentage of Participants With Systemic Events Within 7 Days After Dose 1: BNT162b2 Naive Participants Who Were Enrolled to Receive BNT162b2SA

Systemic events included fever, fatigue, headache, chills, vomiting, diarrhea, new or worsened muscle pain, new or worsened joint pain recorded by participants or parents/legal guardians of participants using e-diary. Fever=temperature \>=38.0 deg C categorized as \>=38.0 to 38.4, \>38.4 to 38.9, \>38.9 to 40.0 and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain, new or worsened joint pain graded as mild (does not interfere with activity), moderate (some interference with activity), severe (prevents daily routine activity), Grade 4 (Emergency room visit/hospitalization). Vomiting: mild (1-2 times in 24 h), moderate (\>2 times in 24 h), severe (requires IV hydration), Grade 4 (emergency room visit/hospitalization for hypotensive shock). Diarrhea: mild (2-3 loose stools in 24h), moderate (4-5 loose stools in 24 h), severe (\>=6 loose stools in 24 h) and Grade 4 (emergency room visit/hospitalization). HIV positive participants were excluded.

Time frame:
Within 7 Days After Dose 1
Reported as:
Number · Percentage of participants
Percentage of Participants With Systemic Events Within 7 Days After Dose 1: BNT162b2 Naive Participants Who Were Enrolled to Receive BNT162b2SA
Percentage of participantsBNT162b2SA (30 mcg)
Fever: 38.0°C to 38.4°C1.0 (0.2 to 3.8)
Fever: >38.4°C to 38.9°C0 (0.0 to 1.2)
Fever: >38.9°C to 40.0°C0 (0.0 to 1.2)
Fever: >40.0°C0 (0.0 to 1.2)
Fatigue: Mild27.8 (22.9 to 33.1)
Fatigue: Moderate21.1 (16.7 to 26.0)
Fatigue: Severe0.6 (0.1 to 2.3)
Fatigue: Grade 40 (0.0 to 1.2)
Headache: Mild22.0 (17.6 to 27.1)
Headache: Moderate9.9 (6.8 to 13.8)
Headache: Severe0.3 (0.0 to 1.8)
Headache: Grade 40 (0.0 to 1.2)
Chills: Mild4.8 (2.7 to 7.8)
Chills: Moderate1.6 (0.5 to 3.7)
Chills: Severe0.3 (0.0 to 1.8)
Chills: Grade 40 (0.0 to 1.2)
Vomiting: Mild1.3 (0.3 to 3.2)
Vomiting: Moderate0 (0.0 to .12)
Vomiting: Severe0 (0.0 to 1.2)
Vomiting: Grade 40 (0.0 to 1.2)
Diarrhea: Mild6.7 (4.2 to 10.1)
Diarrhea: Moderate1.3 (0.3 to 3.2)
Diarrhea: Severe0.3 (0.0 to 1.8)
Diarrhea: Grade 40 (0.0 to 1.2)
New or worsened muscle pain: Mild6.4 (3.9 to 9.7)
New or worsened muscle pain: Moderate5.8 (3.4 to 8.9)
New or worsened muscle pain: Severe0 (0.0 to 1.2)
New or worsened muscle pain: Grade 40 (0.0 to 1.2)
New or worsened joint pain: Mild2.9 (1.3 to 5.4)
New or worsened joint pain: Moderate1.9 (0.7 to 4.1)
New or worsened joint pain: Severe0 (0.0 to 1.2)
New or worsened joint pain: Grade 40 (0.0 to 1.2)
PrimaryPercentage of Participants With Systemic Events Within 7 Days After Dose 2: BNT162b2 Naive Participants Who Were Enrolled to Receive BNT162b2SA

Systemic events included fever, fatigue, headache, chills, vomiting, diarrhea, new or worsened muscle pain, new or worsened joint pain recorded by participants or parents/legal guardians of participants using e-diary. Fever=temperature \>=38.0 deg C categorized as \>=38.0 to 38.4, \>38.4 to 38.9, \>38.9 to 40.0 and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain, new or worsened joint pain graded as mild (does not interfere with activity), moderate (some interference with activity), severe (prevents daily routine activity), Grade 4 (Emergency room visit/hospitalization). Vomiting: mild (1-2 times in 24 h), moderate (\>2 times in 24 h), severe (requires IV hydration), Grade 4 (emergency room visit/hospitalization for hypotensive shock). Diarrhea: mild (2-3 loose stools in 24h), moderate (4-5 loose stools in 24 h), severe (\>=6 loose stools in 24 h) and Grade 4 (emergency room visit/hospitalization). HIV positive participants were excluded.

Time frame:
Within 7 Days After Dose 2
Reported as:
Number · Percentage of participants
Percentage of Participants With Systemic Events Within 7 Days After Dose 2: BNT162b2 Naive Participants Who Were Enrolled to Receive BNT162b2SA
Percentage of participantsBNT162b2SA (30 mcg)
Fever: 38.0°C to 38.4°C1.6 (0.5 to 3.7)
Fever: >38.4°C to 38.9°C1.6 (0.5 to 3.7)
Fever: >38.9°C to 40.0°C0.6 (0.1 to 2.3)
Fever: >40.0°C0 (0.0 to 1.2)
Fatigue: Mild25.3 (20.6 to 30.5)
Fatigue: Moderate36.1 (30.8 to 41.6)
Fatigue: Severe4.1 (2.2 to 6.9)
Fatigue: Grade 40 (0.0 to 1.2)
Headache: Mild29.7 (24.8 to 35.1)
Headache: Moderate17.1 (13.1 to 21.7)
Headache: Severe0.9 (0.2 to 2.7)
Headache: Grade 40 (0.0 to 1.2)
Chills: Mild13.9 (10.3 to 18.2)
Chills: Moderate12.7 (9.2 to 16.8)
Chills: Severe0.9 (0.2 to 2.7)
Chills: Grade 40 (0.0 to 1.2)
Vomiting: Mild0.9 (0.2 to 2.7)
Vomiting: Moderate0 (0.0 to 1.2)
Vomiting: Severe0 (0.0 to 1.2)
Vomiting: Grade 40 (0.0 to 1.2)
Diarrhea: Mild6.0 (3.7 to 9.2)
Diarrhea: Moderate0.6 (0.1 to 2.3)
Diarrhea: Severe0 (0.0 to 1.2)
Diarrhea: Grade 40 (0.0 to 1.2)
New or worsened muscle pain: Mild13.0 (9.5 to 17.2)
New or worsened muscle pain: Moderate16.1 (12.3 to 20.7)
New or worsened muscle pain: Severe1.3 (0.3 to 3.2)
New or worsened muscle pain: Grade 40 (0.0 to 1.2)
New or worsened joint pain: Mild7.9 (5.2 to 11.5)
New or worsened joint pain: Moderate12.7 (9.2 to 16.8)
New or worsened joint pain: Severe0 (0.0 to 1.2)
New or worsened joint pain: Grade 40 (0.0 to 1.2)
PrimaryPercentage of Participants Reporting Adverse Events From Dose 1 to 1 Month After Dose 2: BNT162b2-Naïve Participants Who Were Enrolled to Receive BNT162b2SA

An AE was any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. HIV positive participants were excluded.

Time frame:
From Dose 1 Through 1 Month After Dose 2
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting Adverse Events From Dose 1 to 1 Month After Dose 2: BNT162b2-Naïve Participants Who Were Enrolled to Receive BNT162b2SA
Percentage of participantsBNT162b2SA (30 mcg)
Percentage of Participants Reporting Adverse Events From Dose 1 to 1 Month After Dose 2: BNT162b2-Naïve Participants Who Were Enrolled to Receive BNT162b2SA14.2 (10.6 to 18.5)
PrimaryPercentage of Participants Reporting Serious Adverse Events From Dose 1 to 6 Months After Dose 2: BNT162b2-Naïve Participants Who Were Enrolled to Receive BNT162b2SA

A SAE was any untoward medical occurrence that occurred, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent or significant disability/ incapacity; was a congenital anomaly/birth defect and other important medical events. HIV positive participants were excluded.

Time frame:
From Dose 1 to 6 Months After Dose 2
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting Serious Adverse Events From Dose 1 to 6 Months After Dose 2: BNT162b2-Naïve Participants Who Were Enrolled to Receive BNT162b2SA
Percentage of participantsBNT162b2SA (30 mcg)
Percentage of Participants Reporting Serious Adverse Events From Dose 1 to 6 Months After Dose 2: BNT162b2-Naïve Participants Who Were Enrolled to Receive BNT162b2SA1.2 (0.3 to 3.1)
PrimaryPercentage of Participants With Local Reactions Within 7 Days After Booster Dose: BNT162b2-Experienced Participants Who Were Rerandomized to Receive 1 Booster Dose of BNT162b2 (Lower Dose)

Local reactions included redness, swelling and, pain at the injection site, recorded by participants in an e-diary. Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 cm. Redness and swelling were graded as mild (\> 2.0 to 5.0 cm), moderate (\> 5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis or exfoliative dermatitis for redness and necrosis for swelling). Pain at injection site was graded as mild (does not interfere with activity), moderate (interferes with activity), severe (prevents daily activity) and Grade 4 (emergency room visit or hospitalization for severe pain). HIV positive participants were excluded.

Time frame:
Within 7 days After Booster Dose
Reported as:
Number · Percentage of participants
Percentage of Participants With Local Reactions Within 7 Days After Booster Dose: BNT162b2-Experienced Participants Who Were Rerandomized to Receive 1 Booster Dose of BNT162b2 (Lower Dose)
Percentage of participantsBNT162b2 5 mcg Dose: 18-55 Years of AgeBNT162b2 5 mcg: >55 Years of AgeBNT162b2 10 mcg: 18-55 Years of AgeBNT162b2 10 mcg: >55 Years of Age
Redness: Mild0 (0.0 to 13.7)0 (0.0 to 6.8)0 (0.0 to 13.7)0 (0.0 to 7.0)
Redness: Moderate0 (0.0 to 13.7)1.9 (0.0 to 10.3)0 (0.0 to 13.7)0 (0.0 to 7.0)
Redness: Severe0 (0.0 to 13.7)0 (0.0 to 6.8)0 (0.0 to 13.7)0 (0.0 to 7.0)
Redness: Grade 40 (0.0 to 13.7)0 (0.0 to 6.8)0 (0.0 to 13.7)0 (0.0 to 7.0)
Swelling: Mild0 (0.0 to 13.7)1.9 (0.0 to 10.3)0 (0.0 to 13.7)3.9 (0.5 to 13.5)
Swelling: Moderate0 (0.0 to 13.7)0 (0.0 to 6.8)0 (0.0 to 13.7)2.0 (0.0 to 10.4)
Swelling: Severe0 (0.0 to 13.7)0 (0.0 to 6.8)0 (0.0 to 13.7)0 (0.0 to 7.0)
Swelling: Grade 40 (0.0 to 13.7)0 (0.0 to 6.8)0 (0.0 to 13.7)0 (0.0 to 7.0)
Pain at injection site: Mild56.0 (34.9 to 75.6)34.6 (22.0 to 49.1)48.0 (27.8 to 68.7)66.7 (52.1 to 79.2)
Pain at injection site: Moderate0 (0.0 to 13.7)1.9 (0.0 to 10.3)12.0 (2.5 to 31.2)5.9 (1.2 to 16.2)
Pain at injection site: Severe0 (0.0 to 13.7)0 (0.0 to 6.8)0 (0.0 to 13.7)0 (0.0 to 7.0)
Pain at injection site: Grade 40 (0.0 to 13.7)0 (0.0 to 6.8)0 (0.0 to 13.7)0 (0.0 to 7.0)
PrimaryPercentage of Participants With Systemic Events Within 7 Days After Booster Dose: BNT162b2-Experienced Participants Who Were Rerandomized to Receive 1 Booster Dose of BNT162b2 (Lower Dose)

Systemic events included fever, fatigue, headache, chills, vomiting, diarrhea, new or worsened muscle pain, new or worsened joint pain recorded by participants or parents/legal guardians of participants using e-diary. Fever=temperature \>=38.0 deg C categorized as \>=38.0 to 38.4, \>38.4 to 38.9, \>38.9 to 40.0 and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain, new or worsened joint pain graded as mild (does not interfere with activity), moderate (some interference with activity), severe (prevents daily routine activity), Grade 4 (Emergency room visit/hospitalization). Vomiting: mild (1-2 times in 24 h), moderate (\>2 times in 24 h), severe (requires IV hydration), Grade 4 (emergency room visit/hospitalization for hypotensive shock). Diarrhea: mild (2-3 loose stools in 24h), moderate (4-5 loose stools in 24 h), severe (\>=6 loose stools in 24 h) and Grade 4 (emergency room visit/hospitalization). HIV positive participants were excluded.

Time frame:
Within 7 days After Booster Dose
Reported as:
Number · Percentage of participants
Percentage of Participants With Systemic Events Within 7 Days After Booster Dose: BNT162b2-Experienced Participants Who Were Rerandomized to Receive 1 Booster Dose of BNT162b2 (Lower Dose)
Percentage of participantsBNT162b2 5 mcg Dose: 18-55 Years of AgeBNT162b2 5 mcg: >55 Years of AgeBNT162b2 10 mcg: 18-55 Years of AgeBNT162b2 10 mcg: >55 Years of Age
Fever: 38.0°C to 38.4°C0 (0.0 to 13.7)0 (0.0 to 6.8)4.0 (0.1 to 20.4)0 (0.0 to 7.0)
Fever: >38.4°C to 38.9°C0 (0.0 to 13.7)0 (0.0 to 6.8)0 (0.0 to 13.7)0 (0.0 to 7.0)
Fever: >38.9°C to 40.0°C0 (0.0 to 13.7)0 (0.0 to 6.8)0 (0.0 to 13.7)2.0 (0.0 to 10.4)
Fever: >40.0°C0 (0.0 to 13.7)0 (0.0 to 6.8)0 (0.0 to 13.7)0 (0.0 to 7.0)
Fatigue: Mild20.0 (6.8 to 40.7)15.4 (6.9 to 28.1)32.0 (14.9 to 53.5)29.4 (17.5 to 43.8)
Fatigue: Moderate24.0 (9.4 to 45.1)9.6 (3.2 to 21.0)24.0 (9.4 to 45.1)19.6 (9.8 to 33.1)
Fatigue: Severe0 (0.0 to 13.7)1.9 (0.0 to 10.3)4.0 (0.1 to 20.4)2.0 (0.0 to 10.4)
Fatigue: Grade 40 (0.0 to 13.7)0 (0.0 to 6.8)0 (0.0 to 13.7)0 (0.0 to 7.0)
Headache: Mild20.0 (6.8 to 40.7)15.4 (6.9 to 28.1)20.0 (6.8 to 40.7)23.5 (12.8 to 37.5)
Headache: Moderate4.0 (0.1 to 20.4)7.7 (2.1 to 18.5)16.0 (4.5 to 36.1)13.7 (5.7 to 26.3)
Headache: Severe0 (0.0 to 13.7)0 (0.0 to 6.8)4.0 (0.1 to 20.4)0 (0.0 to 7.0)
Headache: Grade 40 (0.0 to 13.7)0 (0.0 to 6.8)0 (0.0 to 13.7)0 (0.0 to 7.0)
Chills: Mild8.0 (1.0 to 26.0)9.6 (3.2 to 21.0)12.0 (2.5 to 31.2)13.7 (5.7 to 26.3)
Chills: Moderate0 (0.0 to 13.7)1.9 (0.0 to 10.3)12.0 (2.5 to 31.2)7.8 (2.2 to 18.9)
Chills: Severe0 (0.0 to 13.7)0 (0.0 to 6.8)0 (0.0 to 13.7)0 (0.0 to 7.0)
Chills: Grade 40 (0.0 to 13.7)0 (0.0 to 6.8)0 (0.0 to 13.7)0 (0.0 to 7.0)
Vomiting: Mild0 (0.0 to 13.7)0 (0.0 to 6.8)0 (0.0 to 13.7)0 (0.0 to 7.0)
Vomiting: Moderate0 (0.0 to 13.7)3.8 (0.5 to 13.2)0 (0.0 to 13.7)0 (0.0 to 7.0)
Vomiting: Severe0 (0.0 to 13.7)0 (0.0 to 6.8)0 (0.0 to 13.7)0 (0.0 to 7.0)
Vomiting: Grade 40 (0.0 to 13.7)0 (0.0 to 6.8)0 (0.0 to 13.7)0 (0.0 to 7.0)
Diarrhea: Mild8.0 (1.0 to 26.0)0 (0.0 to 6.8)16.0 (4.5 to 36.1)2.0 (0.0 to 10.4)
Diarrhea: Moderate0 (0.0 to 13.7)3.8 (0.5 to 13.2)0 (0.0 to 13.7)0 (0.0 to 7.0)
Diarrhea: Severe0 (0.0 to 13.7)0 (0.0 to 6.8)0 (0.0 to 13.7)0 (0.0 to 7.0)
Diarrhea: Grade 40 (0.0 to 13.7)0 (0.0 to 6.8)0 (0.0 to 13.7)0 (0. to 07.0)
New or worsened muscle pain: Mild24.0 (9.4 to 45.1)11.5 (4.4 to 23.4)16.0 (4.5 to 36.1)5.9 (1.2 to 16.2)
New or worsened muscle pain: Moderate0 (0.0 to 13.7)1.9 (0.0 to 10.3)12.0 (2.5 to 31.2)7.8 (2.2 to 18.9)
New or worsened muscle pain: Severe0 (0.0 to 13.7)0 (0.0 to 6.8)0 (0.0 to 13.7)0 (0.0 to 7.0)
New or worsened muscle pain: Grade 40 (0.0 to 13.7)0 (0.0 to 6.8)0 (0.0 to 13.7)0 (0.0 to 7.0)
New or worsened joint pain: Mild4.0 (0.1 to 20.4)0 (0.0 to 6.8)8.0 (1.0 to 26.0)7.8 (2.2 to 18.9)
New or worsened joint pain: Moderate0 (0.0 to 13.7)0 (0.0 to 6.8)12.0 (2.5 to 31.2)5.9 (1.2 to 16.2)
New or worsened joint pain: Severe0 (0.0 to 13.7)0 (0.0 to 6.8)0 (0.0 to 13.7)0 (0.0 to 7.0)
New or worsened joint pain: Grade 40 (0.0 to 13.7)0 (0.0 to 6.8)0 (0.0 to 13.7)0 (0.0 to 7.0)
PrimaryPercentage of Participants Reporting Adverse Events From Booster Dose to 1 Month After Booster Dose: BNT162b2-Experienced Participants Who Were Rerandomized to Receive 1 Booster Dose of BNT162b2 (Lower Dose)

An AE was any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. HIV positive participants were excluded.

Time frame:
From Booster Dose to 1 Months After Booster Dose
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting Adverse Events From Booster Dose to 1 Month After Booster Dose: BNT162b2-Experienced Participants Who Were Rerandomized to Receive 1 Booster Dose of BNT162b2 (Lower Dose)
Percentage of participantsBNT162b2 5 mcg Dose: 18-55 Years of AgeBNT162b2 5 mcg: >55 Years of AgeBNT162b2 10 mcg: 18-55 Years of AgeBNT162b2 10 mcg: >55 Years of Age
Percentage of Participants Reporting Adverse Events From Booster Dose to 1 Month After Booster Dose: BNT162b2-Experienced Participants Who Were Rerandomized to Receive 1 Booster Dose of BNT162b2 (Lower Dose)11.5 (2.4 to 30.2)3.8 (0.5 to 13.0)8.0 (1.0 to 26.0)0.0 (0.0 to 7.0)
PrimaryPercentage of Participants Reporting Serious Adverse Events From Booster Dose to 6 Months After Booster Dose: BNT162b2-Experienced Participants Who Were Rerandomized to Receive 1 Booster Dose of BNT162b2 (Lower Dose)

A SAE was any untoward medical occurrence that occurred, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent or significant disability/ incapacity; was a congenital anomaly/birth defect and other important medical events. HIV positive participants were excluded.

Time frame:
From Booster Dose to 6 Months after Booster Dose
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting Serious Adverse Events From Booster Dose to 6 Months After Booster Dose: BNT162b2-Experienced Participants Who Were Rerandomized to Receive 1 Booster Dose of BNT162b2 (Lower Dose)
Percentage of participantsBNT162b2 5 mcg Dose: 18-55 Years of AgeBNT162b2 5 mcg: >55 Years of AgeBNT162b2 10 mcg: 18-55 Years of AgeBNT162b2 10 mcg: >55 Years of Age
Percentage of Participants Reporting Serious Adverse Events From Booster Dose to 6 Months After Booster Dose: BNT162b2-Experienced Participants Who Were Rerandomized to Receive 1 Booster Dose of BNT162b2 (Lower Dose)0 (0.0 to 13.2)1.9 (0.0 to 10.1)0 (0.0 to 13.7)0 (0.0 to 7.0)
PrimaryCOVID-19 Incidence Based on Central Laboratory or Locally Confirmed Nucleic Acid Amplification Test (NAAT) in Participants Without Serological or Virological Evidence: Phase 2/3

Occurrences of first COVID-19 infection in participants followed up based on central laboratory or locally confirmed NAAT in participants, without serological or virological evidence of prior SARS-CoV-2 infection were reported in this outcome measure. HIV positive participants were excluded from this analysis.

Time frame:
From 7 days after Dose 2 (Surveillance time [1000 person-years]: BNT162b2 - 6.247, Placebo - 6.003)
Reported as:
Number · Events per 1000 person-years
COVID-19 Incidence Based on Central Laboratory or Locally Confirmed Nucleic Acid Amplification Test (NAAT) in Participants Without Serological or Virological Evidence: Phase 2/3
Events per 1000 person-yearsBNT162b2 (30 mcg)Placebo
COVID-19 Incidence Based on Central Laboratory or Locally Confirmed Nucleic Acid Amplification Test (NAAT) in Participants Without Serological or Virological Evidence: Phase 2/312.326141.596
Statistical analysis
  • BNT162b2 (30 mcg) vs Placebo · Vaccine efficacy: 91.3 · 95% CI 89.0 to 93.2
PrimaryCOVID-19 Incidence Based on Central Laboratory or Locally Confirmed Nucleic Acid Amplification Test (NAAT) in Participants Without Serological or Virological Evidence: Phase 2/3 (Analysis for EUA)

Occurrences of first COVID-19 infection in participants followed up based on central laboratory or locally confirmed NAAT in participants, without serological or virological evidence of prior SARS-CoV-2 infection (analysis for EUA) were reported in this outcome measure.

Time frame:
From 7 days after Dose 2 (Surveillance time [1000 person-years]: BNT162b2 - 2.214, Placebo - 2.222)
Reported as:
Number · Events per 1000 person-years
COVID-19 Incidence Based on Central Laboratory or Locally Confirmed Nucleic Acid Amplification Test (NAAT) in Participants Without Serological or Virological Evidence: Phase 2/3 (Analysis for EUA)
Events per 1000 person-yearsBNT162b2 (30 mcg)Placebo
COVID-19 Incidence Based on Central Laboratory or Locally Confirmed Nucleic Acid Amplification Test (NAAT) in Participants Without Serological or Virological Evidence: Phase 2/3 (Analysis for EUA)3.61372.907
Statistical analysis
  • BNT162b2 (30 mcg) vs Placebo · Beta binomial model: 95.0 · 95% CI 90.3 to 97.6
PrimaryCOVID-19 Incidence Based on Central Laboratory or Locally Confirmed Nucleic Acid Amplification Test (NAAT) in Participants With or Without Serological or Virological Evidence: Phase 2/3

Occurrences of first COVID-19 infection in participants followed up based on central laboratory or locally confirmed NAAT in participants, with or without serological or virological evidence of prior SARS-CoV-2 infection were reported in this outcome measure.

Time frame:
From 7 days after Dose 2 (Surveillance time [1000 person-years]: BNT162b2 - 6.509, Placebo - 6.274)
Reported as:
Number · Events per 1000 person-years
COVID-19 Incidence Based on Central Laboratory or Locally Confirmed Nucleic Acid Amplification Test (NAAT) in Participants With or Without Serological or Virological Evidence: Phase 2/3
Events per 1000 person-yearsBNT162b2 (30 mcg)Placebo
COVID-19 Incidence Based on Central Laboratory or Locally Confirmed Nucleic Acid Amplification Test (NAAT) in Participants With or Without Serological or Virological Evidence: Phase 2/312.444139.146
Statistical analysis
  • BNT162b2 (30 mcg) vs Placebo · Vaccine efficacy (ve): 91.1 · 95% CI 88.8 to 93.0
PrimaryCOVID-19 Incidence Based on Central Laboratory or Locally Confirmed Nucleic Acid Amplification Test (NAAT) in Participants With or Without Serological or Virological Evidence: Phase 2/3 (Analysis for EUA)

Occurrences of first COVID-19 infection in participants followed up based on central laboratory or locally confirmed NAAT in participants, with or without serological or virological evidence (analysis for EUA) of prior SARS-CoV-2 infection were reported in this outcome measure. HIV positive participants were excluded from this analysis.

Time frame:
From 7 days after Dose 2 (Surveillance time [1000 person-years]: BNT162b2 - 2.332, Placebo - 2.345)
Reported as:
Number · Events per 1000 person-years
COVID-19 Incidence Based on Central Laboratory or Locally Confirmed Nucleic Acid Amplification Test (NAAT) in Participants With or Without Serological or Virological Evidence: Phase 2/3 (Analysis for EUA)
Events per 1000 person-yearsBNT162b2 (30 mcg)Placebo
COVID-19 Incidence Based on Central Laboratory or Locally Confirmed Nucleic Acid Amplification Test (NAAT) in Participants With or Without Serological or Virological Evidence: Phase 2/3 (Analysis for EUA)3.85972.068
Statistical analysis
  • BNT162b2 (30 mcg) vs Placebo · Beta binomial model: 94.6 · 95% CI 89.9 to 97.3
PrimaryGMR Based on Geometric Mean Titer (N1a) - Comparison of 1 Month After Dose 2 Between Vaccine Groups: BNT162b2-Naïve Participants Without Evidence of Infection (N1a) up to 1 Month After Dose 2: Phase 3

GMR based on geometric mean titer, comparison of 1 month after dose 2 between vaccine groups: BNT162b2-naive participants without evidence of infection up to 1 month after dose 2 were reported in this outcome measure. HIV positive participants excluded from this analysis.

Time frame:
1 Month After Dose 2
Reported as:
Geometric mean · Titer
GMR Based on Geometric Mean Titer (N1a) - Comparison of 1 Month After Dose 2 Between Vaccine Groups: BNT162b2-Naïve Participants Without Evidence of Infection (N1a) up to 1 Month After Dose 2: Phase 3
TiterBNT162b2SA (30 mcg)BNT162b2 (30 mcg)
GMR Based on Geometric Mean Titer (N1a) - Comparison of 1 Month After Dose 2 Between Vaccine Groups: BNT162b2-Naïve Participants Without Evidence of Infection (N1a) up to 1 Month After Dose 2: Phase 31358.0 (1242.2 to 1484.5)820.3 (745.7 to 902.3)
Statistical analysis
  • BNT162b2SA (30 mcg) vs BNT162b2 (30 mcg) · Geometric mean ratio: 1.66 · 97.5% CI 1.43 to 1.92
PrimaryPercentage Difference of Participants Achieving Seroresponse Comparison (N1b) of 1 Month After Dose 2 Between Vaccine Groups: BNT162b2-Naïve Participants Without Evidence of Infection up to 1 Month After Dose 2: Phase 3

Seroresponse was defined as achieving a \>=4-fold rise from baseline (before Dose 1). If the baseline measurement was below the lower limit of quantification (LLOQ), a post vaccination assay result \>=4 × LLOQ was considered a seroresponse. HIV positive participants excluded.

Time frame:
1 Month After Dose 2
Reported as:
Number · Percentage of participants
Percentage Difference of Participants Achieving Seroresponse Comparison (N1b) of 1 Month After Dose 2 Between Vaccine Groups: BNT162b2-Naïve Participants Without Evidence of Infection up to 1 Month After Dose 2: Phase 3
Percentage of participantsBNT162b2SA (30 mcg)BNT162b2 (30 mcg)
Percentage Difference of Participants Achieving Seroresponse Comparison (N1b) of 1 Month After Dose 2 Between Vaccine Groups: BNT162b2-Naïve Participants Without Evidence of Infection up to 1 Month After Dose 2: Phase 397.1 (94.3 to 98.7)97.3 (94.6 to 98.9)
Statistical analysis
  • BNT162b2SA (30 mcg) vs BNT162b2 (30 mcg) · Percentage difference: -0.3 · 97.5% CI -3.9 to 3.4
PrimaryGMR of Neutralizing Titers (E1a) - Comparison of 1 Month After Booster Dose to 1 Month After Dose 2: BNT162b2-Experienced Participants That Received a Booster Dose of BNT162b2: Phase 3

GMR based on geometric mean titer, comparison of 1 month after booster dose to 1 month after dose 2 for BNT162b2-experienced participants were reported in this outcome measure. HIV positive participants excluded from this analysis.

Time frame:
1 Month After Booster Dose to 1 Month After Dose 2
Reported as:
Geometric mean · Titer
GMR of Neutralizing Titers (E1a) - Comparison of 1 Month After Booster Dose to 1 Month After Dose 2: BNT162b2-Experienced Participants That Received a Booster Dose of BNT162b2: Phase 3
TiterBNT162b2SA (30 mcg)BNT162b2 (30 mcg)
GMR of Neutralizing Titers (E1a) - Comparison of 1 Month After Booster Dose to 1 Month After Dose 2: BNT162b2-Experienced Participants That Received a Booster Dose of BNT162b2: Phase 32466.0 (2202.6 to 2760.8)755.7 (663.1 to 861.2)
Statistical analysis
  • BNT162b2SA (30 mcg) vs BNT162b2 (30 mcg) · Geometric mean ratio: 3.26 · 95% CI 2.76 to 3.86
PrimaryPercentage Difference of Participants Achieving Seroresponse (E1b) - Comparison of 1 Month After Booster Dose to 1 Month After Dose 2: BNT162b2-Experienced Participants That Received a Booster Dose of BNT162b2: Phase 3

Percentage difference of participants achieving seroresponse - comparison of 1 month after booster dose to 1 month after Dose 2 BNT162b2-experienced participants without evidence of infection up to 1 month after booster dose who were rerandomized to receive 1 booster dose were reported in this outcome measure. Seroresponse was defined as achieving a \>=4-fold rise from baseline (before Dose 1). If the baseline measurement was below the LLOQ, a postvaccination assay result \>=4 × LLOQ was considered a seroresponse. HIV positive participants excluded.

Time frame:
1 Month After Booster Dose to 1 Month After Dose 2
Reported as:
Number · Percentage of participants
Percentage Difference of Participants Achieving Seroresponse (E1b) - Comparison of 1 Month After Booster Dose to 1 Month After Dose 2: BNT162b2-Experienced Participants That Received a Booster Dose of BNT162b2: Phase 3
Percentage of participantsBNT162b2 (30 mcg): 1 Month After Booster DoseBNT162b2 (30 mcg): 1 Month After Dose 2
Percentage Difference of Participants Achieving Seroresponse (E1b) - Comparison of 1 Month After Booster Dose to 1 Month After Dose 2: BNT162b2-Experienced Participants That Received a Booster Dose of BNT162b2: Phase 399.5 (97.2 to 100.0)95.0 (91.0 to 97.6)
Statistical analysis
  • BNT162b2 (30 mcg): 1 Month After Booster Dose vs BNT162b2 (30 mcg): 1 Month After Dose 2 · Percentage difference: 4.5 · 97.5% CI 1.0 to 7.9
PrimaryGMR of Neutralizing Titers (E2a) - Comparison of 1 Month After Booster Dose to 1 Month After Dose 2: BNT162b2-Experienced Participants: Phase 3

GMR of neutralizing titers (E2a) for comparison of 1 month after booster dose to 1 month after dose 2: BNT162b2-experienced participants in Phase 3 were reported in this outcome measure. HIV positive participants were excluded from this analysis.

Time frame:
1 Month After Booster Dose to 1 Month After Dose 2
Reported as:
Geometric mean · Titer
GMR of Neutralizing Titers (E2a) - Comparison of 1 Month After Booster Dose to 1 Month After Dose 2: BNT162b2-Experienced Participants: Phase 3
TiterBNT162b2SA (30 mcg):1 Month After Booster DoseBNT162b2SA 30 mcg: 1 Month After Dose 2
GMR of Neutralizing Titers (E2a) - Comparison of 1 Month After Booster Dose to 1 Month After Dose 2: BNT162b2-Experienced Participants: Phase 33580.5 (3146.6 to 4074.3)688.3 (616.1 to 768.8)
Statistical analysis
  • BNT162b2SA (30 mcg):1 Month After Booster Dose vs BNT162b2SA 30 mcg: 1 Month After Dose 2 · Geometric mean ratio: 5.20 · 95% CI 4.50 to 6.01
PrimaryPercentage Difference of Participants Achieving Seroresponse (E2b) - Comparison of 1 Month After Booster Dose to 1 Month After Dose 2: BNT162b2-Experienced Participants: Phase 3

Percentage difference of participants achieving seroresponse - comparison of 1 month after booster dose to 1 month after Dose 2 BNT162b2-experienced participants without evidence of infection up to 1 month after booster dose who were rerandomized to receive 1 booster dose were reported in this outcome measure. Seroresponse was defined as achieving a \>=4-fold rise from baseline (before Dose 1). If the baseline measurement was below the LLOQ, a postvaccination assay result \>=4 × LLOQ was considered a seroresponse. HIV positive participants excluded.

Time frame:
1 Month After Booster Dose to 1 Month After Dose 2
Reported as:
Number · Percentage of participants
Percentage Difference of Participants Achieving Seroresponse (E2b) - Comparison of 1 Month After Booster Dose to 1 Month After Dose 2: BNT162b2-Experienced Participants: Phase 3
Percentage of participantsBNT162b2SA (30 mcg): 1 Month After Booster DoseBNT162b2SA 30 mcg: 1 Month After Dose 2
Percentage Difference of Participants Achieving Seroresponse (E2b) - Comparison of 1 Month After Booster Dose to 1 Month After Dose 2: BNT162b2-Experienced Participants: Phase 399.1 (96.8 to 99.9)94.1 (90.2 to 96.8)
Statistical analysis
  • BNT162b2SA (30 mcg): 1 Month After Booster Dose vs BNT162b2SA 30 mcg: 1 Month After Dose 2 · Percentage difference: 5.0 · 97.5% CI 1.0 to 8.9
SecondaryGeometric Mean Titers (GMTs) of Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Titers: Phase 1

GMTs of severe acute respiratory syndrome coronavirus 2 neutralizing titers were reported in this outcome measure. SARS-CoV-2 neutralization assay - NT50 and SARS-CoV-2 neutralization assay - NT90 were evaluated and reported in this outcome measure.

Time frame:
7, 21 days after Dose 1; 7, 14 days and 1, 6 months after Dose 2
Reported as:
Geometric mean · Titers
Geometric Mean Titers (GMTs) of Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Titers: Phase 1
TitersBNT162b1 10 mcg Dose: 18-55 Years of AgeBNT162b1 20 mcg Dose: 18-55 Years of AgeBNT162b1 30 mcg Dose: 18-55 Years of AgePlacebo: 18-55 Years of Age for BNT162b1BNT162b1 100 mcg Dose, 18-55 Years of AgePlacebo 18-55 Years of Age for BNT162b1 100 mcgBNT162b2 10 mcg Dose, 18-55 Years of AgeBNT162b2 20 mcg Dose, 18-55 Years of AgeBNT162b2 30 mcg Dose, 18-55 Years of AgePlacebo: 18-55 Years of Age for BNT162b2BNT162b1 10 mcg Dose, 65-85 Years of AgeBNT162b1 20 mcg Dose, 65-85 Years of AgeBNT162b1 30 mcg Dose, 65-85 Years of AgePlacebo, 65-85 Years of Age for BNT162b1BNT162b2 10 mcg Dose, 65-85 Years of AgeBNT162b2 20 mcg Dose, 65-85 Years of AgeBNT162b2 30 mcg Dose, 65-85 Years of AgePlacebo: 65-85 Years of Age for BNT162b2
NT50 titer: 7 days after dose 110.0 (10.0 to 10.0)—10.0 (10.0 to 10.0)10.0 (10.0 to 10.0)10.0 (10.0 to 10.0)10.0 (10.0 to 10.0)————————————
NT50 (titer): 21 days after dose 112.7 (9.6 to 16.8)12.5 (9.0 to 17.5)28.6 (17.1 to 47.9)10.0 (10.0 to 10.0)32.5 (17.0 to 62.4)10.0 (10.0 to 10.0)16.6 (9.8 to 27.9)18.9 (11.1 to 32.3)14.4 (10.1 to 20.4)10.0 (10.0 to 10.0)11.2 (8.7 to 14.4)10.0 (10.0 to 10.0)12.5 (9.0 to 17.4)10.0 (10.0 to 10.0)10.0 (10.0 to 10.0)10.0 (10.0 to 10.0)12.0 (9.0 to 16.0)10.0 (10.0 to 10.0)
NT50 (titer): 7 days after dose 2167.9 (111.2 to 253.5)160.3 (80.1 to 320.9)267.1 (172.9 to 412.7)10.0 (10.0 to 10.0)——169.0 (102.7 to 278.2)362.5 (256.9 to 511.6)360.9 (237.4 to 548.6)10.0 (10.0 to 10.0)19.9 (11.7 to 33.9)178.7 (94.5 to 337.7)100.8 (45.7 to 222.3)10.0 (10.0 to 10.0)79.3 (50.6 to 124.5)79.3 (40.9 to 153.5)155.7 (80.4 to 301.7)10.0 (10.0 to 10.0)
NT50 (titer): 14 days after dose 2180.1 (107.2 to 302.5)202.9 (123.4 to 333.4)437.0 (302.6 to 631.1)10.0 (10.0 to 10.0)——108.8 (54.7 to 216.5)292.1 (179.3 to 475.7)161.6 (109.3 to 238.8)10.0 (10.0 to 10.0)28.5 (13.7 to 59.2)104.7 (43.7 to 250.5)105.5 (50.0 to 222.6)10.0 (10.0 to 10.0)111.1 (81.0 to 152.3)73.7 (32.8 to 165.6)214.1 (105.9 to 433.2)10.0 (10.0 to 10.0)
NT50 (titer): 1 month after dose 268.5 (41.8 to 112.0)161.2 (102.5 to 253.4)180.5 (108.4 to 300.7)10.0 (10.0 to 10.0)——105.3 (65.1 to 170.6)251.7 (143.5 to 441.4)143.6 (103.8 to 198.6)10.0 (10.0 to 10.0)22.7 (11.3 to 45.3)125.3 (74.7 to 210.0)144.7 (70.3 to 298.1)10.0 (10.0 to 10.0)69.6 (43.0 to 112.7)49.6 (23.1 to 106.6)152.3 (81.2 to 285.6)10.0 (10.0 to 10.0)
NT50 (titer): 6 months after dose 2————————54.7 (24.7 to 121.1)———————29.0 (19.4 to 43.5)—
NT90 (titer): 7 days after dose 110.0 (10.0 to 10.0)—10.0 (10.0 to 10.0)10.0 (10.0 to 10.0)10.0 (10.0 to 10.0)10.0 (10.0 to 10.0)————————————
NT90 (titer): 21 days after dose 110.0 (10.0 to 10.0)10.0 (10.0 to 10.0)11.9 (9.1 to 15.6)10.0 (10.0 to 10.0)15.0 (9.3 to 24.4)10.0 (10.0 to 10.0)10.9 (9.0 to 13.2)10.7 (9.2 to 12.5)10.8 (9.1 to 12.8)10.0 (10.0 to 10.0)10.0 (10.0 to 10.0)10.0 (10.0 to 10.0)10.0 (10.0 to 10.0)10.0 (10.0 to 10.0)10.0 (10.0 to 10.0)10.0 (10.0 to 10.0)10.0 (10.0 to 10.0)10.0 (10.0 to 10.0)
NT90 (titer): 7 days after dose 256.8 (35.2 to 91.4)67.0 (40.3 to 111.3)121.6 (78.8 to 187.6)10.0 (10.0 to 10.0)——70.1 (42.7 to 115.0)142.2 (103.3 to 195.7)122.8 (79.2 to 190.4)10.0 (10.0 to 10.0)12.1 (9.0 to 16.3)73.7 (34.6 to 157.1)47.6 (22.1 to 102.3)10.0 (10.0 to 10.0)40.0 (26.5 to 60.3)33.4 (18.1 to 61.4)53.5 (26.1 to 109.4)10.0 (10.0 to 10.0)
NT90 (titer): 14 days after dose 276.5 (44.4 to 131.6)110.4 (71.4 to 170.5)188.1 (126.4 to 279.8)10.0 (10.0 to 10.0)——46.6 (25.1 to 86.5)112.7 (73.9 to 171.8)54.3 (37.5 to 78.6)10.0 (10.0 to 10.0)16.5 (9.6 to 28.1)49.0 (25.0 to 95.9)50.3 (25.4 to 99.5)10.0 (10.0 to 10.0)56.0 (35.4 to 88.6)29.3 (16.3 to 52.6)60.3 (25.2 to 144.1)10.0 (10.0 to 10.0)
NT90 (titer): 1 month after dose 237.0 (24.6 to 55.5)40.1 (25.0 to 64.3)62.0 (35.5 to 108.3)10.0 (10.0 to 10.0)——34.4 (18.4 to 64.7)60.0 (33.3 to 108.2)54.7 (41.2 to 72.6)10.0 (10.0 to 10.0)14.2 (9.0 to 22.4)48.4 (26.0 to 90.2)59.9 (30.4 to 118.0)10.0 (10.0 to 10.0)20.2 (12.1 to 33.7)24.6 (12.9 to 47.0)50.9 (28.3 to 91.6)10.0 (10.0 to 10.0)
SecondaryGeometric Mean Concentrations (GMCs) of Severe Acute Respiratory Syndrome Coronavirus 2: S1-binding and RBD-binding IgG Level Assay: Phase 1

GMCs of severe acute respiratory syndrome coronavirus S1-binding and RBD-binding IgG level were reported in this outcome measure.

Time frame:
7, 21 days after Dose 1; 7, 14 days and 1, 6 months after Dose 2
Reported as:
Geometric mean · Units per milliliter
Geometric Mean Concentrations (GMCs) of Severe Acute Respiratory Syndrome Coronavirus 2: S1-binding and RBD-binding IgG Level Assay: Phase 1
Units per milliliterBNT162b1 10 mcg Dose: 18-55 Years of AgeBNT162b1 20 mcg Dose: 18-55 Years of AgeBNT162b1 30 mcg Dose: 18-55 Years of AgePlacebo: 18-55 Years of Age for BNT162b1BNT162b1 100 mcg Dose, 18-55 Years of AgePlacebo 18-55 Years of Age for BNT162b1 100 mcgBNT162b2 10 mcg Dose, 18-55 Years of AgeBNT162b2 20 mcg Dose, 18-55 Years of AgeBNT162b2 30 mcg Dose, 18-55 Years of AgePlacebo: 18-55 Years of Age for BNT162b2BNT162b1 10 mcg Dose, 65-85 Years of AgeBNT162b1 20 mcg Dose, 65-85 Years of AgeBNT162b1 30 mcg Dose, 65-85 Years of AgePlacebo, 65-85 Years of Age for BNT162b1BNT162b2 10 mcg Dose, 65-85 Years of AgeBNT162b2 20 mcg Dose, 65-85 Years of AgeBNT162b2 30 mcg Dose, 65-85 Years of AgePlacebo: 65-85 Years of Age for BNT162b2
S1-binding IgG level assay:7 days after Dose10.8 (0.5 to 1.1)—0.9 (0.5 to 1.4)1.0 (0.5 to 2.2)0.9 (0.4 to 1.9)0.6 (0.6 to 0.6)————————————
S1-binding IgG level assay: 21 days after Dose 1294.2 (126.8 to 682.8)204.1 (57.5 to 723.9)852.7 (479.5 to 1516.4)0.8 (0.4 to 1.6)1074.4 (702.2 to 1643.9)0.6 (0.6 to 0.6)611.7 (332.0 to 1126.8)546.7 (346.3 to 863.1)1264.8 (912.6 to 1753.1)0.6 (0.6 to 0.6)34.1 (9.7 to 120.2)125.1 (56.2 to 278.4)86.3 (27.7 to 269.2)1.1 (0.6 to 2.3)172.0 (92.0 to 321.7)80.9 (31.7 to 206.8)283.2 (115.7 to 693.2)0.8 (0.6 to 1.2)
S1-binding IgG level assay:7 days after Dose 23868.2 (2052.5 to 7290.0)3243.1 (689.9 to 15244.1)23516.5 (16552.7 to 33409.8)1.2 (0.5 to 2.7)——6014.0 (4061.6 to 8904.9)12464.0 (9249.2 to 16796.1)9136.4 (6385.0 to 13073.3)0.6 (0.6 to 0.6)860.7 (372.4 to 1989.3)10622.7 (5607.8 to 20122.3)6579.6 (2827.6 to 15310.2)1.3 (0.5 to 3.2)3203.3 (2314.5 to 4433.4)2734.2 (1211.8 to 6169.3)7547.9 (4224.0 to 13487.6)0.9 (0.6 to 1.5)
S1-binding IgG level assay:14 days after Dose 25120.2 (3529.2 to 7428.5)7480.5 (4670.8 to 11980.2)13940.1 (9746.7 to 19937.5)0.9 (0.5 to 1.9)——4757.7 (2926.8 to 7733.9)7366.9 (4774.3 to 11367.4)7639.4 (6308.6 to 9251.1)0.6 (0.6 to 0.6)1436.6 (760.1 to 2715.0)6399.4 (3481.6 to 11762.3)4798.4 (2209.3 to 10421.9)0.9 (0.5 to 1.7)3560.2 (2282.4 to 5553.5)2522.7 (1182.4 to 5382.1)5844.0 (3620.4 to 9433.3)0.8 (0.6 to 1.1)
S1-binding IgG level assay:1Month after Dose 22530.8 (1684.3 to 3802.5)5329.2 (3789.4 to 7494.7)8095.2 (5563.4 to 11779.1)0.9 (0.5 to 1.7)——3098.6 (2088.1 to 4598.0)5784.7 (4131.4 to 8099.8)5296.0 (4139.6 to 6775.4)0.8 (0.5 to 1.2)1089.8 (556.7 to 2133.4)5138.2 (2788.0 to 9469.5)4151.0 (1872.9 to 9200.2)1.2 (0.6 to 2.6)2350.5 (1787.1 to 3091.7)1491.5 (682.0 to 3262.0)4592.4 (2874.1 to 7337.9)0.8 (0.5 to 1.3)
S1-binding IgG level assay:6Months after Dose 2————————960.8 (483.8 to 1908.1)———————559.6 (363.0 to 862.8)—
RBD-binding IgG level assay:7 days after Dose10.9 (0.5 to 1.6)—0.8 (0.5 to 1.5)0.9 (0.4 to 2.1)1.2 (0.6 to 2.6)0.8 (0.2 to 3.2)————————————
RBD-binding IgG level assay:21 days after Dose1534.4 (244.1 to 1169.6)362.5 (89.5 to 1468.4)1535.9 (938.1 to 2514.6)0.8 (0.5 to 1.6)1778.3 (1218.9 to 2594.7)0.9 (0.5 to 1.0)338.9 (172.6 to 665.4)347.2 (223.0 to 540.4)862.3 (581.2 to 1279.5)0.9 (0.5 to 1.6)61.2 (17.1 to 218.9)234.4 (102.9 to 533.9)99.2 (30.3 to 324.3)1.2 (0.4 to 3.6)83.6 (26.6 to 262.6)50.9 (16.7 to 155.2)198.6 (67.6 to 583.5)1.0 (0.5 to 2.1)
RBD-binding IgG level assay:7 days after Dose 24813.1 (2479.5 to 9343.1)4033.8 (832.8 to 19538.0)27871.8 (19430.0 to 39981.4)0.9 (0.5 to 1.5)——4926.8 (3239.2 to 7493.7)12258.1 (8875.8 to 16929.4)7759.7 (5537.3 to 10874.0)0.9 (0.5 to 1.6)1283.5 (535.2 to 3078.4)12932.8 (7091.0 to 23587.3)7527.5 (3564.2 to 15897.7)1.4 (0.4 to 5.0)2521.8 (1642.3 to 3872.3)2567.2 (979.5 to 6728.1)5877.3 (3426.5 to 10080.9)1.1 (0.5 to 2.6)
RBD-binding IgG level assay:14 days after Dose 25880.4 (4249.8 to 8136.8)6376.7 (4314.0 to 9425.7)16165.9 (11013.3 to 23729.2)0.7 (0.5 to 1.0)——3984.8 (2278.2 to 6969.9)6383.2 (4422.7 to 9212.7)6825.6 (5103.5 to 9129.0)0.9 (0.5 to 1.7)1771.9 (947.6 to 3313.3)6983.1 (3878.5 to 12573.1)6006.5 (2821.3 to 12787.6)1.4 (0.4 to 4.2)2941.7 (1915.7 to 4517.2)1734.0 (775.0 to 3879.8)5642.0 (3344.2 to 9518.5)1.0 (0.5 to 2.2)
RBD-binding IgG level assay:1Month after Dose 23674.2 (2595.4 to 5201.4)6215.2 (4312.8 to 8956.8)9489.6 (6258.7 to 14388.4)0.7 (0.4 to 1.3)——2612.6 (1711.1 to 3989.0)4183.7 (3011.7 to 5811.6)5059.8 (3974.2 to 6442.0)1.0 (0.5 to 2.3)1495.4 (825.3 to 2709.5)5641.9 (3114.1 to 10221.3)4488.5 (2131.3 to 9452.6)1.2 (0.4 to 4.0)2214.5 (1631.6 to 3005.7)1272.1 (540.7 to 2993.2)3468.6 (1998.4 to 6020.4)0.9 (0.4 to 1.9)
SecondaryGeometric Mean Fold Rise (GMFR) of SARS-CoV-2 Neutralizing Titers: Phase 1

GMFR of SARS-CoV-2 neutralizing titers were reported in this outcome measure. HIV positive participants excluded.

Time frame:
7, 21 days after Dose 1; 7, 14 days and 1, 6 months after Dose 2
Reported as:
Geometric mean · Fold rise
Geometric Mean Fold Rise (GMFR) of SARS-CoV-2 Neutralizing Titers: Phase 1
Fold riseBNT162b1 10 mcg Dose: 18-55 Years of AgeBNT162b1 20 mcg Dose: 18-55 Years of AgeBNT162b1 30 mcg Dose: 18-55 Years of AgePlacebo: 18-55 Years of Age for BNT162b1BNT162b1 100 mcg Dose, 18-55 Years of AgePlacebo 18-55 Years of Age for BNT162b1 100 mcgBNT162b2 10 mcg Dose, 18-55 Years of AgeBNT162b2 20 mcg Dose, 18-55 Years of AgeBNT162b2 30 mcg Dose, 18-55 Years of AgePlacebo: 18-55 Years of Age for BNT162b2BNT162b1 10 mcg Dose, 65-85 Years of AgeBNT162b1 20 mcg Dose, 65-85 Years of AgeBNT162b1 30 mcg Dose, 65-85 Years of AgePlacebo, 65-85 Years of Age for BNT162b1BNT162b2 10 mcg Dose, 65-85 Years of AgeBNT162b2 20 mcg Dose, 65-85 Years of AgeBNT162b2 30 mcg Dose, 65-85 Years of AgePlacebo: 65-85 Years of Age for BNT162b2
NT50 titer: 7 days after dose 11.0 (1.0 to 1.0)—1.0 (1.0 to 1.0)1.0 (1.0 to 1.0)1.0 (1.0 to 1.0)1.0 (1.0 to 1.0)————————————
NT50 (titer): 21 days after dose 11.3 (1.0 to 1.7)1.3 (0.9 to 1.8)2.9 (1.7 to 4.8)1.0 (1.0 to 1.0)3.3 (1.7 to 6.2)1.0 (1.0 to 1.0)1.7 (1.0 to 2.8)1.9 (1.1 to 3.2)1.4 (1.0 to 2.0)1.0 (1.0 to 1.0)1.1 (0.9 to 1.4)1.0 (1.0 to 1.0)1.2 (0.9 to 1.7)1.0 (1.0 to 1.0)1.0 (1.0 to 1.0)1.0 (1.0 to 1.0)1.2 (0.9 to 1.6)1.0 (1.0 to 1.0)
NT50 (titer): 7 days after dose 216.8 (11.1 to 25.3)16.0 (8.0 to 32.1)26.7 (17.3 to 41.3)1.0 (1.0 to 1.0)——16.9 (10.3 to 27.8)36.3 (25.7 to 51.2)36.1 (23.7 to 54.9)1.0 (1.0 to 1.0)2.0 (1.2 to 3.4)17.9 (9.5 to 33.8)10.1 (4.6 to 22.2)1.0 (1.0 to 1.0)7.9 (5.1 to 12.4)7.9 (4.1 to 15.3)15.6 (8.0 to 30.2)1.0 (1.0 to 1.0)
NT50 (titer): 14 days after dose 218.0 (10.7 to 30.3)20.3 (12.3 to 33.3)43.7 (30.3 to 63.1)1.0 (1.0 to 1.0)——10.9 (5.5 to 21.7)29.2 (17.9 to 47.6)16.2 (10.9 to 23.9)1.0 (1.0 to 1.0)2.8 (1.4 to 5.9)10.5 (4.4 to 25.0)10.5 (5.0 to 22.3)1.0 (1.0 to 1.0)11.1 (8.1 to 15.2)7.4 (3.3 to 16.6)21.4 (10.6 to 43.3)1.0 (1.0 to 1.0)
NT50 (titer): 1 month after dose 26.8 (4.2 to 11.2)16.1 (10.3 to 25.3)18.1 (10.8 to 30.1)1.0 (1.0 to 1.0)——10.5 (6.5 to 17.1)25.2 (14.3 to 44.1)14.4 (10.4 to 19.9)1.0 (1.0 to 1.0)2.3 (1.1 to 4.5)12.5 (7.5 to 21.0)14.5 (7.0 to 29.8)1.0 (1.0 to 1.0)7.0 (4.3 to 11.3)5.0 (2.3 to 10.7)15.2 (8.1 to 28.6)1.0 (1.0 to 1.0)
NT50 (titer): 6 months after dose 2————————5.5 (2.5 to 12.1)———————2.9 (1.9 to 4.3)—
NT90 (titer): 7 days after dose 11.0 (1.0 to 1.0)—1.0 (1.0 to 1.0)1.0 (1.0 to 1.0)1.0 (1.0 to 1.0)1.0 (1.0 to 1.0)————————————
NT90 (titer): 21 days after dose 11.0 (1.0 to 1.0)1.0 (1.0 to 1.0)1.2 (0.9 to 1.6)1.0 (1.0 to 1.0)1.5 (0.9 to 2.4)1.0 (1.0 to 1.0)1.1 (0.9 to 1.3)1.1 (0.9 to 1.2)1.1 (0.9 to 1.3)1.0 (1.0 to 1.0)1.0 (1.0 to 1.0)1.0 (1.0 to 1.0)1.0 (1.0 to 1.0)1.0 (1.0 to 1.0)1.0 (1.0 to 1.0)1.0 (1.0 to 1.0)1.0 (1.0 to 1.0)1.0 (1.0 to 1.0)
NT90 (titer): 7 days after dose 25.7 (3.5 to 9.1)6.7 (4.0 to 11.1)12.2 (7.9 to 18.8)1.0 (1.0 to 1.0)——7.0 (4.3 to 11.5)14.2 (10.3 to 19.6)12.3 (7.9 to 19.0)1.0 (1.0 to 1.0)1.2 (0.9 to 1.6)7.4 (3.5 to 15.7)4.8 (2.2 to 10.2)1.0 (1.0 to 1.0)4.0 (2.7 to 6.0)3.3 (1.8 to 6.1)5.3 (2.6 to 10.9)1.0 (1.0 to 1.0)
NT90 (titer): 14 days after dose 27.6 (4.4 to 13.2)11.0 (7.1 to 17.1)18.8 (12.6 to 28.0)1.0 (1.0 to 1.0)——4.7 (2.5 to 8.7)11.3 (7.4 to 17.2)5.4 (3.8 to 7.9)1.0 (1.0 to 1.0)1.6 (1.0 to 2.8)4.9 (2.5 to 9.6)5.0 (2.5 to 10.0)1.0 (1.0 to 1.0)5.6 (3.5 to 8.9)2.9 (1.6 to 5.3)6.0 (2.5 to 14.4)1.0 (1.0 to 1.0)
NT90 (titer): 1 month after dose 23.7 (2.5 to 5.5)4.0 (2.5 to 6.4)6.2 (3.5 to 10.8)1.0 (1.0 to 1.0)——3.4 (1.8 to 6.5)6.0 (3.3 to 10.8)5.5 (4.1 to 7.3)1.0 (1.0 to 1.0)1.4 (0.9 to 2.2)4.8 (2.6 to 9.0)6.0 (3.0 to 11.8)1.0 (1.0 to 1.0)2.0 (1.2 to 3.4)2.5 (1.3 to 4.7)5.1 (2.8 to 9.2)1.0 (1.0 to 1.0)
SecondaryGeometric Mean Fold Rise (GMFR) of SARS-CoV-2 S1-binding and RBD-binding IgG Level Assay: Phase 1

GMFR of SARS-CoV-2 S1-binding and RBD-binding IgG level assay in Phase 1 were reported in this outcome measure. HIV positive participants were excluded from this analysis.

Time frame:
7, 21 days after Dose 1; 7, 14 days and 1, 6 months after Dose 2
Reported as:
Geometric mean · Fold rise
Geometric Mean Fold Rise (GMFR) of SARS-CoV-2 S1-binding and RBD-binding IgG Level Assay: Phase 1
Fold riseBNT162b1 10 mcg Dose: 18-55 Years of AgeBNT162b1 20 mcg Dose: 18-55 Years of AgeBNT162b1 30 mcg Dose: 18-55 Years of AgePlacebo: 18-55 Years of Age for BNT162b1BNT162b1 100 mcg Dose, 18-55 Years of AgePlacebo 18-55 Years of Age for BNT162b1 100 mcgBNT162b2 10 mcg Dose, 18-55 Years of AgeBNT162b2 20 mcg Dose, 18-55 Years of AgeBNT162b2 30 mcg Dose, 18-55 Years of AgePlacebo: 18-55 Years of Age for BNT162b2BNT162b1 10 mcg Dose, 65-85 Years of AgeBNT162b1 20 mcg Dose, 65-85 Years of AgeBNT162b1 30 mcg Dose, 65-85 Years of AgePlacebo, 65-85 Years of Age for BNT162b1BNT162b2 10 mcg Dose, 65-85 Years of AgeBNT162b2 20 mcg Dose, 65-85 Years of AgeBNT162b2 30 mcg Dose, 65-85 Years of AgePlacebo: 65-85 Years of Age for BNT162b2
S1-binding IgG level assay:7days after dose11.0 (1.0 to 1.0)—1.1 (0.8 to 1.3)0.8 (0.5 to 1.4)1.1 (0.9 to 1.5)1.0 (1.0 to 1.0)————————————
S1-binding IgG level assay:21days after dose1387.6 (182.9 to 821.1)271.3 (77.3 to 951.6)1027.5 (543.5 to 1942.4)0.9 (0.7 to 1.1)1378.3 (718.0 to 2645.9)1.0 (1.0 to 1.0)965.9 (524.4 to 1779.4)636.8 (296.9 to 1365.6)1997.4 (1441.1 to 2768.4)1.0 (1.0 to 1.0)34.4 (7.3 to 161.9)162.6 (81.8 to 323.1)124.8 (41.4 to 376.3)1.0 (1.0 to 1.1)223.5 (112.1 to 445.8)98.2 (36.4 to 265.2)447.2 (182.6 to 1094.7)1.0 (1.0 to 1.1)
S1-binding IgG level assay:7days after dose25095.8 (2819.1 to 9211.0)4311.2 (899.3 to 20668.6)28336.5 (17881.6 to 44904.3)1.3 (0.9 to 1.8)——9497.1 (6413.9 to 14062.2)14516.5 (9188.0 to 22935.3)14427.7 (10082.9 to 20644.7)1.0 (1.0 to 1.0)868.3 (276.9 to 2722.5)13807.8 (7573.0 to 25175.6)9516.4 (4262.5 to 21246.3)1.2 (0.9 to 1.6)4162.5 (2679.8 to 6465.4)3240.5 (1349.3 to 7782.7)11919.3 (6670.3 to 21299.0)1.2 (0.9 to 1.6)
S1-binding IgG level assay:14days after dose26745.2 (4430.5 to 10269.0)9944.3 (5315.2 to 18604.8)16797.3 (10604.5 to 26606.6)1.0 (0.9 to 1.0)——7513.2 (4621.9 to 12213.0)8580.1 (5164.3 to 14255.0)12063.8 (9962.2 to 14608.8)1.0 (1.0 to 1.0)1449.3 (521.4 to 4028.2)8318.2 (4793.1 to 14435.8)6940.3 (3323.6 to 14492.3)0.8 (0.6 to 1.1)4545.1 (2529.5 to 8166.6)2989.8 (1255.2 to 7121.5)9228.6 (5717.2 to 14896.6)1.0 (0.9 to 1.1)
S1-binding IgG level assay:1month after dose23333.9 (2382.9 to 4664.5)7084.4 (4443.5 to 11295.0)9754.4 (5820.9 to 16346.0)0.9 (0.8 to 1.0)——4893.1 (3297.4 to 7261.0)6553.4 (3787.8 to 11338.5)8363.2 (6537.1 to 10699.5)1.2 (0.8 to 1.9)1099.4 (364.6 to 3314.9)6678.8 (3844.9 to 11601.5)6003.8 (2793.3 to 12904.6)1.1 (0.9 to 1.4)3054.4 (2015.9 to 4627.9)1767.7 (700.5 to 4460.6)7252.1 (4538.7 to 11587.7)1.0 (0.6 to 1.7)
S1-binding IgG level assay:6months after dose2————————1517.2 (764.0 to 3013.2)———————883.7 (573.2 to 1362.5)—
RBD-binding IgG level assay:7days after dose11.1 (0.8 to 1.4)—1.0 (0.9 to 1.0)1.0 (0.6 to 1.7)1.3 (1.0 to 1.8)1.4 (0.3 to 5.6)————————————
RBD-binding IgG level assay:21days after dose1640.7 (321.9 to 1275.0)292.9 (71.9 to 1193.1)1763.1 (930.9 to 3339.4)1.1 (0.8 to 1.6)1966.5 (1039.6 to 3719.6)1.5 (0.3 to 8.7)516.9 (230.3 to 1160.4)557.1 (347.7 to 892.7)821.1 (456.9 to 1475.9)1.2 (0.7 to 1.8)44.4 (9.3 to 212.1)407.4 (178.8 to 928.2)159.6 (49.1 to 518.9)1.0 (0.9 to 1.0)89.6 (30.5 to 263.0)62.9 (17.4 to 227.0)316.3 (116.5 to 858.6)1.2 (0.7 to 2.2)
RBD-binding IgG level assay:7days after dose25770.9 (2945.0 to 11308.3)3258.8 (646.1 to 16436.3)31996.2 (16410.0 to 62386.2)1.1 (0.7 to 1.8)——7514.3 (4609.8 to 12249.0)19671.3 (12848.3 to 30117.6)8442.8 (4885.5 to 14590.4)1.1 (0.6 to 2.1)931.4 (217.9 to 3982.1)22482.1 (12326.8 to 41003.5)12115.3 (5507.4 to 26651.4)1.1 (0.9 to 1.4)2703.3 (1629.0 to 4486.1)3070.3 (905.7 to 10408.5)9357.1 (6075.0 to 14412.3)1.4 (0.7 to 2.8)
RBD-binding IgG level assay:14days after dose27050.6 (4405.1 to 11284.8)5151.7 (2469.6 to 10747.0)18558.1 (9354.8 to 36815.6)0.9 (0.7 to 1.2)——6077.6 (3328.1 to 11098.6)10243.4 (6509.5 to 16119.2)8213.0 (5507.4 to 12247.7)1.2 (0.8 to 1.7)1285.8 (329.7 to 5015.2)12139.3 (6742.2 to 21856.7)9667.2 (4456.0 to 20972.9)1.1 (0.8 to 1.5)3017.9 (1697.6 to 5364.9)2073.9 (698.9 to 6153.9)8982.5 (5966.6 to 13522.8)1.2 (0.6 to 2.6)
RBD-binding IgG level assay:1month after dose24405.3 (2727.7 to 7114.7)5021.3 (2410.1 to 10461.6)10893.9 (5125.4 to 23154.7)1.0 (0.8 to 1.1)——3984.7 (2412.4 to 6581.7)6665.1 (4292.1 to 10350.2)5505.3 (3394.8 to 8927.8)1.3 (0.7 to 2.3)1085.2 (274.9 to 4283.7)9807.7 (5413.5 to 17768.4)7224.1 (3355.8 to 15551.5)1.0 (0.9 to 1.1)2373.9 (1454.3 to 3875.1)1521.5 (511.7 to 4523.9)5522.3 (3610.4 to 8446.6)1.3 (0.6 to 2.8)
SecondaryPercentage of Participants Achieving a >= 4-Fold Rise From Before Vaccination to After Vaccination: Neutralizing Titers: Phase 1

Percentage of participants achieving a \>= 4-fold rise from before vaccination to after vaccination: neutralizing titers in Phase 1 were reported in this outcome measure. HIV positive participants were excluded from this analysis.

Time frame:
7, 21 days after Dose 1; 7, 14 days and 1, 6 months after Dose 2
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving a >= 4-Fold Rise From Before Vaccination to After Vaccination: Neutralizing Titers: Phase 1
Percentage of participantsBNT162b1 10 mcg Dose: 18-55 Years of AgeBNT162b1 20 mcg Dose: 18-55 Years of AgeBNT162b1 30 mcg Dose: 18-55 Years of AgePlacebo: 18-55 Years of Age for BNT162b1BNT162b1 100 mcg Dose, 18-55 Years of AgePlacebo 18-55 Years of Age for BNT162b1 100 mcgBNT162b2 10 mcg Dose, 18-55 Years of AgeBNT162b2 20 mcg Dose, 18-55 Years of AgeBNT162b2 30 mcg Dose, 18-55 Years of AgePlacebo: 18-55 Years of Age for BNT162b2BNT162b1 10 mcg Dose, 65-85 Years of AgeBNT162b1 20 mcg Dose, 65-85 Years of AgeBNT162b1 30 mcg Dose, 65-85 Years of AgePlacebo, 65-85 Years of Age for BNT162b1BNT162b2 10 mcg Dose, 65-85 Years of AgeBNT162b2 20 mcg Dose, 65-85 Years of AgeBNT162b2 30 mcg Dose, 65-85 Years of AgePlacebo: 65-85 Years of Age for BNT162b2
NT50 titer: 7 days after dose 10.0 (0.0 to 26.5)—0.0 (0.0 to 26.5)0.0 (0.0 to 45.9)0.0 (0.0 to 26.5)0.0 (0.0 to 70.8)————————————
NT50 (titer): 21 days after dose 10.0 (0.0 to 26.5)8.3 (0.2 to 38.5)25.0 (5.5 to 57.2)0.0 (0.0 to 33.6)50.0 (21.1 to 78.9)0.0 (0.0 to 70.8)18.2 (2.3 to 51.8)25.0 (5.5 to 57.2)0.0 (0.0 to 26.5)0.0 (0.0 to 41.0)0.0 (0.0 to 28.5)0.0 (0.0 to 26.5)8.3 (0.2 to 38.5)0.0 (0.0 to 33.6)0.0 (0.0 to 26.5)0.0 (0.0 to 26.5)0.0 (0.0 to 28.5)0.0 (0.0 to 33.6)
NT50 (titer): 7 days after dose 291.7 (61.5 to 99.8)91.7 (61.5 to 99.8)100.0 (73.5 to 100.0)0.0 (0.0 to 33.6)——100.0 (71.5 to 100.0)100.0 (73.5 to 100.0)100.0 (71.5 to 100.0)0.0 (0.0 to 41.0)9.1 (0.2 to 41.3)91.7 (61.5 to 99.8)75.0 (42.8 to 94.5)0.0 (0.0 to 33.6)83.3 (51.6 to 97.9)81.8 (48.2 to 97.7)90.9 (58.7 to 99.8)0.0 (0.0 to 33.6)
NT50 (titer): 14days after dose 291.7 (61.5 to 99.8)100.0 (73.5 to 100.0)100.0 (73.5 to 100.0)0.0 (0.0 to 33.6)——90.9 (58.7 to 99.8)100.0 (73.5 to 100.0)100.0 (66.4 to 100.0)0.0 (0.0 to 41.0)36.4 (10.9 to 69.2)75.0 (42.8 to 94.5)83.3 (51.6 to 97.9)0.0 (0.0 to 33.6)100.0 (71.5 to 100.0)72.7 (39.0 to 94.0)100.0 (71.5 to 100.0)0.0 (0.0 to 33.6)
NT50 (titer): 1 month after dose 283.3 (51.6 to 97.9)100.0 (73.5 to 100.0)91.7 (61.5 to 99.8)0.0 (0.0 to 33.6)——100.0 (71.5 to 100.0)100.0 (71.5 to 100.0)100.0 (71.5 to 100.0)0.0 (0.0 to 41.0)18.2 (2.3 to 51.8)91.7 (61.5 to 99.8)81.3 (51.6 to 97.9)0.0 (0.0 to 33.6)75.0 (42.8 to 94.5)54.5 (23.4 to 83.3)100.0 (71.5 to 100.0)0.0 (0.0 to 36.9)
NT50 (titer): 6 months after dose 2————————60.0 (26.2 to 87.8)———————27.3 (6.0 to 61.0)—
NT90 (titer): 7 days after dose 10.0 (0.0 to 26.5)—0.0 (0.0 to 26.5)0.0 (0.0 to 45.9)0.0 (0.0 to 26.5)0.0 (0.0 to 70.8)————————————
NT90 (titer): 21 days after dose 10.0 (0.0 to 26.5)0.0 (0.0 to 26.5)0.0 (0.0 to 26.5)0.0 (0.0 to 33.6)16.7 (2.1 to 48.4)0.0 (0.0 to 70.8)0.0 (0.0 to 28.5)0.0 (0.0 to 26.5)0.0 (0.0 to 26.5)0.0 (0.0 to 41.0)0.0 (0.0 to 28.5)0.0 (0.0 to 26.5)0.0 (0.0 to 26.5)0.0 (0.0 to 33.6)0.0 (0.0 to 26.5)0.0 (0.0 to 26.5)0.0 (0.0 to 28.5)0.0 (0.0 to 33.6)
NT90 (titer): 7 days after dose 283.3 (51.6 to 97.9)81.8 (48.2 to 97.7)91.7 (61.5 to 99.8)0.0 (0.0 to 33.6)——81.8 (48.2 to 97.7)100.0 (73.5 to 100.0)100.0 (71.5 to 100.0)0.0 (0.0 to 41.0)0.0 (0.0 to 28.5)66.7 (34.9 to 90.1)58.3 (27.7 to 84.8)0.0 (0.0 to 33.6)41.7 (15.2 to 72.3)45.5 (16.7 to 76.6)63.6 (30.8 to 89.1)0.0 (0.0 to 33.6)
NT90 (titer): 14 days after dose 283.3 (51.6 to 97.9)91.7 (61.5 to 99.8)100.0 (73.5 to 100.0)0.0 (0.0 to 33.6)——45.5 (16.7 to 76.6)91.7 (61.5 to 99.8)66.7 (29.9 to 92.5)0.0 (0.0 to 41.0)18.2 (2.3 to 51.8)58.3 (27.7 to 84.8)63.6 (30.8 to 89.1)0.0 (0.0 to 33.6)81.8 (48.2 to 97.7)27.3 (6.0 to 61.0)60.0 (26.2 to 87.8)0.0 (0.0 to 33.6)
NT90 (titer): 1 month after dose 241.7 (15.2 to 72.3)54.5 (23.4 to 83.3)63.6 (30.8 to 89.1)0.0 (0.0 to 33.6)——45.5 (16.7 to 76.6)81.8 (48.2 to 97.7)72.7 (39.0 to 94.0)0.0 (0.0 to 41.0)9.1 (0.2 to 41.3)66.7 (34.9 to 90.1)66.7 (34.9 to 90.1)0.0 (0.0 to 33.6)16.7 (2.1 to 48.4)27.3 (6.0 to 61.0)63.6 (30.8 to 89.1)0.0 (0.0 to 36.9)
SecondaryPercentage of Participants Achieving a >= 4-Fold Rise From Before Vaccination to After Vaccination: S1-binding and RBD-binding IgG Level Assay: Phase 1

Percentage of participants achieving a \>= 4-fold rise from before vaccination to after vaccination: S1-binding and RBD-binding IgG level assay in Phase 1 were reported in this outcome measure. HIV positive participants were excluded from this analysis.

Time frame:
From before vaccination to after vaccination
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving a >= 4-Fold Rise From Before Vaccination to After Vaccination: S1-binding and RBD-binding IgG Level Assay: Phase 1
Percentage of participantsBNT162b1 10 mcg Dose: 18-55 Years of AgeBNT162b1 20 mcg Dose: 18-55 Years of AgeBNT162b1 30 mcg Dose: 18-55 Years of AgePlacebo: 18-55 Years of Age for BNT162b1BNT162b1 100 mcg Dose, 18-55 Years of AgePlacebo 18-55 Years of Age for BNT162b1 100 mcgBNT162b2 10 mcg Dose, 18-55 Years of AgeBNT162b2 20 mcg Dose, 18-55 Years of AgeBNT162b2 30 mcg Dose, 18-55 Years of AgePlacebo: 18-55 Years of Age for BNT162b2BNT162b1 10 mcg Dose, 65-85 Years of AgeBNT162b1 20 mcg Dose, 65-85 Years of AgeBNT162b1 30 mcg Dose, 65-85 Years of AgePlacebo, 65-85 Years of Age for BNT162b1BNT162b2 10 mcg Dose, 65-85 Years of AgeBNT162b2 20 mcg Dose, 65-85 Years of AgeBNT162b2 30 mcg Dose, 65-85 Years of AgePlacebo: 65-85 Years of Age for BNT162b2
S1-binding IgG level assay:7days after dose10.0 (0.0 to 26.5)—0.0 (0.0 to 26.5)0.0 (0.0 to 45.9)8.3 (0.2 to 38.5)0.0 (0.0 to 70.8)————————————
S1-binding IgG level assay:21days after dose1100.0 (73.5 to 100.0)91.7 (61.5 to 99.8)100.0 (73.5 to 100.0)0.0 (0.0 to 33.6)100.0 (73.5 to 100.0)0.0 (0.0 to 70.8)100.0 (71.5 to 100.0)100.0 (73.5 to 100.0)100.0 (73.5 to 100.0)0.0 (0.0 to 41.0)72.7 (39.0 to 94.0)100.0 (73.5 to 100.0)91.7 (61.5 to 99.8)0.0 (0.0 to 33.6)100.0 (73.5 to 100.0)91.7 (61.5 to 99.8)100.0 (71.5 to 100.0)0.0 (0.0 to 33.6)
S1-binding IgG level assay:7days after dose2100.0 (73.5 to 100.0)91.7 (61.5 to 99.8)100.0 (73.5 to 100.0)0.0 (0.0 to 33.6)——100.0 (71.5 to 100.0)100.0 (73.5 to 100.0)100.0 (71.5 to 100.0)0.0 (0.0 to 41.0)100.0 (71.5 to 100.0)100.0 (73.5 to 100.0)100.0 (73.5 to 100.0)0.0 (0.0 to 33.6)100.0 (73.5 to 100.0)100.0 (71.5 to 100.0)100.0 (71.5 to 100.0)0.0 (0.0 to 33.6)
S1-binding IgG level assay:14days after dose2100.0 (73.5 to 100.0)100.0 (73.5 to 100.0)100.0 (73.5 to 100.0)0.0 (0.0 to 33.6)——100.0 (71.5 to 100.0)100.0 (73.5 to 100.0)100.0 (66.4 to 100.0)0.0 (0.0 to 41.0)100.0 (71.5 to 100.0)100.0 (73.5 to 100.0)100.0 (73.5 to 100.0)0.0 (0.0 to 33.6)100.0 (71.5 to 100.0)100.0 (71.5 to 100.0)100.0 (71.5 to 100.0)0.0 (0.0 to 33.6)
S1-binding IgG level assay:1month after dose2100.0 (73.5 to 100.0)100.0 (73.5 to 100.0)100.0 (73.5 to 100.0)0.0 (0.0 to 33.6)——100.0 (71.5 to 100.0)100.0 (71.5 to 100.0)100.0 (71.5 to 100.0)0.0 (0.0 to 41.0)100.0 (71.5 to 100.0)100.0 (73.5 to 100.0)100.0 (73.5 to 100.0)0.0 (0.0 to 33.6)100.0 (73.5 to 100.0)100.0 (71.5 to 100.0)100.0 (71.5 to 100.0)0.0 (0.0 to 36.9)
S1-binding IgG level assay:6months after dose2————————100.0 (69.2 to 100.0)———————100.0 (71.5 to 100.0)—
RBD-binding IgG level assay:7days after dose10.0 (0.0 to 26.5)—0.0 (0.0 to 26.5)0.0 (0.0 to 45.9)8.3 (0.2 to 38.5)0.0 (0.0 to 70.8)————————————
RBD-binding IgG level assay:21days after dose1100.0 (73.5 to 100.0)91.7 (61.5 to 99.8)100.0 (73.5 to 100.0)0.0 (0.0 to 33.6)100.0 (73.5 to 100.0)0.0 (0.0 to 70.8)100.0 (71.5 to 100.0)100.0 (73.5 to 100.0)100.0 (73.5 to 100.0)0.0 (0.0 to 41.0)72.7 (39.0 to 94.0)100.0 (73.5 to 100.0)100.0 (73.5 to 100.0)0.0 (0.0 to 33.6)91.7 (61.5 to 99.8)83.3 (51.6 to 97.9)100.0 (71.5 to 100.0)11.1 (0.3 to 48.2)
RBD-binding IgG level assay:7days after dose2100.0 (73.5 to 100.0)91.7 (61.5 to 99.8)100.0 (73.5 to 100.0)0.0 (0.0 to 33.6)——100.0 (71.5 to 100.0)100.0 (73.5 to 100.0)100.0 (71.5 to 100.0)0.0 (0.0 to 41.0)100.0 (71.5 to 100.0)100.0 (73.5 to 100.0)100.0 (73.5 to 100.0)0.0 (0.0 to 33.6)100.0 (73.5 to 100.0)100.0 (71.5 to 100.0)100.0 (71.5 to 100.0)11.1 (0.3 to 48.2)
RBD-binding IgG level assay:14days after dose2100.0 (73.5 to 100.0)100.0 (73.5 to 100.0)100.0 (73.5 to 100.0)0.0 (0.0 to 33.6)——100.0 (71.5 to 100.0)100.0 (73.5 to 100.0)100.0 (66.4 to 100.0)0.0 (0.0 to 41.0)100.0 (71.5 to 100.0)100.0 (73.5 to 100.0)100.0 (73.5 to 100.0)0.0 (0.0 to 33.6)100.0 (71.5 to 100.0)100.0 (71.5 to 100.0)100.0 (71.5 to 100.0)11.1 (0.3 to 48.2)
RBD-binding IgG level assay:1month after dose2100.0 (73.5 to 100.0)100.0 (73.5 to 100.0)100.0 (73.5 to 100.0)0.0 (0.0 to 33.6)——100.0 (71.5 to 100.0)100.0 (71.5 to 100.0)100.0 (71.5 to 100.0)0.0 (0.0 to 41.0)100.0 (71.5 to 100.0)100.0 (73.5 to 100.0)100.0 (73.5 to 100.0)0.0 (0.0 to 33.6)100.0 (73.5 to 100.0)100.0 (71.5 to 100.0)100.0 (71.5 to 100.0)12.5 (0.3 to 52.7)
SecondaryGMR Based on Reference Strain NT - Comparison of Participants 12 to 15 Years of Age to Participants 16 to 25 Years of Age- Participants Without Evidence of Infection up to 1 Month After Dose 2 - Dose 2 Evaluable Immunogenicity Population: Phase2/3

GMR based on reference strain NT, comparison of participants 12 to 15 years of age to participants 16 to 25 years of age of participants without evidence of infection up to 1 month after dose 2 in Phase2/3 were reported in this outcome measure. HIV positive participants were excluded from this analysis.

Time frame:
1 Month After Dose 2
Reported as:
Geometric mean · Titer
GMR Based on Reference Strain NT - Comparison of Participants 12 to 15 Years of Age to Participants 16 to 25 Years of Age- Participants Without Evidence of Infection up to 1 Month After Dose 2 - Dose 2 Evaluable Immunogenicity Population: Phase2/3
TiterBNT162b2 (30 mcg): 12-15 Years of AgeBNT162b2 (30 mcg): 16-25 Years of Age
GMR Based on Reference Strain NT - Comparison of Participants 12 to 15 Years of Age to Participants 16 to 25 Years of Age- Participants Without Evidence of Infection up to 1 Month After Dose 2 - Dose 2 Evaluable Immunogenicity Population: Phase2/31239.5 (1095.5 to 1402.5)705.1 (621.4 to 800.2)
Statistical analysis
  • BNT162b2 (30 mcg): 12-15 Years of Age vs BNT162b2 (30 mcg): 16-25 Years of Age · Geometric mean ratio: 1.76 · 95% CI 1.47 to 2.10
SecondaryIncidence of Asymptomatic SARS-CoV-2 Infection Per 1000 Person Years Follow-up Without Serological or Virological Evidence (Up to Start of Asymptomatic Surveillance Period) of Past Infection: Phase 3

Incidence of asymptomatic SARS-CoV-2 infection per 1000 person years follow-up without serological or virological evidence (up to start of asymptomatic surveillance period) of past infection were reported in this outcome measure.

Time frame:
From start of asymptomatic surveillance (Surveillance time [1000 person-years]: BNT162b2 - 0.383; Placebo - 0.200
Reported as:
Number · Events per 1000 person-years
Incidence of Asymptomatic SARS-CoV-2 Infection Per 1000 Person Years Follow-up Without Serological or Virological Evidence (Up to Start of Asymptomatic Surveillance Period) of Past Infection: Phase 3
Events per 1000 person-yearsBNT162b2 (30 mcg)Placebo
Incidence of Asymptomatic SARS-CoV-2 Infection Per 1000 Person Years Follow-up Without Serological or Virological Evidence (Up to Start of Asymptomatic Surveillance Period) of Past Infection: Phase 362.663100.000
Statistical analysis
  • BNT162b2 (30 mcg) vs Placebo · Vaccine efficacy: 37.2 · 95% CI -20.0 to 66.7
SecondaryIncidence of Asymptomatic SARS-CoV-2 Infection Per 1000 Person Years Follow-up Without Serological or Virological Evidence of Past Infection Based on N-binding Antibody Seroconversion: Phase 3

Incidence of asymptomatic SARS-CoV-2 infection per 1000 person years follow-up without serological or virological evidence of past infection based on N-binding antibody seroconversion were reported in this outcome measure.

Time frame:
From Dose 2 to the end of the surveillance period ([1000 person-years]: BNT162b2 - 13.840, Placebo - 6.481)
Reported as:
Number · Events per 1000 person-years
Incidence of Asymptomatic SARS-CoV-2 Infection Per 1000 Person Years Follow-up Without Serological or Virological Evidence of Past Infection Based on N-binding Antibody Seroconversion: Phase 3
Events per 1000 person-yearsBNT162b2 (30 mcg)Placebo
Incidence of Asymptomatic SARS-CoV-2 Infection Per 1000 Person Years Follow-up Without Serological or Virological Evidence of Past Infection Based on N-binding Antibody Seroconversion: Phase 344.22093.813
Statistical analysis
  • BNT162b2 (30 mcg) vs Placebo · Vaccine efficacy (ve): 52.9 · 95% CI 47.2 to 57.9
SecondaryCOVID-19 Incidence Per 1000 Person-Years of Follow-up With or Without Evidence of Infection 7 Days After Second Dose of BNT162b2 Based on CDC-Defined Symptoms (Analysis for EUA): Phase 3

COVID-19 incidence per 1000 person years follow-up with or without the evidence of infection were reported in this outcome measure.

Time frame:
From 7 Days After Dose 2 (Surveillance time [1000 person-years]: BNT162b2 - 2.330, Placebo - 2.343)
Reported as:
Number · Events per 1000 person-years
COVID-19 Incidence Per 1000 Person-Years of Follow-up With or Without Evidence of Infection 7 Days After Second Dose of BNT162b2 Based on CDC-Defined Symptoms (Analysis for EUA): Phase 3
Events per 1000 person-yearsBNT162b2 (30 mcg)Placebo
COVID-19 Incidence Per 1000 Person-Years of Follow-up With or Without Evidence of Infection 7 Days After Second Dose of BNT162b2 Based on CDC-Defined Symptoms (Analysis for EUA): Phase 33.86373.410
Statistical analysis
  • BNT162b2 (30 mcg) vs Placebo · Vaccine efficacy: 94.7 · 95% CI 89.8 to 97.6
SecondaryCOVID-19 Incidence Per 1000 Person-Years of Follow-up With or Without Evidence of Infection 14 Days After Second Dose of BNT162b2 Based on CDC-Defined Symptoms (Analysis for EUA): Phase 3

COVID-19 incidence per 1000 person years follow-up with or without the evidence of infection were reported in this outcome measure.

Time frame:
From 14 Days After Dose 2 (Surveillance time [1000 person-years]: BNT162b2 - 1.983, Placebo - 1.993)
Reported as:
Number · Events per 1000 person-years
COVID-19 Incidence Per 1000 Person-Years of Follow-up With or Without Evidence of Infection 14 Days After Second Dose of BNT162b2 Based on CDC-Defined Symptoms (Analysis for EUA): Phase 3
Events per 1000 person-yearsBNT162b2 (30 mcg)Placebo
COVID-19 Incidence Per 1000 Person-Years of Follow-up With or Without Evidence of Infection 14 Days After Second Dose of BNT162b2 Based on CDC-Defined Symptoms (Analysis for EUA): Phase 34.03473.256
Statistical analysis
  • BNT162b2 (30 mcg) vs Placebo · Vaccine efficacy: 94.5 · 95% CI 88.9 to 97.7
SecondaryCOVID-19 Incidence Per 1000 Person-Years of Follow-up Without Evidence of Infection: 7 Days After Dose 2 Based on CDC Defined Symptoms (Analysis for EUA): Phase 3

COVID-19 incidence per 1000 person years follow-up without the evidence of infection (analysis for EUA) were reported in this outcome measure.

Time frame:
From 7 days after Dose 2 (Surveillance time [1000 person-years]: BNT162b2 - 2.213; Placebo - 2.220)
Reported as:
Number · Events per 1000 person-years
COVID-19 Incidence Per 1000 Person-Years of Follow-up Without Evidence of Infection: 7 Days After Dose 2 Based on CDC Defined Symptoms (Analysis for EUA): Phase 3
Events per 1000 person-yearsBNT162b2 (30 mcg)Placebo
COVID-19 Incidence Per 1000 Person-Years of Follow-up Without Evidence of Infection: 7 Days After Dose 2 Based on CDC Defined Symptoms (Analysis for EUA): Phase 33.61574.324
Statistical analysis
  • BNT162b2 (30 mcg) vs Placebo · Vaccine efficacy: 95.1 · 95% CI 90.2 to 97.9
SecondaryCOVID-19 Incidence Per 1000 Person-Years of Follow-up Without Evidence of Infection: 14 Days After Dose 2 Based on CDC Defined Symptoms (Analysis for EUA): Phase 3

COVID-19 incidence per 1000 person years follow-up without the evidence of infection were reported in this outcome measure.

Time frame:
From 14 days after Dose 2 (Surveillance time [1000 person-years]: BNT162b2 - 1.886; Placebo - 1.891)
Reported as:
Number · Events per 1000 person-years
COVID-19 Incidence Per 1000 Person-Years of Follow-up Without Evidence of Infection: 14 Days After Dose 2 Based on CDC Defined Symptoms (Analysis for EUA): Phase 3
Events per 1000 person-yearsBNT162b2 (30 mcg)Placebo
COVID-19 Incidence Per 1000 Person-Years of Follow-up Without Evidence of Infection: 14 Days After Dose 2 Based on CDC Defined Symptoms (Analysis for EUA): Phase 34.24274.564
Statistical analysis
  • BNT162b2 (30 mcg) vs Placebo · Vaccine efficacy: 94.3 · 95% CI 88.5 to 97.6
SecondarySevere COVID-19 Incidence Per 1000 Person-Years of Follow-up With or Without Evidence of Infection: 7 Days After Dose 2: Phase 3

Severe COVID-19 incidence per 1000 person years follow-up with or without the evidence of infection were reported in this outcome measure.

Time frame:
From 7 days after Dose 2 (Surveillance time [1000 person-years]: BNT162b2 - 6.522; Placebo - 6.404)
Reported as:
Number · Events per 1000 person-years
Severe COVID-19 Incidence Per 1000 Person-Years of Follow-up With or Without Evidence of Infection: 7 Days After Dose 2: Phase 3
Events per 1000 person-yearsBNT162b2 (30 mcg)Placebo
Severe COVID-19 Incidence Per 1000 Person-Years of Follow-up With or Without Evidence of Infection: 7 Days After Dose 2: Phase 30.1533.279
Statistical analysis
  • BNT162b2 (30 mcg) vs Placebo · Vaccine efficacy: 95.3 · 95% CI 70.9 to 99.9
SecondarySevere COVID-19 Incidence Per 1000 Person-Years of Follow-up With or Without Evidence of Infection: 14 Days After Dose 2 (Analysis for EUA): Phase 3

Severe COVID-19 incidence per 1000 person years follow-up with or without the evidence of infection (analysis for EUA) were reported in this outcome measure.

Time frame:
From 14 days after Dose 2 (Surveillance time [1000 person-years]: BNT162b2 - 1.985; Placebo - 2.007)
Reported as:
Number · Events per 1000 person-years
Severe COVID-19 Incidence Per 1000 Person-Years of Follow-up With or Without Evidence of Infection: 14 Days After Dose 2 (Analysis for EUA): Phase 3
Events per 1000 person-yearsBNT162b2 (30 mcg)Placebo
Severe COVID-19 Incidence Per 1000 Person-Years of Follow-up With or Without Evidence of Infection: 14 Days After Dose 2 (Analysis for EUA): Phase 30.5041.495
Statistical analysis
  • BNT162b2 (30 mcg) vs Placebo · Vaccine efficacy: 66.3 · 95% CI -125.6 to 96.3
SecondarySevere COVID-19 Incidence Per 1000 Person-Years of Follow-up Without Evidence of Infection: 7 Days After Dose 2: Phase 3

Severe COVID-19 incidence per 1000 person years follow-up without the evidence of infection were reported in this outcome measure.

Time frame:
From 7 days after Dose 2 (Surveillance time [1000 person-years]: BNT162b2 - 6.257; Placebo - 6.120)
Reported as:
Number · Events per 1000 person-years
Severe COVID-19 Incidence Per 1000 Person-Years of Follow-up Without Evidence of Infection: 7 Days After Dose 2: Phase 3
Events per 1000 person-yearsBNT162b2 (30 mcg)Placebo
Severe COVID-19 Incidence Per 1000 Person-Years of Follow-up Without Evidence of Infection: 7 Days After Dose 2: Phase 30.1603.431
Statistical analysis
  • BNT162b2 (30 mcg) vs Placebo · Vaccine efficacy: 95.3 · 95% CI 71.0 to 99.9
SecondarySevere COVID-19 Incidence Per 1000 Person-Years of Follow-up Without Evidence of Infection: 14 Days After Dose 2 (Analysis for EUA): Phase 3

Severe COVID-19 incidence per 1000 person years follow-up without the evidence of infection (analysis for EUA) were reported in this outcome measure.

Time frame:
From 14 days after Dose 2 (Surveillance time [1000 person-years]: BNT162b2 - 1.888; Placebo - 1.901)
Reported as:
Number · Events per 1000 person-years
Severe COVID-19 Incidence Per 1000 Person-Years of Follow-up Without Evidence of Infection: 14 Days After Dose 2 (Analysis for EUA): Phase 3
Events per 1000 person-yearsBNT162b2 (30 mcg)Placebo
Severe COVID-19 Incidence Per 1000 Person-Years of Follow-up Without Evidence of Infection: 14 Days After Dose 2 (Analysis for EUA): Phase 30.5301.578
Statistical analysis
  • BNT162b2 (30 mcg) vs Placebo · Vaccine efficacy: 66.4 · 95% CI -124.7 to 96.3
SecondaryCOVID-19 Incidence Per 1000 Person-Years of With or Without Evidence of Infection: 14 Days After Dose 2 (EUA Analysis): Phase 3

COVID-19 incidence per 1000 person years follow-up with or without the evidence of infection (analysis for EUA) were reported in this outcome measure.

Time frame:
From 14 days after Dose 2 (Surveillance time [1000 person-years]: BNT162b2 - 1.984; Placebo - 1.995)
Reported as:
Number · Events per 1000 person-years
COVID-19 Incidence Per 1000 Person-Years of With or Without Evidence of Infection: 14 Days After Dose 2 (EUA Analysis): Phase 3
Events per 1000 person-yearsBNT162b2 (30 mcg)Placebo
COVID-19 Incidence Per 1000 Person-Years of With or Without Evidence of Infection: 14 Days After Dose 2 (EUA Analysis): Phase 34.03272.180
Statistical analysis
  • BNT162b2 (30 mcg) vs Placebo · Vaccine efficacy: 94.4 · 95% CI 89.1 to 97.3
SecondaryCOVID-19 Incidence Per 1000 Person-Years of Follow-up Without Evidence of Infection: 14 Days After Dose 2 (EUA Analysis): Phase 3

COVID-19 incidence per 1000 person years follow-up without the evidence of infection (analysis for EUA) were reported in this outcome measure.

Time frame:
From 14 days after Dose 2 (Surveillance time [1000 person-years]: BNT162b2 - 1.887; Placebo - 1.893)
Reported as:
Number · Events per 1000 person-years
COVID-19 Incidence Per 1000 Person-Years of Follow-up Without Evidence of Infection: 14 Days After Dose 2 (EUA Analysis): Phase 3
Events per 1000 person-yearsBNT162b2 (30 mcg)Placebo
COVID-19 Incidence Per 1000 Person-Years of Follow-up Without Evidence of Infection: 14 Days After Dose 2 (EUA Analysis): Phase 34.24073.428
Statistical analysis
  • BNT162b2 (30 mcg) vs Placebo · Vaccine efficacy: 94.2 · 95% CI 88.7 to 97.2
SecondaryPercentage Difference of Participants Achieving Seroresponse (Reference Strain) 1 Month After Second Dose in BNT162b2-Naive Participants: Phase 3

Seroresponse was defined as achieving a \>=4-fold rise from baseline (before Dose 1). If the baseline measurement was below the lower limit of quantification (LLOQ), a post vaccination assay result \>=4 × LLOQ was considered a seroresponse. HIV positive participants were excluded from this analysis.

Time frame:
1 Month After Dose 2
Reported as:
Number · Percentage of participants
Percentage Difference of Participants Achieving Seroresponse (Reference Strain) 1 Month After Second Dose in BNT162b2-Naive Participants: Phase 3
Percentage of participantsBNT162b2SA (30 mcg)BNT162b2 (30 mcg)
Percentage Difference of Participants Achieving Seroresponse (Reference Strain) 1 Month After Second Dose in BNT162b2-Naive Participants: Phase 384.8 (71.1 to 93.7)97.3 (94.6 to 98.9)
Statistical analysis
  • BNT162b2SA (30 mcg) vs BNT162b2 (30 mcg) · Percentage difference: -12.5 · 95% CI -25.7 to -4.5
SecondaryGMR Based on Geometric Mean Titer (Reference Strain) 1 Month After Second Dose in BNT162b2-Naive Participants: Phase 3

GMR based on GMT (Reference Strain) 1 month after second dose of BNT162b2SA and 1 month after the second dose of BNT162b2 in BNT162b2-naive participant were reported in this outcome measure.

Time frame:
1 Month After Dose 2
Reported as:
Geometric mean · Titer
GMR Based on Geometric Mean Titer (Reference Strain) 1 Month After Second Dose in BNT162b2-Naive Participants: Phase 3
TiterBNT162b2SA (30 mcg)BNT162b2 (30 mcg)
GMR Based on Geometric Mean Titer (Reference Strain) 1 Month After Second Dose in BNT162b2-Naive Participants: Phase 3356.7 (260.9 to 487.6)820.3 (745.7 to 902.3)
Statistical analysis
  • BNT162b2SA (30 mcg) vs BNT162b2 (30 mcg) · Geometric mean ratio: 0.43 · 95% CI 0.31 to 0.60
SecondaryGMR Based on Geometric Mean Titer of SA NT 1 Month After Second Dose of BNT162b2SA to 1 Month After the Second Dose (N2a) of BNT162b2 Naive Participants: Phase 3

GMR based on geometric mean titer of SA NT 1 Month after second dose of BNT162b2SA to 1 Month after the second dose (N2a) of BNT162b2 naive participants of Phase 3 were reported in this outcome measure.

Time frame:
1 month after the second dose
Reported as:
Geometric mean · Titer
GMR Based on Geometric Mean Titer of SA NT 1 Month After Second Dose of BNT162b2SA to 1 Month After the Second Dose (N2a) of BNT162b2 Naive Participants: Phase 3
TiterBNT162b2SA (30 mcg)BNT162b2 (30 mcg)
GMR Based on Geometric Mean Titer of SA NT 1 Month After Second Dose of BNT162b2SA to 1 Month After the Second Dose (N2a) of BNT162b2 Naive Participants: Phase 31358.0 (1242.0 to 1484.0)273.1 (245.6 to 303.7)
Statistical analysis
  • BNT162b2SA (30 mcg) vs BNT162b2 (30 mcg) · Geometric mean ratio: 4.97 · 97.5% CI 4.24 to 5.83
SecondaryPercentage Difference of Participants Achieving Seroresponse (N2b) Comparison of 1 Month After Dose 2 Between Vaccine Groups: BNT162b2-Naïve Participants Without Evidence of Infection up to 1 Month After Dose 2: Phase 3

Seroresponse was defined as achieving a \>=4-fold rise from baseline (before Dose 1). If the baseline measurement was below the LLOQ, a postvaccination assay result \>=4 × LLOQ was considered a seroresponse.

Time frame:
1 Month After Dose 2
Reported as:
Number · Percentage of participants
Percentage Difference of Participants Achieving Seroresponse (N2b) Comparison of 1 Month After Dose 2 Between Vaccine Groups: BNT162b2-Naïve Participants Without Evidence of Infection up to 1 Month After Dose 2: Phase 3
Percentage of participantsBNT162b2SA (30 mcg)BNT162b2 (30 mcg)
Percentage Difference of Participants Achieving Seroresponse (N2b) Comparison of 1 Month After Dose 2 Between Vaccine Groups: BNT162b2-Naïve Participants Without Evidence of Infection up to 1 Month After Dose 2: Phase 397.1 (94.3 to 98.7)57.6 (51.8 to 63.2)
Statistical analysis
  • BNT162b2SA (30 mcg) vs BNT162b2 (30 mcg) · Percentage difference: 39.5 · 97.5% CI 32.7 to 46.2
SecondaryGMR of Neutralizing Titers (E3a) - Comparison of 1 Month After Booster Dose to 1 Month After Dose 2: BNT162b2-Experienced Participants That Received a Booster Dose of BNT162b2: Phase 3

GMR of neutralizing titers (E3a) - comparison of 1 month after booster dose to 1 month after dose 2: BNT162b2-experienced participants of Phase 3 were reported in this outcome measure.

Time frame:
1 Month After Booster Dose to 1 Month After Dose 2
Reported as:
Geometric mean · Titer
GMR of Neutralizing Titers (E3a) - Comparison of 1 Month After Booster Dose to 1 Month After Dose 2: BNT162b2-Experienced Participants That Received a Booster Dose of BNT162b2: Phase 3
TiterBNT162b2 (30 mcg): 1 Month After Booster DoseBNT162b2 (30 mcg): 1 Month After Dose 2
GMR of Neutralizing Titers (E3a) - Comparison of 1 Month After Booster Dose to 1 Month After Dose 2: BNT162b2-Experienced Participants That Received a Booster Dose of BNT162b2: Phase 32562.1 (2284.9 to 2872.8)745.7 (656.5 to 847.1)
Statistical analysis
  • BNT162b2 (30 mcg): 1 Month After Booster Dose vs BNT162b2 (30 mcg): 1 Month After Dose 2 · Geometric mean ratio: 3.44 · 97.5% CI 2.93 to 4.03
SecondaryPercentage Difference of Participants Achieving Seroresponse (E3b) - Comparison of 1 Month After Booster Dose to 1 Month After Dose 2: BNT162b2-Experienced Participants That Received a Booster Dose of BNT162b2: Phase 3

Percentage difference of participants achieving seroresponse (E3b) - comparison of 1 month after booster dose to 1 month after dose 2 BNT162b2-experienced participants without evidence of infection up to 1 month after booster dose who were rerandomized to receive 1 booster dose were reported in this outcome measure.

Time frame:
1 Month After Booster Dose to 1 Month After Dose 2
Reported as:
Number · Percentage of participants
Percentage Difference of Participants Achieving Seroresponse (E3b) - Comparison of 1 Month After Booster Dose to 1 Month After Dose 2: BNT162b2-Experienced Participants That Received a Booster Dose of BNT162b2: Phase 3
Percentage of participantsBNT162b2 (30 mcg): 1 Month After Booster DoseBNT162b2 (30 mcg): 1 Month After Dose 2
Percentage Difference of Participants Achieving Seroresponse (E3b) - Comparison of 1 Month After Booster Dose to 1 Month After Dose 2: BNT162b2-Experienced Participants That Received a Booster Dose of BNT162b2: Phase 3100.0 (98.2 to 100.0)95.2 (91.3 to 97.7)
Statistical analysis
  • BNT162b2 (30 mcg): 1 Month After Booster Dose vs BNT162b2 (30 mcg): 1 Month After Dose 2 · Percentage difference: 4.8 · 97.5% CI 1.3 to 8.3
SecondaryGMR of Neutralizing Titers (E4a) - Comparison of 1 Month After Booster Dose to 1 Month After Dose 2: BNT162b2-Experienced Participants: Phase 3

GMR of neutralizing titers (E4a) - comparison of 1 month after booster dose to 1 month after dose 2: BNT162b2-experienced participants of Phase 3 were reported in this outcome measure.

Time frame:
1 Month After Booster Dose to 1 Month After Dose 2
Reported as:
Geometric mean · Titer
GMR of Neutralizing Titers (E4a) - Comparison of 1 Month After Booster Dose to 1 Month After Dose 2: BNT162b2-Experienced Participants: Phase 3
TiterBNT162b2SA (30 mcg):1 Month After Booster DoseBNT162b2SA 30 mcg: 1 Month After Dose 2
GMR of Neutralizing Titers (E4a) - Comparison of 1 Month After Booster Dose to 1 Month After Dose 2: BNT162b2-Experienced Participants: Phase 31676.0 (1496.2 to 1877.3)686.0 (612.0 to 769.0)
Statistical analysis
  • BNT162b2SA (30 mcg):1 Month After Booster Dose vs BNT162b2SA 30 mcg: 1 Month After Dose 2 · Geometric mean ratio: 2.44 · 97.5% CI 2.14 to 2.80
SecondaryPercentage Difference of Participants Achieving Seroresponse (E4b) - Comparison of 1 Month After Booster Dose to 1 Month After Dose 2: BNT162b2-Experienced Participants: Phase 3

Percentage difference of participants achieving seroresponse (E4b) - comparison of 1 month after booster dose to 1 month after dose 2 BNT162b2-experienced participants without evidence of infection up to 1 month after booster dose who were rerandomized to receive 1 booster dose were reported in this outcome measure.

Time frame:
1 Month After Booster Dose to 1 Month After Dose 2
Reported as:
Number · Percentage of participants
Percentage Difference of Participants Achieving Seroresponse (E4b) - Comparison of 1 Month After Booster Dose to 1 Month After Dose 2: BNT162b2-Experienced Participants: Phase 3
Percentage of participantsBNT162b2SA (30 mcg): 1 Month After Booster DoseBNT162b2SA 30 mcg: 1 Month After Dose 2
Percentage Difference of Participants Achieving Seroresponse (E4b) - Comparison of 1 Month After Booster Dose to 1 Month After Dose 2: BNT162b2-Experienced Participants: Phase 399.5 (97.4 to 100.0)94.0 (89.9 to 96.7)
Statistical analysis
  • BNT162b2SA (30 mcg): 1 Month After Booster Dose vs BNT162b2SA 30 mcg: 1 Month After Dose 2 · Percentage difference: 5.6 · 97.5% CI 1.6 to 9.4
SecondaryPercentage Difference of Participants Achieving Seroresponse for SA Variant NT Comparison of 1 Month After Second Booster Dose to 1 Month After Dose 2 of BNT162b2 in Participants Assigned to Receive 2 Booster Doses of BNT162b2SA: Phase 3

Percentage difference of participants achieving seroresponse for SA variant NT comparison of 1 Month after second booster dose to 1 Month after Dose 2 of BNT162b2 in participants assigned to receive 2 booster doses of BNT162b2SA of Phase 3 were reported in this outcome measure.

Time frame:
1 Month after Second Booster Dose to 1 Month After Dose 2 of BNT162b2
Reported as:
Number · Percentage of participants
Percentage Difference of Participants Achieving Seroresponse for SA Variant NT Comparison of 1 Month After Second Booster Dose to 1 Month After Dose 2 of BNT162b2 in Participants Assigned to Receive 2 Booster Doses of BNT162b2SA: Phase 3
Percentage of participantsBNT162b2 (30 mcg): 1 Month After Second Booster DoseBNT162b2 (30 mcg): 1 Month After Dose 2
Percentage Difference of Participants Achieving Seroresponse for SA Variant NT Comparison of 1 Month After Second Booster Dose to 1 Month After Dose 2 of BNT162b2 in Participants Assigned to Receive 2 Booster Doses of BNT162b2SA: Phase 3100.0 (87.2 to 100.0)100.0 (87.2 to 100.0)
Statistical analysis
  • BNT162b2 (30 mcg): 1 Month After Second Booster Dose vs BNT162b2 (30 mcg): 1 Month After Dose 2 · Percentage difference: 0 · 95% CI -6.8 to 6.8
SecondaryGMR of SA Variant NT 1 Month After Second Booster Dose to 1 Month After Dose 2 of BNT162b2 in Participants Assigned to Receive 2 Booster Doses of BNT1612b2SA: Phase 3

GMR of SA variant NT 1 month after second booster dose to 1 month after dose 2 of BNT162b2 in participants assigned to receive 2 booster doses of BNT1612b2SA were reported in this outcome measure.

Time frame:
1 Month After Second Booster Dose to 1 Month After Dose 2 of BNT162b2
Reported as:
Geometric mean · Titer
GMR of SA Variant NT 1 Month After Second Booster Dose to 1 Month After Dose 2 of BNT162b2 in Participants Assigned to Receive 2 Booster Doses of BNT1612b2SA: Phase 3
TiterBNT162b2 (30 mcg): 1 Month After Second Booster DoseBNT162b2 (30 mcg): 1 Month After Dose 2
GMR of SA Variant NT 1 Month After Second Booster Dose to 1 Month After Dose 2 of BNT162b2 in Participants Assigned to Receive 2 Booster Doses of BNT1612b2SA: Phase 34981.2 (3690.8 to 6722.8)1076.5 (854.5 to 1356.1)
Statistical analysis
  • BNT162b2 (30 mcg): 1 Month After Second Booster Dose vs BNT162b2 (30 mcg): 1 Month After Dose 2 · Geometric mean ratio: 4.63 · 95% CI 3.56 to 6.01
SecondaryPercentage Difference of Participants Achieving Seroresponse for SA Variant NT: BNT162b2-Experienced Participants Without Evidence of Infection up to 1 Month After Booster Dose Who Were Rerandomized to Receive 1 Booster Dose: Phase 3

Percentage difference of participants achieving seroresponse for SA variant NT: BNT162b2-experienced participants without evidence of infection up to 1 month after booster dose who were rerandomized to receive 1 booster dose were reported in this outcome measure.

Time frame:
1 Month After Booster Dose
Reported as:
Number · Percentage of participants
Percentage Difference of Participants Achieving Seroresponse for SA Variant NT: BNT162b2-Experienced Participants Without Evidence of Infection up to 1 Month After Booster Dose Who Were Rerandomized to Receive 1 Booster Dose: Phase 3
Percentage of participantsBNT162b2SA (30 mcg)BNT162b2 (30 mcg)
Percentage Difference of Participants Achieving Seroresponse for SA Variant NT: BNT162b2-Experienced Participants Without Evidence of Infection up to 1 Month After Booster Dose Who Were Rerandomized to Receive 1 Booster Dose: Phase 399.2 (97.3 to 99.9)99.6 (97.7 to 100.0)
Statistical analysis
  • BNT162b2SA (30 mcg) vs BNT162b2 (30 mcg) · Percentage difference: -0.4 · 95% CI -2.4 to 1.6
SecondaryGMR of SA Variant NT: BNT162b2-Experienced Participants Without Evidence of Infection up to 1 Month After Booster Dose Who Were Rerandomized to Receive 1 Booster Dose: Phase 3

GMR of SA Variant NT: BNT162b2-experienced participants without evidence of infection up to 1 month after booster dose who were rerandomized to receive 1 booster dose were reported in this outcome measure.

Time frame:
1 Month After Booster Dose
Reported as:
Geometric mean · Titer
GMR of SA Variant NT: BNT162b2-Experienced Participants Without Evidence of Infection up to 1 Month After Booster Dose Who Were Rerandomized to Receive 1 Booster Dose: Phase 3
TiterBNT162b2SA (30 mcg)BNT162b2 (30 mcg)
GMR of SA Variant NT: BNT162b2-Experienced Participants Without Evidence of Infection up to 1 Month After Booster Dose Who Were Rerandomized to Receive 1 Booster Dose: Phase 33536.4 (3131.3 to 3994.0)2453.0 (2190.0 to 2747.7)
Statistical analysis
  • BNT162b2SA (30 mcg) vs BNT162b2 (30 mcg) · Geometric mean ratio: 1.44 · 95% CI 1.22 to 1.70

Adverse events

Collected over AEs: From Dose 1 to 1 Month after each dose (up to a maximum of 2 years); SAEs: From Dose 1 to 6 Months after each dose (up to a maximum of 2 years); Local reactions/systemic events: Within 7 days after each dose. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
PC Fup Period - Ph1 - BNT162b1 10 mcg0/24 (0%)0/24 (0%)23/24 (95.8%)
PC Fup Period - Ph1 - BNT162b1 20 mcg0/24 (0%)0/24 (0%)23/24 (95.8%)
PC Fup Period - Ph1 - BNT162b1 30 mcg0/24 (0%)0/24 (0%)23/24 (95.8%)
PC Fup Period - Ph1 - BNT162b1 100 mcg0/12 (0%)0/12 (0%)12/12 (100%)
PC Fup Period - Ph1 - BNT162b2 10 mcg0/24 (0%)0/24 (0%)18/24 (75%)
PC Fup Period - Ph1 - BNT162b2 20 mcg0/24 (0%)1/24 (4.2%)22/24 (91.7%)
PC Fup Period - Ph1 - BNT162b2 30 mcg0/24 (0%)1/24 (4.2%)23/24 (95.8%)
OL Fup Period - Ph1 - Placebo/BNT162b2 30 mcg0/35 (0%)0/35 (0%)7/35 (20%)
PC Fup Period - Ph1 - Placebo0/39 (0%)0/39 (0%)24/39 (61.5%)
PC Fup Period - Ph2/3 Sub >=16 YOA (Final) - Placebo23/22,012 (0.1%)293/22,012 (1.3%)3,848/22,012 (17.5%)
PC Fup Period - Ph2/3 Sub >=16 YOA (Final) - BNT162b2 (30 mcg)61/22,010 (0.3%)430/22,010 (2%)9,587/22,010 (43.6%)
OL Fup Period - Ph2/3 Sub >=16 YOA (Final) - Pla/B2 (30 mcg)38/20,357 (0.2%)354/20,357 (1.7%)5,446/20,357 (26.8%)
PC Fup Period - Ph3 Sub 12-15 YOA - Placebo0/1,129 (0%)2/1,129 (0.2%)760/1,129 (67.3%)
PC Fup Period - Ph3 Sub 12-15 YOA - BNT162b2 (30 mcg)0/1,131 (0%)13/1,131 (1.1%)1,091/1,131 (96.5%)
OL Fup Period - Ph3 Sub 12-15 YOA - Placebo/BNT162b2 (30 mcg)1/1,014 (0.1%)13/1,014 (1.3%)238/1,014 (23.5%)
Ph2/3 - Subjects Who Are Part of PA 18 - BNT162b2 (30 mcg)47/23,403 (0.2%)69/23,403 (0.3%)3,326/23,403 (14.2%)
Add Booster for 1 Booster Dose Sub - BNT162b2 (30 mcg)0/381 (0%)1/381 (0.3%)27/381 (7.1%)
Add Booster for 2 Booster Doses Sub - BNT162b2 (30 mcg)0/15 (0%)0/15 (0%)1/15 (6.7%)
Add Booster for Low Dose Booster Sub - BNT162b2 (30 mcg)0/71 (0%)0/71 (0%)1/71 (1.4%)
Naive Sub Received Booster Dose (PA 18) - BNT162b2 (30 mcg)0/242 (0%)0/242 (0%)23/242 (9.5%)
Sub Assigned to 2 Booster Doses - BNT162b2SA (30 mcg, 2 Doses)0/30 (0%)1/30 (3.3%)26/30 (86.7%)
Sub Rerand to 1 Booster Dose - BNT162b2 (30 mcg)0/306 (0%)2/306 (0.7%)263/306 (85.9%)
Sub Rerand to Receive 1 Booster Dose - BNT162b2SA (30 mcg)0/318 (0%)2/318 (0.6%)270/318 (84.9%)
BNT162b2-Naive Subjects / BNT162b2SA (30 mcg)0/330 (0%)4/330 (1.2%)309/330 (93.6%)
Sub Rerand to Receive 1 Booster Dose - BNT162b2 (5 mcg)0/79 (0%)1/79 (1.3%)47/79 (59.5%)
Sub Rerand to Receive 1 Booster Dose - BNT162b2 (10 mcg)0/76 (0%)0/76 (0%)64/76 (84.2%)
PC Fup Period - Ph2 - BNT162b2 (30 mcg)2/180 (1.1%)1/180 (0.6%)166/180 (92.2%)
PC Fup Period - Ph2 - Placebo0/180 (0%)0/180 (0%)100/180 (55.6%)
Most frequent serious events
Showing 10 of 628
Most frequent serious events
EventPC Fup Period - Ph1 - BNT162b1 10 mcgPC Fup Period - Ph1 - BNT162b1 20 mcgPC Fup Period - Ph1 - BNT162b1 30 mcgPC Fup Period - Ph1 - BNT162b1 100 mcgPC Fup Period - Ph1 - BNT162b2 10 mcgPC Fup Period - Ph1 - BNT162b2 20 mcgPC Fup Period - Ph1 - BNT162b2 30 mcgOL Fup Period - Ph1 - Placebo/BNT162b2 30 mcgPC Fup Period - Ph1 - PlaceboPC Fup Period - Ph2/3 Sub >=16 YOA (Final) - PlaceboPC Fup Period - Ph2/3 Sub >=16 YOA (Final) - BNT162b2 (30 mcg)OL Fup Period - Ph2/3 Sub >=16 YOA (Final) - Pla/B2 (30 mcg)PC Fup Period - Ph3 Sub 12-15 YOA - PlaceboPC Fup Period - Ph3 Sub 12-15 YOA - BNT162b2 (30 mcg)OL Fup Period - Ph3 Sub 12-15 YOA - Placebo/BNT162b2 (30 mcg)Ph2/3 - Subjects Who Are Part of PA 18 - BNT162b2 (30 mcg)Add Booster for 1 Booster Dose Sub - BNT162b2 (30 mcg)Add Booster for 2 Booster Doses Sub - BNT162b2 (30 mcg)Add Booster for Low Dose Booster Sub - BNT162b2 (30 mcg)Naive Sub Received Booster Dose (PA 18) - BNT162b2 (30 mcg)Sub Assigned to 2 Booster Doses - BNT162b2SA (30 mcg, 2 Doses)Sub Rerand to 1 Booster Dose - BNT162b2 (30 mcg)Sub Rerand to Receive 1 Booster Dose - BNT162b2SA (30 mcg)BNT162b2-Naive Subjects / BNT162b2SA (30 mcg)Sub Rerand to Receive 1 Booster Dose - BNT162b2 (5 mcg)Sub Rerand to Receive 1 Booster Dose - BNT162b2 (10 mcg)PC Fup Period - Ph2 - BNT162b2 (30 mcg)PC Fup Period - Ph2 - Placebo
AppendicitisInfections and infestations0/240/240/240/120/241/240/240/350/399/2201217/220101/203572/11291/11312/10143/234030/3810/150/710/2421/300/3060/3180/3300/790/760/1800/180
NeuritisNervous system disorders0/240/240/240/120/240/241/240/350/390/220120/220100/203570/11290/11310/10140/234030/3810/150/710/2420/300/3060/3180/3300/790/760/1800/180
Back painMusculoskeletal and connective tissue disorders0/240/240/240/120/240/240/240/350/390/220121/220101/203570/11290/11310/10141/234030/3810/150/710/2420/300/3060/3180/3301/790/760/1800/180
Adenocarcinoma gastricNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/240/240/240/120/240/240/240/350/390/220121/220100/203570/11290/11310/10140/234030/3810/150/710/2420/300/3060/3180/3300/790/761/1800/180
Suicidal ideationPsychiatric disorders0/240/240/240/120/240/240/240/350/392/220120/220105/203570/11294/11311/10141/234030/3810/150/710/2420/300/3060/3180/3300/790/760/1800/180
Acute myocardial infarctionCardiac disorders0/240/240/240/120/240/240/240/350/393/2201213/220106/203570/11290/11310/10140/234030/3810/150/710/2420/301/3060/3180/3300/790/760/1800/180
Ovarian cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/240/240/240/120/240/240/240/350/390/220120/220101/203570/11290/11310/10140/234030/3810/150/710/2420/301/3060/3180/3300/790/760/1800/180
Kidney infectionInfections and infestations0/240/240/240/120/240/240/240/350/390/220120/220101/203570/11290/11310/10140/234030/3810/150/710/2420/300/3061/3180/3300/790/760/1800/180
Deep vein thrombosisVascular disorders0/240/240/240/120/240/240/240/350/394/220124/220104/203570/11290/11310/10140/234030/3810/150/710/2420/300/3061/3180/3300/790/760/1800/180
Eosinophilic oesophagitisGastrointestinal disorders0/240/240/240/120/240/240/240/350/390/220120/220100/203570/11290/11310/10140/234030/3810/150/710/2420/300/3060/3181/3300/790/760/1800/180
Most frequent other events
Showing 10 of 94
Most frequent other events
EventPC Fup Period - Ph1 - BNT162b1 10 mcgPC Fup Period - Ph1 - BNT162b1 20 mcgPC Fup Period - Ph1 - BNT162b1 30 mcgPC Fup Period - Ph1 - BNT162b1 100 mcgPC Fup Period - Ph1 - BNT162b2 10 mcgPC Fup Period - Ph1 - BNT162b2 20 mcgPC Fup Period - Ph1 - BNT162b2 30 mcgOL Fup Period - Ph1 - Placebo/BNT162b2 30 mcgPC Fup Period - Ph1 - PlaceboPC Fup Period - Ph2/3 Sub >=16 YOA (Final) - PlaceboPC Fup Period - Ph2/3 Sub >=16 YOA (Final) - BNT162b2 (30 mcg)OL Fup Period - Ph2/3 Sub >=16 YOA (Final) - Pla/B2 (30 mcg)PC Fup Period - Ph3 Sub 12-15 YOA - PlaceboPC Fup Period - Ph3 Sub 12-15 YOA - BNT162b2 (30 mcg)OL Fup Period - Ph3 Sub 12-15 YOA - Placebo/BNT162b2 (30 mcg)Ph2/3 - Subjects Who Are Part of PA 18 - BNT162b2 (30 mcg)Add Booster for 1 Booster Dose Sub - BNT162b2 (30 mcg)Add Booster for 2 Booster Doses Sub - BNT162b2 (30 mcg)Add Booster for Low Dose Booster Sub - BNT162b2 (30 mcg)Naive Sub Received Booster Dose (PA 18) - BNT162b2 (30 mcg)Sub Assigned to 2 Booster Doses - BNT162b2SA (30 mcg, 2 Doses)Sub Rerand to 1 Booster Dose - BNT162b2 (30 mcg)Sub Rerand to Receive 1 Booster Dose - BNT162b2SA (30 mcg)BNT162b2-Naive Subjects / BNT162b2SA (30 mcg)Sub Rerand to Receive 1 Booster Dose - BNT162b2 (5 mcg)Sub Rerand to Receive 1 Booster Dose - BNT162b2 (10 mcg)PC Fup Period - Ph2 - BNT162b2 (30 mcg)PC Fup Period - Ph2 - Placebo
Injection site pain (PAIN)General disorders19/2423/2423/2412/1215/2419/2423/240/358/39861/220124200/220100/20357341/11291023/11310/10140/234030/3810/150/710/24223/30240/306250/318285/33033/7952/76156/18026/180
Headache (HEADACHE)Nervous system disorders15/2418/2421/249/1211/2410/2413/240/358/391741/220122836/220100/20357506/1129854/11310/10140/234030/3810/150/710/24218/30140/306158/318190/33018/7929/7695/18054/180
Chills (CHILLS)General disorders7/2415/2414/2410/123/248/2410/240/353/39389/220121723/220100/20357159/1129557/11310/10140/234030/3810/150/710/24214/3084/306110/318102/3308/7917/7661/1809/180
Fatigue (FATIGUE)General disorders14/2418/2420/2410/128/2414/2415/240/3517/391779/220123217/220100/20357538/1129876/11310/10140/234030/3810/150/710/24222/30184/306209/318248/33025/7941/76117/18067/180
Myalgia (MUSCLE PAIN)Musculoskeletal and connective tissue disorders9/2416/2414/247/126/247/2411/240/353/39706/220121997/220100/20357196/1129477/11310/10140/234030/3810/150/710/24214/30113/306115/318121/33013/7914/7676/18015/180
Pyrexia (FEVER)General disorders1/248/2415/246/120/241/245/240/350/390/22012758/220100/2035717/1129275/11310/10140/234030/3810/150/710/2425/3025/30628/31815/3300/792/7627/1800/180
Arthralgia (JOINT PAIN)Musculoskeletal and connective tissue disorders8/2410/246/243/122/241/244/240/352/39453/220121245/220100/20357107/1129229/11310/10140/234030/3810/150/710/24213/3073/30668/31875/3301/7912/7634/18013/180
Injection site swelling (SWELLING)General disorders1/246/248/245/122/240/240/240/350/390/22012554/220100/2035713/1129104/11310/10140/234030/3810/150/710/2420/3023/30620/31823/3301/793/7621/1800/180
Injection site erythema (REDNESS)General disorders0/241/244/244/120/240/241/240/350/390/22012491/220100/2035718/112997/11310/10140/234030/3810/150/710/2420/3017/30615/31823/3301/790/7614/1801/180
Diarrhoea (DIARRHEA)Gastrointestinal disorders3/243/243/244/120/241/241/240/352/39674/22012766/220100/20357106/1129141/11310/10140/234030/3810/150/710/2424/3025/30629/31842/3304/795/7641/18029/180

Baseline characteristics

Safety Analysis Set included randomized participants who received at least 1 dose of the study intervention.

Age, Customized
Age, Customized(Participants)Phase 1: BNT162b1 10 mcg Dose: 18-85 Years of AgePhase 1: BNT162b1 20 mcg Dose:18-85 Years of AgePhase 1: BNT162b1 30 mcg Dose:18-85 Years of AgePhase 1: BNT162b1 100 mcg Dose:18-55 Years of AgePhase 1: Placebo: 18-85 Years of AgePhase 1: BNT162b2 10 mcg Dose: 18-85 Years of AgePhase 1: BNT162b2 20 mcg Dose: 18-85 Years of AgePhase 1: BNT162b2 30 mcg Dose: 18-85 Years of AgePhase 2/3: BNT162b2 (30 mcg): >=16 Years of AgePhase 2/3: Placebo: >=16 Years of AgePhase 2/3: BNT162b2 30mcg: 12-15 Years of AgePhase 2/3: Placebo: 12-15 Years of AgePhase 3: BNT162b2 SA 30 mcg: 18-55 Years of AgeTotal
<=18 years000000003783771134113003019
Between 18 and 65 years121212122112121217130171410033334709
>=65 years121212018121212456345530009206
Sex: Female, Male
Sex: Female, Male(Participants)Phase 1: BNT162b1 10 mcg Dose: 18-85 Years of AgePhase 1: BNT162b1 20 mcg Dose:18-85 Years of AgePhase 1: BNT162b1 30 mcg Dose:18-85 Years of AgePhase 1: BNT162b1 100 mcg Dose:18-55 Years of AgePhase 1: Placebo: 18-85 Years of AgePhase 1: BNT162b2 10 mcg Dose: 18-85 Years of AgePhase 1: BNT162b2 20 mcg Dose: 18-85 Years of AgePhase 1: BNT162b2 30 mcg Dose: 18-85 Years of AgePhase 2/3: BNT162b2 (30 mcg): >=16 Years of AgePhase 2/3: Placebo: >=16 Years of AgePhase 2/3: BNT162b2 30mcg: 12-15 Years of AgePhase 2/3: Placebo: 12-15 Years of AgePhase 3: BNT162b2 SA 30 mcg: 18-55 Years of AgeTotal
Female131114722171315107241095256454416023056
Male1113105177119113471111957058617323878
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Phase 1: BNT162b1 10 mcg Dose: 18-85 Years of AgePhase 1: BNT162b1 20 mcg Dose:18-85 Years of AgePhase 1: BNT162b1 30 mcg Dose:18-85 Years of AgePhase 1: BNT162b1 100 mcg Dose:18-55 Years of AgePhase 1: Placebo: 18-85 Years of AgePhase 1: BNT162b2 10 mcg Dose: 18-85 Years of AgePhase 1: BNT162b2 20 mcg Dose: 18-85 Years of AgePhase 1: BNT162b2 30 mcg Dose: 18-85 Years of AgePhase 2/3: BNT162b2 (30 mcg): >=16 Years of AgePhase 2/3: Placebo: >=16 Years of AgePhase 2/3: BNT162b2 30mcg: 12-15 Years of AgePhase 2/3: Placebo: 12-15 Years of AgePhase 3: BNT162b2 SA 30 mcg: 18-55 Years of AgeTotal
Hispanic or Latino10101110571657101321304211735
Not Hispanic or Latino23242212382323241628116261100099728835016
Unknown or Not Reported0010000074100233183
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Phase 1: BNT162b1 10 mcg Dose: 18-85 Years of AgePhase 1: BNT162b1 20 mcg Dose:18-85 Years of AgePhase 1: BNT162b1 30 mcg Dose:18-85 Years of AgePhase 1: BNT162b1 100 mcg Dose:18-55 Years of AgePhase 1: Placebo: 18-85 Years of AgePhase 1: BNT162b2 10 mcg Dose: 18-85 Years of AgePhase 1: BNT162b2 20 mcg Dose: 18-85 Years of AgePhase 1: BNT162b2 30 mcg Dose: 18-85 Years of AgePhase 2/3: BNT162b2 (30 mcg): >=16 Years of AgePhase 2/3: Placebo: >=16 Years of AgePhase 2/3: BNT162b2 30mcg: 12-15 Years of AgePhase 2/3: Placebo: 12-15 Years of AgePhase 3: BNT162b2 SA 30 mcg: 18-55 Years of AgeTotal
American Indian or Alaska Native00000000222217430446
Asian304111029519477271262079
Native Hawaiian or Other Pacific Islander00000000533130087
Black or African American12000001209821215257404372
White2022201138232421180901810397396326138569
More than one race00000000580540242941177
Unknown or Not Reported0000000077112672204
08

Study locations

175 sites
  • North Alabama Research Center, LLC
    Athens, Alabama 35611, United States
  • Birmingham Clinical Research Unit
    Birmingham, Alabama 35216, United States
  • Medical Affiliated Research Center
    Huntsville, Alabama 35801, United States
  • Optimal Research, LLC
    Huntsville, Alabama 35802, United States
  • Alliance for Multispecialty Research, LLC
    Mobile, Alabama 36608, United States
  • Chinle Comprehensive Health Care Facility
    Chinle, Arizona 86503, United States
  • Johns Hopkins Center for American Indian Health
    Chinle, Arizona 86503, United States
  • HOPE Research Institute
    Phoenix, Arizona 85018, United States
  • The Pain Center of Arizona
    Phoenix, Arizona 85018, United States
  • HOPE Research Institute
    Phoenix, Arizona 85023, United States
  • Alliance for Multispecialty Research, LLC
    Tempe, Arizona 85281, United States
  • Johns Hopkins Center for American Indian Health
    Whiteriver, Arizona 85941, United States
  • Whiteriver Indian Hospital - Garrett Building
    Whiteriver, Arizona 85941, United States
  • Whiteriver Indian Hospital
    Whiteriver, Arizona 85941, United States
  • Anaheim Clinical Trials, LLC
    Anaheim, California 92801, United States
  • Collaborative Neuroscience Research, LLC. - Investigator Site File Location
    Garden Grove, California 92845, United States
  • Collaborative Neuroscience Research, LLC
    Long Beach, California 90806, United States
  • Long Beach Clinical Trials Services Inc.
    Long Beach, California 90806, United States
  • Kaiser Permanente Los Angeles Medical Center
    Los Angeles, California 90027, United States
  • National Research Institute
    Los Angeles, California 90057, United States
  • Velocity Clinical Research, North Hollywood
    North Hollywood, California 91606, United States
  • Paradigm Clinical Research Center
    Redding, California 96001, United States
  • Kaiser Permanente Sacramento
    Sacramento, California 95815, United States
  • Clinical and Translational Science Center (CTSC) Clinical Research Center (CCRC)
    Sacramento, California 95817, United States
  • University of California Davis Health
    Sacramento, California 95817, United States
  • California Research Foundation
    San Diego, California 92123, United States
  • Kaiser Permanente Santa Clara
    Santa Clara, California 95051, United States
  • Bayview Research Group
    Valley Village, California 91607, United States
  • Diablo Clinical Research, Inc.
    Walnut Creek, California 94598, United States
  • Lynn Institute of Denver
    Aurora, Colorado 80012, United States
  • Clinical Research Consulting, LLC
    Milford, Connecticut 06460, United States
  • Yale University
    New Haven, Connecticut 06510, United States
  • Yale Center for Clinical Investigations (CSRU)
    New Haven, Connecticut 06519, United States
  • Alliance for Multispecialty Research
    Coral Gables, Florida 33134, United States
  • DeLand Clinical Research Unit
    DeLand, Florida 32720, United States
  • Fleming Island Center for Clinical Research
    Fleming Island, Florida 32003, United States
  • Indago Research & Health Center, Inc
    Hialeah, Florida 33012, United States
  • Research Centers of America
    Hollywood, Florida 33024, United States
  • Jacksonville Center for Clinical Research
    Jacksonville, Florida 32216, United States
  • Clinical Neuroscience Solutions, Inc.
    Jacksonville, Florida 32256, United States
  • Acevedo Clinical Research Associates
    Miami, Florida 33142, United States
  • Clinical Neuroscience Solutions, Inc. dba CNS Healthcare
    Orlando, Florida 32801, United States
  • Atlanta Center for Medical Research
    Atlanta, Georgia 30331, United States
  • IACT Health
    Columbus, Georgia 31904, United States
  • Meridian Clinical Research
    Savannah, Georgia 31406, United States
  • Velocity Clinical Research, Washington DC
    Savannah, Georgia 31406, United States
  • Clinical Research Atlanta
    Stockbridge, Georgia 30281, United States
  • East-West Medical Research Institute
    Honolulu, Hawaii 96814, United States
  • Solaris Clinical Research
    Meridian, Idaho 83646, United States
  • Optimal Research
    Peoria, Illinois 61614, United States
  • University of Iowa Hospitals & Clinics Investigational Drug Servces
    Iowa City, Iowa 42242, United States
  • University of Iowa Hospitals & Clinics
    Iowa City, Iowa 52242, United States
  • Velocity Clinical Research, Norfolk
    Sioux City, Iowa 51106, United States
  • Alliance for Multispecialty Research, LLC
    Newton, Kansas 67114, United States
  • Alliance for Multispecialty Research, LLC
    Wichita, Kansas 67207, United States
  • Kentucky Pediatric/ Adult Research
    Bardstown, Kentucky 40004, United States
  • Benchmark Research
    Metairie, Louisiana 70006, United States
  • Ochsner Clinic Foundation
    New Orleans, Louisiana 70121, United States
  • LSU Health Sciences Center at Shreveport Clinical Trials Office
    Shreveport, Louisiana 71101, United States
  • LSUHSC-Shreveport
    Shreveport, Louisiana 71103, United States
  • Pharmaron CPC, Inc.
    Baltimore, Maryland 21201, United States
  • University of Maryland Medical Center Investigational Drug Service Pharmacy
    Baltimore, Maryland 21201, United States
  • University of Maryland, Baltimore, Health Sciences Research Facility III
    Baltimore, Maryland 21201, United States
  • University of Maryland, Center for Vaccine Development and Global Health
    Baltimore, Maryland 21201, United States
  • Johns Hopkins Bayview Medical Center
    Baltimore, Maryland 21224, United States
  • Boston Medical Center
    Boston, Massachusetts 02118, United States
  • UMass Memorial Medical Center - University Campus
    Worcester, Massachusetts 01655, United States
  • Michigan Center for Medical Research
    Farmington Hills, Michigan 48334, United States
  • MedPharmics, LLC
    Gulfport, Mississippi 39503, United States
  • Clinical Research Professionals
    Chesterfield, Missouri 63005, United States
  • Sundance Clinical Research, LLC
    St Louis, Missouri 63141, United States
  • Bozeman Health Deaconess Hospital dba Bozeman Health Clinical Research
    Bozeman, Montana 59715, United States
  • Bozeman Health Deaconess Hospital
    Bozeman, Montana 59715, United States
  • Methodist Physicians Clinic / CCT Research
    Fremont, Nebraska 68025, United States
  • Velocity Clinical Research, Norfolk
    Norfolk, Nebraska 68701, United States
  • Quality Clinical Research, Inc.
    Omaha, Nebraska 68114, United States
  • Meridian Clinical Research, LLC
    Omaha, Nebraska 68134, United States
  • Wake Research-Clinical Research Center of Nevada, LLC
    Las Vegas, Nevada 89106, United States
  • Amici Clinical Research
    Raritan, New Jersey 08869, United States
  • South Jersey Infectious Disease
    Somers Point, New Jersey 08244, United States
  • Gallup Indian Medical Center
    Gallup, New Mexico 87301, United States
  • Johns Hopkins Center for American Indian Health
    Gallup, New Mexico 87301, United States
  • Johns Hopkins Center for American Indian Health
    Shiprock, New Mexico 87420, United States
  • Northern Navajo Medical Center
    Shiprock, New Mexico 87420, United States
  • Meridian Clinical Research, LLC
    Binghamton, New York 13901, United States
  • Meridian Clinical Research LLC
    Binghamton, New York 13905, United States
  • NYU Langone Health
    New York, New York 10016, United States
  • Icahn School of Medicine at Mount Sinai - Investigational Drug Service
    New York, New York 10029, United States
  • Icahn School of Medicine at Mount Sinai
    New York, New York 10029, United States
  • Rochester Clinical Research, Inc.
    Rochester, New York 14609, United States
  • University of Rochester Medical Center- Kari Steinmetz
    Rochester, New York 14642, United States
  • University of Rochester Medical Center
    Rochester, New York 14642, United States
  • SUNY Upstate Medical University Global Health Research Unit
    Syracuse, New York 13215, United States
  • Meridian Clinical Research LLC
    Vestal, New York 13850, United States
  • PMG Research of Raleigh, LLC d/b/a PMG Research of Cary
    Cary, North Carolina 27518, United States
  • PMG Research of Charlotte LLC
    Charlotte, North Carolina 28209, United States
  • Duke University - Main Hospital and Clinics
    Durham, North Carolina 27703, United States
  • PharmQuest
    Greensboro, North Carolina 27408, United States
  • PMG Research of Hickory, LLC
    Hickory, North Carolina 28601, United States
  • PMG Research of Raleigh, LLC
    Raleigh, North Carolina 27609, United States

Showing the first 100 of 175 sites across 6 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Zorger AM, Hirsch C, Baumann M, Feldmann M, Brockelmann PJ, Mellinghoff S, Monsef I, Skoetz N, Kreuzberger N. Vaccines for preventing infections in adults with haematological malignancies. Cochrane Database Syst Rev. 2025 May 21;5(5):CD015530. doi: 10.1002/14651858.CD015530.pub2. PubMed 40396505 ↗
  • Hirsch C, Zorger AM, Baumann M, Park YS, Brockelmann PJ, Mellinghoff S, Monsef I, Skoetz N, Kreuzberger N. Vaccines for preventing infections in adults with solid tumours. Cochrane Database Syst Rev. 2025 Apr 16;4(4):CD015551. doi: 10.1002/14651858.CD015551.pub2. PubMed 40237463 ↗
  • Pather S, Charpentier N, van den Ouweland F, Rizzi R, Finlayson A, Salisch N, Muik A, Lindemann C, Khanim R, Abduljawad S, Smith ER, Gurwith M, Chen RT; Benefit-Risk Assessment of VAccines by TechnolOgy Working Group (BRAVATO; ex-V3SWG). A Brighton Collaboration standardized template with key considerations for a benefit-risk assessment for the Comirnaty COVID-19 mRNA vaccine. Vaccine. 2024 Sep 17;42(22):126165. doi: 10.1016/j.vaccine.2024.126165. Epub 2024 Aug 27. PubMed 39197299 ↗
  • Killeen T, Kermer V, Troxler Saxer R. mRNA vaccine development during the COVID-19 pandemic: a retrospective review from the perspective of the Swiss affiliate of a global biopharmaceutical company. J Pharm Policy Pract. 2023 Nov 27;16(1):158. doi: 10.1186/s40545-023-00652-y. PubMed 38012751 ↗
  • Fraiman J, Erviti J, Jones M, Greenland S, Whelan P, Kaplan RM, Doshi P. Serious adverse events of special interest following mRNA COVID-19 vaccination in randomized trials in adults. Vaccine. 2022 Sep 22;40(40):5798-5805. doi: 10.1016/j.vaccine.2022.08.036. Epub 2022 Aug 31. PubMed 36055877 ↗
  • Kurhade C, Zou J, Xia H, Liu M, Yang Q, Cutler M, Cooper D, Muik A, Sahin U, Jansen KU, Ren P, Xie X, Swanson KA, Shi PY. Neutralization of Omicron sublineages and Deltacron SARS-CoV-2 by three doses of BNT162b2 vaccine or BA.1 infection. Emerg Microbes Infect. 2022 Dec;11(1):1828-1832. doi: 10.1080/22221751.2022.2099305. PubMed 35792746 ↗
  • Kurhade C, Zou J, Xia H, Cai H, Yang Q, Cutler M, Cooper D, Muik A, Jansen KU, Xie X, Swanson KA, Shi PY. Neutralization of Omicron BA.1, BA.2, and BA.3 SARS-CoV-2 by 3 doses of BNT162b2 vaccine. Nat Commun. 2022 Jun 23;13(1):3602. doi: 10.1038/s41467-022-30681-1. PubMed 35739094 ↗
  • De Santis F, Gubbiotti S. Borrowing historical information for non-inferiority trials on Covid-19 vaccines. Int J Biostat. 2022 Apr 27;19(1):177-189. doi: 10.1515/ijb-2021-0120. eCollection 2023 May 1. PubMed 35472295 ↗
  • Thomas SJ, Perez JL, Lockhart SP, Hariharan S, Kitchin N, Bailey R, Liau K, Lagkadinou E, Tureci O, Sahin U, Xu X, Koury K, Dychter SS, Lu C, Gentile TC, Gruber WC. Efficacy and safety of the BNT162b2 mRNA COVID-19 vaccine in participants with a history of cancer: subgroup analysis of a global phase 3 randomized clinical trial. Vaccine. 2022 Mar 1;40(10):1483-1492. doi: 10.1016/j.vaccine.2021.12.046. Epub 2021 Dec 24. PubMed 35131133 ↗
  • Thomas SJ, Moreira ED Jr, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Perez Marc G, Polack FP, Zerbini C, Bailey R, Swanson KA, Xu X, Roychoudhury S, Koury K, Bouguermouh S, Kalina WV, Cooper D, Frenck RW Jr, Hammitt LL, Tureci O, Nell H, Schaefer A, Unal S, Yang Q, Liberator P, Tresnan DB, Mather S, Dormitzer PR, Sahin U, Gruber WC, Jansen KU; C4591001 Clinical Trial Group. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months. N Engl J Med. 2021 Nov 4;385(19):1761-1773. doi: 10.1056/NEJMoa2110345. Epub 2021 Sep 15. PubMed 34525277 ↗
  • Frenck RW Jr, Klein NP, Kitchin N, Gurtman A, Absalon J, Lockhart S, Perez JL, Walter EB, Senders S, Bailey R, Swanson KA, Ma H, Xu X, Koury K, Kalina WV, Cooper D, Jennings T, Brandon DM, Thomas SJ, Tureci O, Tresnan DB, Mather S, Dormitzer PR, Sahin U, Jansen KU, Gruber WC; C4591001 Clinical Trial Group. Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents. N Engl J Med. 2021 Jul 15;385(3):239-250. doi: 10.1056/NEJMoa2107456. Epub 2021 May 27. PubMed 34043894 ↗
  • Vogel AB, Kanevsky I, Che Y, Swanson KA, Muik A, Vormehr M, Kranz LM, Walzer KC, Hein S, Guler A, Loschko J, Maddur MS, Ota-Setlik A, Tompkins K, Cole J, Lui BG, Ziegenhals T, Plaschke A, Eisel D, Dany SC, Fesser S, Erbar S, Bates F, Schneider D, Jesionek B, Sanger B, Wallisch AK, Feuchter Y, Junginger H, Krumm SA, Heinen AP, Adams-Quack P, Schlereth J, Schille S, Kroner C, de la Caridad Guimil Garcia R, Hiller T, Fischer L, Sellers RS, Choudhary S, Gonzalez O, Vascotto F, Gutman MR, Fontenot JA, Hall-Ursone S, Brasky K, Griffor MC, Han S, Su AAH, Lees JA, Nedoma NL, Mashalidis EH, Sahasrabudhe PV, Tan CY, Pavliakova D, Singh G, Fontes-Garfias C, Pride M, Scully IL, Ciolino T, Obregon J, Gazi M, Carrion R Jr, Alfson KJ, Kalina WV, Kaushal D, Shi PY, Klamp T, Rosenbaum C, Kuhn AN, Tureci O, Dormitzer PR, Jansen KU, Sahin U. BNT162b vaccines protect rhesus macaques from SARS-CoV-2. Nature. 2021 Apr;592(7853):283-289. doi: 10.1038/s41586-021-03275-y. Epub 2021 Feb 1. PubMed 33524990 ↗
  • Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Perez Marc G, Moreira ED, Zerbini C, Bailey R, Swanson KA, Roychoudhury S, Koury K, Li P, Kalina WV, Cooper D, Frenck RW Jr, Hammitt LL, Tureci O, Nell H, Schaefer A, Unal S, Tresnan DB, Mather S, Dormitzer PR, Sahin U, Jansen KU, Gruber WC; C4591001 Clinical Trial Group. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020 Dec 31;383(27):2603-2615. doi: 10.1056/NEJMoa2034577. Epub 2020 Dec 10. PubMed 33301246 ↗
  • Walsh EE, Frenck RW Jr, Falsey AR, Kitchin N, Absalon J, Gurtman A, Lockhart S, Neuzil K, Mulligan MJ, Bailey R, Swanson KA, Li P, Koury K, Kalina W, Cooper D, Fontes-Garfias C, Shi PY, Tureci O, Tompkins KR, Lyke KE, Raabe V, Dormitzer PR, Jansen KU, Sahin U, Gruber WC. Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. N Engl J Med. 2020 Dec 17;383(25):2439-2450. doi: 10.1056/NEJMoa2027906. Epub 2020 Oct 14. PubMed 33053279 ↗
  • Mulligan MJ, Lyke KE, Kitchin N, Absalon J, Gurtman A, Lockhart S, Neuzil K, Raabe V, Bailey R, Swanson KA, Li P, Koury K, Kalina W, Cooper D, Fontes-Garfias C, Shi PY, Tureci O, Tompkins KR, Walsh EE, Frenck R, Falsey AR, Dormitzer PR, Gruber WC, Sahin U, Jansen KU. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature. 2020 Oct;586(7830):589-593. doi: 10.1038/s41586-020-2639-4. Epub 2020 Aug 12. PubMed 32785213 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2020 to primary completion in Feb 2023, 33 months.

Results were first posted in Mar 2026, 3 years 1 month after primary completion.

Of 73 industry-sponsored phase 2/3 interventional studies under COVID-19, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 18. This study's 33 months is above that.

Counting every sponsor, half of 168 studies reached it within 11 months; a quarter within 5 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 27, 2020
First posted
Apr 30, 2020
StartActual
Apr 29, 2020
Primary completionActual
Feb 10, 2023
CompletionActual
Feb 10, 2023
Results first posted
Mar 25, 2026
Last update
Mar 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04368728
Lead sponsor
BioNTech SE
Collaborators
Pfizer
Responsible party
Sponsor
First posted
Apr 30, 2020
Start date
Apr 29, 2020
Primary completion
Feb 10, 2023
Completion
Feb 10, 2023
Results posted
Mar 25, 2026
Last update
Mar 25, 2026

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BNT162 Vaccine

Start the discussion